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Genomics driven diagnosis: a new era
Next generation sequencing (NGS) has altered genetic practice in a revolutionary 
way, by enabling rapid genome wide sequencing to identify a single gene defect for a 
fraction of the costs of traditional Sanger sequencing.1-4 
In 2003, 50 years after the description of the chemical structure of DNA by Watson 
and Crick and 13 years after its initiation, the Human Genome Project was successfully 
completed: scientists had succeeded in completing our full DNA-structure, the human 
genome sequence.5,6
Within five subsequent years, the introduction of next generation sequencing 
facilitated DNA-sequencing of the complete genome of an individual by massively 
parallel DNA sequencing in just two months.7
The development of next generation sequencing brought about a staggering cost 
reduction: the Human Genome Project cost 2.7 billion dollars, while the first massively 
parallel sequenced genome of a single individual cost 1.5 million dollars. However, 
since these costs were still high and only ~1-2% of our genome encodes for proteins, 
researchers developed ‘whole exome sequencing’ (WES): a technique for targeted 
sequencing of all protein-coding exons of the genome of one individual through 
massively parallel sequencing in a single test.8
In 2015, an individual genome could be sequenced for approximately 1750 dollars, 
bringing the targeted price of 1000 dollar per genome within reach. However, 
even though the costs of the actual sequencing have been reduced, the costs of the 
sequencing facilities and storage and analysis of data are still relatively high, hampering 
its unrestricted worldwide use in a diagnostic setting.9 Still, in prosperous countries, 
whole exome sequencing is slowly replacing Sanger sequencing and chromosomal 
micro-arrays as a first tier diagnostic tool.
The use of whole exome sequencing has led to the identification of the underlying 
molecular cause of both well known and newly established syndromes.10-13 This is 
reflected in the database of Online Mendelian Inheritance in Man (OMIM), where 
the number of phenotype descriptions with a known molecular basis has almost 
doubled from 2385 in September 2008 (just before the introduction of whole exome 
sequencing) to 4734 in May 2016, whilst the number of phenotype descriptions with an 
unknown molecular basis has remained relatively stable (1643 to 1622) and the number 
of other entries, mainly phenotypes with a suspected Mendelian basis has decreased 
only slightly (2080 to 1805) (Figure 1).14 
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Figure 1. The number of Entries in the database of Online Mendelian Inheritance in Man (OMIM).14
The number of phenotype descriptions with a known molecular basis has increased from 2385 in September 2008 
(a few months before the introduction of whole exome sequencing in 2009) to 4734 in May 2016. The number 
of phenotype descriptions or loci without a known molecular basis though, remains relatively stable (1643 in 
September 2008 and 1622 in May 2016) and the number of other entries, mainly phenotypes with a suspected 
Mendelian base, has only slightly decreased (2080 in September 2008 to 1805 in May 2016). Possible explanations 
are that these phenotypes are not caused by an underlying (mono)genetic defect or that the genetic defect 
could not be detected by the current molecular techniques thus far. However, these numbers also include newly 
described phenotypes and new possible genetic abnormalities.
The introduction of whole exome sequencing subsequently brought about a new era 
of genomics driven diagnosis: the use of whole exome sequencing in a diagnostic 
setting has led to an expansion of the diagnostic range in genetics, providing patients 
with a diagnosis more often and in a shorter period of time. Before genome wide 
sequencing techniques were implemented in genetic practice, patients were often 
subjected to extensive and invasive investigations over the course of several years. After 
the introduction of whole exome sequencing, the duration of the diagnostic process 
is reduced and unnecessary investigations can be avoided, thereby reducing the 
diagnostic burden for patients as well as the financial burden for society.15 Furthermore, 
an early diagnosis provides parents more often with reproductive options such as 
prenatal diagnosis (PND) or preimplantation genetic diagnosis (PGD).
Moreover, the unearthing of the genetic defect has led to increased knowledge of the 
phenotypic spectrum of many syndromes and has enabled fundamental research (e.g. 
through animal studies) to gain insights into the function of these genes and their role 
in developmental pathways.11,16-19
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The specialty of clinical genetics and the role of clinical genetic phenotyping
What is the role of clinical genetics as a primary specialty in this new era of genomics 
driven diagnosis? Do we still need clinical geneticists?20,21
The UK Clinical Genetics Society states on their website (www.clingensoc.org/
whatisclinicalgenetics):
‘Clinical Genetics is the medical specialty which provides a diagnostic service and ‘genetic 
counselling’ for individuals or families with, or at risk of, conditions which may have a genetic 
basis. Genetic disorders can affect any body system and any age group. The aim of Genetic Services 
is to help those affected by, or at risk of, a genetic disorder to live and reproduce as normally as 
possible. Genetic disorders include:
 ·  Chromosomal abnormalities, which cause birth defects, mental retardation and/or 
reproductive problems.
 ·  Single gene disorders such as cystic fibrosis, muscular dystrophy, Huntington’s disease 
and sickle cell disease.
 ·  Familial cancer and cancer-prone syndromes such as inherited breast or colorectal cancer 
and neurofibromatosis.
 ·  Birth defects with a genetic component such as neural tube defects and cleft lip and 
palate.
In addition, a large number of individuals with birth defects and/or learning disabilities are 
referred and investigated for genetic factors. Individuals identified through childhood or 
pregnancy screening programmes also require genetic services. In the future, as the genetic 
contributions to common later-onset disorders such as diabetes and coronary heart disease are 
identified, genetic services may be required for those at high risk. Testing for genetic factors that 
affect drug prescribing will also increasingly become an important activity.’
Clinical geneticists specialize in characterizing and distinguishing many rare genetic 
disorders. They aim to establish a clinical and molecular diagnosis in a patient, ensure 
proper clinical management and appropriate surveillance, resulting in earlier detection 
and treatment of associated disease manifestations. Furthermore, they inform patients 
and their parents about the prognosis, risks for other family-members, recurrence-risk 
in future pregnancies and reproductive options.
‘Phenotyping’ plays a key role in clinical genetics. In the Oxford Desk Reference for 
Clinical Genetics, phenotype is defined as: ‘the appearance or other characteristics of the 
organism, resulting from the interaction of its genetic constitution with the environment’.22
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Phenotyping in clinical genetics encompasses an assessment and description of the 
clinical characteristics of a patient through taking a medical history, family history 
and by performing a physical examination and, if necessary, additional clinical 
investigations (e.g. X-rays or ophthalmologic examination). Seemingly unimportant 
phenotypic details can be the clue to a specific diagnosis (e.g. hypoplastic or absent fifth 
nails of the fingers and toes in Coffin-Siris syndrome, or large upper central incisors in 
KBG syndrome (KBG are the initials of the surnames of the first patients described)23,24), 
so careful and thorough phenotyping is essential.
Clinical genetic practice in a historical perspective
The basis of clinical genetic practice and clinical genetic phenotyping was created in the 
nineteenth century, when Georg Mendel presented his work on what is now referred 
to as ‘Mendelian inheritance’ (1865; he described dominant and recessive inheritance, 
independent inheritance of separate genes and the passing of one randomly selected 
allele of a pair of alleles from each parent to their offspring) and Langdon Down 
identified Down’s syndrome as a clinically distinct entity, based on overlapping facial 
features that were present in several patients with intellectual disability (ID; 1866).25,26 
Until then, no clear distinction was made between separate syndromes with ID, but 
afterwards, various other syndromes that involve ID (e.g. Tuberous Sclerosis Complex 
in 1880)27 were categorized.
A similar development was seen in syndromes with short stature, where achondroplasia 
was identified as a separate clinical entity in several patients in 1878, based on the 
presence of a disproportionate short stature with rhizomelic shortening of limbs, short 
trident hands, lumbar lordosis, an enlarged head and a depressed nasal bridge.28 This 
instigated the identification and description of numerous new syndromes with short 
stature (e.g. Morquio syndrome, now known as mucopolysaccharidosis type IV).29 
At that time, every diagnosis was made clinically, since diagnostic cytogenetic, 
molecular genetic and biochemical techniques were not yet available.
Changes in clinical genetic practice were induced by the development of diagnostic 
cytogenetic, molecular genetic and biochemical techniques over the course of the 
nineteenth and twentieth century.
The evolution and widespread introduction of these techniques was complex and only 
slowly gained pace. It was predated by the first description of cells by Robert Hooke in 
1665 and nuclei (‘globules’) by Antoni van Leeuwenhoek in 1674.30,31 Their work eventually 
led to the extraction of DNA from white blood cells by Johann Friedrich Miescher in 
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1869, the description of chromosomes and the principle of mitosis in 1878 by Walther 
Flemming, the formation of the chromosome theory of heredity by Theodor Boveri and 
Walter Sutton in 1902, the introduction of the terms ‘gene’, ‘genotype’ and ‘phenotype’ 
by Wilhelm Johanssen between 1903 and 1909, the discovery that chromosomes carry 
genes by Thomas Hunt Morgan and the elucidation of the structure of DNA in 1953 by 
James Watson, Rosalind Franklin and Francis Crick.5,32-39
Genetic testing became a reality after the elucidation that the human karyotype 
includes 46 chromosomes in 1956 and the discovery that Down’s syndrome is caused 
by an extra chromosome 21 in 1959.40,41 Subsequent discoveries broadened the scope of 
genetic investigations: the development of in situ hybridization in 1969, chromosome 
banding in 1970, Sanger sequencing in 1977 and polymerase chain reaction (PCR) in 
1985.42-45 Genome wide microarray based studies (in which microscopic DNA spots are 
attached to a chip in order to genotype multiple regions of a genome or to measure 
expression levels of various genes) were the first high throughput techniques in 
1995.46,47
The development of cytogenetics as the first diagnostic tool coincided with the 
establishment of clinical genetics as a separate specialty in medicine. Before clinical 
genetics evolved into a separate medical specialty, pediatric departments were leading 
in the clinical description of genetic disorders, syndromes and malformations. In the 
1950s, the first medical doctors started to work as clinical geneticists and founded the 
American Society of Human Genetics (ASHG; www.ashg.org). Among these pioneers 
were famous clinical geneticists, such as Robert J. Gorlin (a dentist and a father of 
syndromology), Victor A. McKusick (a cardiologist and the author of the Mendelian 
Inheritance in Man (MIM), a catalogue of human genes and genetic disorders)48 and 
David W. Smith (a pediatrician). In Europe, Jan Mohr (a geneticist) founded the European 
Society of Human Genetics (ESHG; www.eshg.org) in 1967. In the Netherlands, clinical 
genetics was only officially recognized as a separate medical specialty in 1987, followed 
by the foundation of the Vereniging Klinische Genetica Nederland (VKGN; www.vkgn.
org) in 1988.
A timeline of the history of genetics with an overview of the discoveries and 
developments of cyto-, molecular and clinical genetics is provided in Figure 2.
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Figure 2. Timeline of the field of Genetics in a historic perspective.5-8,25,26,28,30-42,44-47 
The discoveries and developments in the fields of cytogenetics and molecular genetics are listed above the black 
timeline, those in the field of clinical genetics are listed below the black timeline.
Important discoveries in molecular biology are represented in red, cytogenetic and molecular techniques in green. 
Important genetic theories are represented in brown and developments in clinical genetics in blues.
Clinical genetic phenotyping: developments over time
Before the introduction of genetic diagnostic laboratory techniques, a patient was 
clinically diagnosed with a syndrome when a specific combination of clinical features 
could be recognized. This was most evident in the field of dysmorphology (a term 
first introduced by David W. Smith in 1966).49 Dysmorphology is a clinical genetic 
subspecialty that aims to diagnose patients with syndromes through the description of 
the morphology of body parts and the recognition of specific patterns of malformations.
When Sanger sequencing was introduced, targeted molecular genetic testing ensued, 
confirming or discarding the clinical diagnosis/suspicion. However, physicians were 
often unable to establish a definitive diagnosis, since many syndromes are difficult to 
recognize clinically and can show considerable phenotypic variability and overlap with 
other syndromes. Also, the molecular cause of countless syndromes was unknown and 
the vagaries of clinical presentation of disorders resulted in misdiagnosis. 
In many syndromes, the true phenotypic spectrum was only established after the 
identification of the molecular cause. This was the case for FG syndrome (FGS; FG 
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are the initials of the surnames of the first patients described).50 In 2007, mutations 
in the X-linked gene MED12 were identified as a cause of FGS. Around the same time, 
mutations in FLNA, BRWD3 and UPF3B were associated with phenotypes overlapping 
with FGS.51-54 Many patients previously diagnosed with FGS, however, did not have 
mutations in MED12. In one particular study, only one out of thirty clinically diagnosed 
patients had a mutation in this gene.55 This patient exhibited the typical features 
associated with this mutation. No mutations in the MED12 or FLNA genes could be 
detected in the other 29 patients (DNA analysis of the BRWD3 and UPF3B genes was 
not performed). Only three of the 29 patients without mutations were thought to have 
clinical features falling within the FGS phenotypic spectrum. The phenotype of the 
remaining 26 varied widely. In seven of these patients an alternative diagnosis (ATRX 
syndrome, Rett syndrome and submicroscopic chromosomal aberrations) could 
subsequently be made. Clearly, the absence of molecular verification had allowed 
patients with a wide range of phenotypes to be erroneously grouped under a single 
unifying clinical diagnosis. After the elucidation of the underlying molecular defect, 
the phenotypic spectrum of FG syndrome was narrowed considerably.56
The development of genome wide techniques, such as microarrays and especially 
exome sequencing, has not only led to the discovery of the molecular origin of known 
syndromes and subsequent delineation of the phenotype of these syndromes, but also 
to the recognition of many new syndromes. These syndromes and their phenotypic 
spectrum could be distinguished only after the identification of their molecular cause. 
An example of such a syndrome is Koolen-de Vries syndrome, caused by a recurrent 
microdeletion of chromosome 17q21.31 or by a mutation in the KANSL1 gene.57-61
Clinical genetic practice in the era of genomics: next generation phenotyping
The widespread use of whole exome sequencing has dramatically increased the 
diagnostic yield of genetic investigations in Mendelian disorders by approximately 
25%, which is most apparent in the field of ID (Figure 3).62,63 This means that the 
accuracy of the diagnostic process has roughly doubled by adding just this single test. 
The introduction of new, genome-wide genetic techniques has given rise to the term 
‘next generation phenotyping’, a process in which thorough clinical phenotyping 
remains of the utmost importance to make a correct diagnosis in patients with genetic 
disorders.64
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Figure 3. Diagnostic yield of different cytogenetic and molecular techniques in intellectual disability (in 
percentages).62,99-111
Whole exome sequencing in ID, for instance, reveals from 0 to 7 (average 1.5) non-
synonymous de novo mutations per person.12 Careful clinical phenotyping is essential 
to interpret these results and determine which molecular finding(s) is (are) causative 
by comparing the phenotypic features of the patient to those of other humans (or 
animals) with mutations in the same gene.
Furthermore, many variants identified have not previously been detected in any 
laboratory or described in literature. It is impossible to diagnose a new syndrome in one 
individual with a mutation in a novel gene. An accurate description of the phenotype 
will contribute to matchmaking efforts in order to recognize other individuals with an 
overlapping phenotype and a mutation in the same gene and subsequently establish 
a new syndrome. Moreover, whole exome sequencing in two patients with the same 
clinical phenotype can be of great use in finding the molecular cause of this phenotype, 
by focusing on overlapping mutations in a single gene.
As phenotyping-experts, clinical geneticists continue to play a key role in the process 
of next generation phenotyping: dissecting the genetic, epigenetic and environmental 
influences that cause a phenotype necessitates ‘ongoing and detailed phenotyping, 
refinement of clinical diagnostic assignments and iterative analyses of NGS data’.64
Genotype-phenotype studies
Genotype-phenotype studies remain essential in this era of next generation 
phenotyping, where the number of (rare) disorders with a known molecular genetic 
basis increases on a daily basis. For these studies, expert detailed phenotypic 
descriptions of patients are crucial.
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Genotype-phenotype studies help us learn more about genetic disorders, through:
1.  Delineation of the full phenotypic spectrum and prognosis of disorders. This knowledge 
enables us to provide tailor-made management advice for specific disorders.
2.  Investigating the presence of clinical heterogeneity in patients with mutations in 
the same gene.
  Different types of mutations and mutations at different locations in the same 
gene can cause clinically separate disorders, as is the case in FGFR3-related 
syndromes, where specific mutations cause disorders such as achondroplasia, 
hypochondroplasia, thanatophoric dysplasia, SADDAN (severe achondroplasia 
with developmental delay and acanthosis nigricans), Crouzon syndrome with 
acanthosis nigricans and Muenke syndrome.65-71
3.   Determining whether variability in clinical expression of a disorder can be related 
to specific mutations and their effects on protein formation.
  This has been shown in Duchenne and Becker muscular dystrophy, for instance.72,73 
The more severe phenotype of Duchenne muscular dystrophy is caused by 
pathogenic mutations in the DMD gene that typically disrupt the reading frame, 
leading to the production of a truncated dystrophin protein that is degraded. 
However, when some functional, but shortened dystrophin is left, patients develop 
the milder Becker muscular dystrophy. Becker patients generally have in-frame 
mutations in the DMD gene. 
4.   Establishing whether patients with a clinical diagnosis, but without a molecular 
diagnosis, really share a significant overlap in phenotypic features compared to 
patients in whom the diagnosis was molecularly confirmed. If this is not the case, 
the clinical diagnosis in these patients may be incorrect and other diagnoses 
(supported by additional genetic testing), should be (re-)considered.
  When the phenotype of a patient without a molecular diagnosis does significantly 
overlap with the original diagnosis, this suggests genetic heterogeneity. One 
of the well-known genetically heterogeneous disorders is Noonan syndrome, 
in which mutations in several genes cause the same or a highly similar disorder. 
Noonan syndrome can be caused by mutations in PTPN11, SOS1, RAF1, KRAS, 
NRAS, BRAF, MAP2K1, RIT1, SHOC2 and CBL and exhibits numerous overlapping 
phenotypic features with Noonan syndrome with multiple lentigines, Costello 
syndrome, cardio-facio-cutaneous syndrome, neurofibromatosis type 1, capillary 
malformation-arteriovenous malformation syndrome and Legius syndrome.74-85 
Together, these disorders constitute a group of clinically well described genetic 
disorders called ‘Rasopathies’ caused by mutations in genes encoding components 
of regulators of the RAS/MAPK signal transduction pathway.86
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5.   Determining which specific phenotypic features or patterns predict involvement 
of a specific syndrome of gene. For instance, the knowledge that certain specific 
features of that syndrome are only seen in patients with mutations in gene A and 
not in patients with mutations in gene B, can prompt the physician to perform 
targeted mutation analysis of gene A. This has been extensively studied in Noonan 
syndrome as well, where it is shown that patients with pulmonary stenosis most 
likely have a mutation in PTPN11 whereas hypertrophic cardiomyopathy points to 
involvement of other Noonan genes.74,87 This is important, since, at this moment, 
exome sequencing is still more expensive than Sanger sequencing of a single gene 
and exome sequencing is not yet available for everyone.
The expertise of clinical geneticists is a fundamental part of next-generation 
phenotyping in a time where the number of syndromes with a known molecular cause 
rapidly expands: in order to improve clinical patient care and enable genetic counselling, 
clinical geneticists distinguish and characterize individually rare syndromes and select 
homogeneous groups of patients for studies of the basic molecular genetic defect and 
pathophysiology of syndromes.88
Next-generation phenotyping of genetic disorders with a short stature
Next-generation phenotyping was performed in our cohorts of patients with 
(disorders resembling) Meier-Gorlin syndrome and Floating-Harbor syndrome, two 
rare syndromes with short stature in which the underlying molecular causes were 
identified by whole exome sequencing recently.
Meier-Gorlin syndrome (MGS) is a rare autosomal recessive disorder characterized 
by microtia, patellar a-/hypoplasia and pre- and postnatal growth retardation, first 
described by Meier et al. 56 years ago.89 Associated features include specific facial 
features (a small mouth with full lips and micrognathia in infants, a narrow nose with 
broad nasal bridge in adults (Figure 4)), congenital pulmonary emphysema, feeding 
problems, mammary hypoplasia, genitourinary and skeletal anomalies.
Over the past 15 years, several patients with MGS were seen in the Radboud University 
Medical Centre Nijmegen in the Netherlands and clinical data and DNA of these patients 
and patients from Canada, France, India, New-Zealand, Saudi-Arabia, the UK and the USA 
were collected. In collaboration with the University of Edinburgh Western General Hospital 
in Scotland, biallelic mutations in ORC1, ORC4, ORC6, CDT1 and CDC6 were identified as 
the underlying genetic cause of MGS in 2011.90,91 Simultaneously, Guernsey et al. identified 
ORC4, ORC1 and CDT1 mutations in eight MGS patients.92 These genes encode proteins of 
the pre-replication complex, essential for the initiation of DNA replication.93,94
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Floating-Harbor syndrome (FHS) was first described in 1973.95 It is a rare autosomal 
dominant disorder defined by growth retardation, expressive language delays and 
distinctive facial features (a triangular shaped face, deep set eyes with long eye lashes, 
a narrow nose with broad nasal tip, a low columella, short philtrum and thin upper lip 
with everted lower lip) (Figure 4).
Figure 4. Facial features (frontal and lateral view) of two patients with Meier-Gorlin syndrome and Floating-
Harbor syndrome. (A) Note microtia, the narrow nose with small profile, the small mouth and retrognathia in the 
individual with Meier-Gorlin syndrome. (B) In the individual with Floating-Harbor syndrome, deep-set eyes, a 
narrow root of the nose with a broad base, a short philtrum and low-set ears can be appreciated. 
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As part of the AnEUploidy project, the clinical data and DNA of 15 patients suspected to 
have FHS were collected over a time period of more than 10 years. 
In 2011, we saw three additional patients who had been diagnosed clinically with FHS 
and received the medical data and DNA of two other patients by collaboration with 
clinical geneticists from Rotterdam, the Netherlands and Bilbao, Spain. That made for 
a total of 20 patients with a clinical diagnosis/suspicion of FHS. In 2012, monoallelic 
mutations in SRCAP were detected as the underlying cause of FHS.96 SRCAP encodes 
a SNF2-related chromatin-remodeling ATPase, a coactivator for CREB-binding 
protein.97,98
We were able to perform molecular analysis of the SRCAP gene in our patients 
afterwards and identified de novo SRCAP mutations in seven patients out of our cohort 
of 20 patients.
Only two of the five patients we saw in 2011 could be diagnosed with FHS, based on 
the presence of an SRCAP mutation. In the third patient, we performed whole exome 
sequencing and we identified a de novo nonsense mutation in the ZBTB18 gene.
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The objective of this thesis was to improve clinical care and management for patients 
with MGS and FHS syndrome by increasing insight into the phenotypic and molecular 
genetic characteristics of these syndromes. Furthermore, we aimed to unravel new 
genetic syndromes in patients with phenotypes similar to MGS or FHS syndrome.
First, we performed genotype-phenotype studies in patients with MGS and FHS 
syndrome, to further delineate the phenotype of these syndromes, enabling us to 
propose specific management advice for follow-up of patients with these syndromes. 
Secondly, we contemplated to identify new molecular defects by whole exome 
sequencing in patients with a phenotype resembling MGS or FHS, but in whom 
no molecular diagnosis could be made thus far. We aimed to discover new genetic 
syndromes, increase the diagnostic yield in our patients and subsequently improve 
management of these patients.
We established genotype-phenotype correlations in MGS, expanded the phenotype 
of MGS by providing an overview of the clinical problems of these patients (Chapters 
2.1 and 2.3) and studying growth (Chapter 2.2) and proposed experience based 
management advice for MGS (Chapter 2.3).
We further delineated the phenotype of patients with FHS syndrome and provided 
management advice for this disorder (Chapter 3). 
In Chapter 4, we described the first patient with a de novo nonsense mutation in ZBTB18 
and a phenotype resembling FHS without an SRCAP mutation. The ZBTB18 gene is 
located in the chromosome 1q43q44 microdeletion syndrome region. We proposed 
that ZBTB18 is a strong candidate gene for a part of the 1q43q44 microdeletion 
syndrome, which shows some clinical overlap with FHS.
In this era of next generation sequencing, our studies highlight the importance of 
next generation phenotyping: establishing a correct clinical and molecular genetic 
diagnosis, perform genotype-phenotype studies to delineate the phenotypic spectrum 
of rare syndromes and unravel previously unrecognized, new genetic syndromes 
through whole exome sequencing.
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Abstract
Meier–Gorlin syndrome (MGS) is an autosomal recessive disorder characterized by 
microtia, patellar aplasia/hypoplasia and short stature. Recently, mutations in five 
genes from the pre-replication complex (ORC1, ORC4, ORC6, CDT1 and CDC6), crucial 
in cell-cycle progression and growth, were identified in individuals with MGS. Here, 
we report on genotype–phenotype studies in 45 individuals with MGS (27 females, 18 
males; age 3 months–47 years). Thirty-five individuals had biallelic mutations in one of 
the five causative pre-replication genes. No homozygous or compound heterozygous 
null mutations were detected. In ten individuals, no definitive molecular diagnosis was 
made. The triad of microtia, absent/hypoplastic patellae and short stature was observed 
in 82% of individuals with MGS. Additional frequent clinical features were mammary 
hypoplasia (100%) and abnormal genitalia (42%; predominantly cryptorchidism 
and hypoplastic labia minora/majora). One individual with ORC1 mutations only 
had short stature, emphasizing the highly variable clinical spectrum of MGS. 
Individuals with ORC1 mutations had significantly shorter stature and smaller head 
circumferences than individuals from other gene categories. Furthermore, compared 
with homozygous missense mutations, compound heterozygous mutations appeared 
to have a more severe effect on phenotype, causing more severe growth retardation 
in ORC4 and more frequently pulmonary emphysema in CDT1. A lethal phenotype 
was seen in four individuals with compound heterozygous ORC1 and CDT1 mutations. 
No other clear genotype–phenotype association was observed. Growth hormone and 
estrogen treatment may be of some benefit, respectively, to growth retardation and 
breast hypoplasia, though further studies in this patient group are needed.
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Introduction
Meier–Gorlin syndrome (MGS; MIM #224690) is a form of primordial dwarfism, 
characterized by microtia, short stature and absent or hypoplastic patellae. Furthermore, 
pulmonary emphysema, feeding problems, various skeletal abnormalities, 
genitourinary anomalies and mammary hypoplasia frequently accompany this 
autosomal recessive disorder. Characteristic facial features, which gradually change 
with age, are frequently described. Infants typically have a small mouth with full lips 
and micrognathia, whereas in adults, a high forehead and a more prominent, narrow 
nose with a broad nasal bridge are distinguishable.
The first patient was reported by Meier in 1959.1 Gorlin reported the second patient with 
a similar phenotype.2 In total, only 53 cases have been described in the literature thus 
far.1–21
Recently, mutations in ORC1, a pre-replication complex member gene, were identified 
in 5 out of 204 individuals with microcephalic primordial dwarfism.13
As individuals with mutations in ORC1 showed overlapping features with MGS, 
mutation analysis of ORC1 was performed in 33 individuals with MGS and revealed 
mutations in four individuals from three families.13 Mutation analysis of other genes 
of this pre-replication complex showed mutations in ORC4, ORC6, CDT1 and CDC6 in 
14 individuals from nine families with MGS.14 Simultaneously, beginning with a family-
based mapping approach in individuals with MGS with a founder effect, Guernsey 
et al. identified mutations in ORC1, ORC4 and CDT1 in eight individuals from five 
families with MGS.15 The pre-replication complex forms at origins of DNA replication 
and is essential to initiate genome replication.22,23 The complex consists of the origin 
recognition complex (encompassing the subunits ORC1 to ORC6), two regulatory 
proteins (CDC6 and CDT1) and the putative helicase complex (minichromosome 
maintenance (MCM) proteins). The origin recognition complex is loaded onto the 
chromatin during M and G1 phases. Afterwards, other proteins (including CDT1 and 
CDC6) bind to the pre-replication complex, facilitating repeated loading of the MCM 
helicase. The MCM helicase unwinds DNA and recruits additional replication proteins 
at the beginning of the S phase, thereby initiating replication. Mutations in genes from 
the pre-replication complex are expected to disturb this process of DNA replication. 
In vitro studies using lymphoblastoid cell lines or skin fibroblast cell lines from two 
individuals with mutations in ORC1 showed reduced levels of ORC1, ORC2 and MCM2 
in chromatin-enriched cell fractions.13 Furthermore, the S phase entry/progression in 
both individuals was delayed.
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The five genes known to cause MGS are part of the same pre-replication complex. We 
posed the question whether mutations in the different genes from the pre-replication 
complex have a different effect on the MGS phenotype. To answer that question, we 
performed genotype–phenotype studies in 45 individuals with MGS, including all 
individuals with a molecular diagnosis of MGS thus far known.
Methods
Patients
Of the 45 individuals included in this study, 35 carried mutations in one of the five 
known genes for MGS. Ten individuals with a clinical diagnosis of MGS without a 
known molecular cause are described, including one individual carrying a monoallelic 
mutation in ORC1 and two carrying a monoallelic mutation in CDT1. Molecular testing 
showed no abnormalities in five other individuals with a clinical diagnosis of MGS, but 
the authors had insufficient clinical information to include them in this study.
Thirty-five individuals were described previously in literature.2–5,8,11,13–17,21 The remaining 
ten individuals were not yet described in literature. These ten individuals were 
referred to the Human Genetics departments of the Radboud University Nijmegen 
Medical Centre, the Netherlands and the Western General Hospital in Edinburgh, UK 
for molecular analysis from the Netherlands, the UK, Ireland and India. The medical 
history and most recent clinical data of all individuals were obtained by sending a 
questionnaire to the referring physicians or by physical examination by the authors. 
The growth data were converted to standard deviations from the mean (SDs), using 
two different growth charts for growth around birth and postnatal growth.24,25 Intra-
uterine growth retardation was defined as weight for gestational age more than 1.3 SDs 
(10th centile) under the mean, postnatal growth retardation as height for age more 
than 2 SDs under the mean and microcephaly as head circumference for age more than 
3 SDs under the mean.26–28 Informed consent to perform molecular investigations and 
to publish the medical data and photographs of the patients was obtained.
Molecular data
Sequence analysis of the ORC1, ORC4, ORC6, CDT1 and CDC6 genes was performed 
on DNA isolated from peripheral blood from the affected children and the parents 
as previously described.13–15 Copy number variation analysis of ORC4 was performed 
in eight individuals.15 In the individual with monoallelic mutations in ORC1, DNA 
40970 Munnik, Sonja de.indd   38 04-07-16   14:02
Meier-Gorlin syndrome
39
2.1
was screened for intragenic deletions/duplications of ORC1, using Multiplex ligation-
dependent Probe Amplification.
Statistical analysis
Differences in birth weight, height and head circumference between the different gene 
categories of MGS (individuals with biallelic mutations in ORC1, ORC4, ORC6, CDT1 and 
CDC6 and individuals with a clinical diagnosis of MGS without a definitive molecular 
diagnosis) were analyzed using the Student’s t-test. The significance level was set at 
the 5% probability level. Statistical analysis was performed using standard statistical 
software (SPSS version 16.0, Inc., Chicago, IL, USA).
Results
Patients and molecular data
The clinical data of all 45 individuals from 35 families with MGS are summarized in 
Table 1. Thirty-five individuals from 26 families had biallelic mutations in one of the 
five pre-replication genes underlying MGS. In ten individuals from nine families, no 
definitive underlying molecular cause could be identified.
Of the 35 individuals with mutations, 14 were male (40%), 21 were female (60%). The 
average age at most recent examination was 12 years and 9 months (ranging from 3 
months to 47 years). Seventeen individuals (49%) had reached puberty or adulthood. 
Four individuals were deceased: two siblings with mutations in ORC1, of which one 
passed away at the age of 3 months with a severe cortical dysplasia, pachygyria and 
ventricular enlargement, cranial suture stenosis, congenital emphysema of the lung 
and absence of the pancreatic tail, in addition to the classical triad of MGS (microtia, 
patellar anomalies and short stature) (individual P1, Table 2).14 His brother, deceased at 
17 weeks of gestation, also exhibited microtia and severe growth retardation (individual 
P2, Table 2). The other two individuals were siblings with mutations in CDT1 (I6 and 
I7 respectively, Table 2). One died after a sudden cardiac arrest and had congenital 
lobar emphysema for which he required surgery. His sister succumbed after 3 months 
of severe respiratory problems due to a tracheobronchomalacia with progressive 
pulmonary emphysema. Both showed clinical features of the classical triad of MGS.
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Of the ten individuals without a known molecular cause, one had a monoallelic 
missense mutation in ORC1 (I1, Table 2) and two siblings had a monoallelic missense 
mutation in CDT1 (I8 and I9, Table 2). The healthy fathers of these three individuals 
carried the same mutation. Of the ten individuals, three were male (30%), seven were 
female (70%), with an average age at last examination of 11 years and 2 months. Three 
individuals had reached puberty or adulthood.
Homozygous or compound heterozygous mutations in ORC1, ORC4, ORC6, CDT1 and 
CDC6 were identified in 35 individuals. Ten had mutations in ORC1 (29%), seven in ORC4 
(20%), seven in ORC6 (20%), ten in CDT1 (29%) and one in CDC6 (3%). The mutations 
identified are presented in Table 2. No homozygous or compound heterozygous null 
mutations were detected consistent with MGS mutations acting through partial loss of 
pre-replication complex function. Homozygous missense mutations were detected in 
ten out of 35 individuals with biallelic mutations from eight families (29%), compound 
heterozygous missense mutations in two unrelated individuals (6%). Compound 
heterozygous missense and frameshift mutations were identified in four individuals 
from three families (11%), compound heterozygous missense and splice site mutations 
in eight individuals from seven families (23%), compound heterozygous missense and 
nonsense mutations in ten individuals from five families (29%). One individual (3%) 
had a heterozygous missense mutation and a partial gene deletion.
The classical triad of clinical features
The clinical diagnosis of MGS was previously based on the classical triad of microtia, 
absent or hypoplastic patellae and short stature. In our cohort, all three features were 
generally present, although not all three features had to be present to diagnose MGS.
Seven individuals did not show all the features of the classical triad. They had mutations 
in ORC1, ORC4, ORC6 and CDT1. One individual without mutations had microtia, with 
normal stature and normal patellae. Of the 35 individuals, four with biallelic mutations 
(11%; one with ORC4, one with ORC6 and two with CDT1 mutations) had a normal 
stature, but small ears and absent patellae. One individual (3%) with ORC6 mutations 
had microtia and short stature, without patellar aplasia/hypoplasia. One individual 
(3%) with ORC1 mutations had normal sized ears and normal patellae. This individual 
was originally diagnosed with microcephalic primordial dwarfism.13
Ears. Microtia was present in 34 out of 35 individuals (97%) with mutations and all 
individuals clinically diagnosed with MGS. One individual with mutations in ORC1 
had normal sized and shaped, though posteriorly rotated ears. Microtia ranged from 
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slightly small, normal shaped and positioned ears to abnormally formed (27/39; 69%), 
low set (24/38; 63%) and posteriorly rotated (13/27; 48%) ears (microtia grade 2) (Figure 
1).29 Conductive hearing loss was detected in two individuals with mutations in ORC1 
and ORC6, accompanied by a narrow ear canal in one.
Figure 1. Facial features of individuals with Meier-Gorlin syndrome. Frontal and lateral view of ten individuals 
with Meier-Gorlin syndrome. Note the different grades of microtia and the microstomia with full lips at young age. 
In the older individuals, the nose is more prominent and narrow, with a convex profile. Individuals (A) and (B) have 
mutations in ORC1 (individuals P3 and P4, Table 2);13 individual (C) has mutations in ORC4 (individual P5, Table 2);14 
individual (D) has mutations in CDT1 (individual P11, Table 2);14 individual (E) has mutations in CDC6 (individual 
P18, Table 2);14 individuals (F), (G) and (H) are new individuals with mutations in ORC6 (individuals I2-I4, Table 2). 
In individuals (I) and (J), no definitive molecular diagnosis could be made. Individual (J) was previously described 
by Bongers et al. in 2001.3
Patellae. Patellar malformations were reported in 30 out of 32 individuals (94%) with 
mutations, including all individuals with mutations in ORC6, CDT1 and CDC6. The 
patellae were absent in 21 individuals (70%), hypoplastic in 9 (30%). The patellae of the 
monozygotic twins with homozygous missense mutations in ORC4 were reported to 
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be palpable in early childhood, but were not palpable at several examinations during 
adolescence.14,15 However, in both twins, no radiological examinations were performed.
Two individuals were reported to have dimples over their knees, highly suggestive of 
patellar anomalies, at the age of 3 and 11 months, but no ultrasound examination was 
performed. 
The two individuals without patellar anomalies had mutations in ORC1 and ORC6. 
Patellar aplasia/hypoplasia was reported in nine individuals (90%) clinically diagnosed 
with MGS.
Growth and growth hormone treatment
No significant difference in birth weight was detected compared for the individuals 
with mutations in the different genes and without a known molecular cause (P > 0.05). 
Postnatal growth (P < 0.02) and head circumference (P < 0.004) were significantly 
more delayed in individuals with ORC1 mutations, compared with individuals from 
other gene groups (Figures 2a and b). Microcephaly was generally more apparent in 
older individuals.
Figure 2 a. Comparison of height (SDs) of individuals with Meier-Gorlin syndrome per gene category. 33 
individuals with biallelic mutations and 9 individuals without definitive molecular diagnosis: n=9 ORC1; n=7 
ORC4; n=7 ORC6; n=9 CDT1; n=1 CDC6; n=9 no definitive molecular diagnosis.
40970 Munnik, Sonja de.indd   48 04-07-16   14:02
Meier-Gorlin syndrome
49
2.1
Figure 2b. Comparison of head circumference (SDs) of individuals with Meier-Gorlin syndrome per gene 
category. 29 individuals with biallelic mutations and ten individuals without defi nitive molecular diagnosis: n=8 
ORC1; n=5 ORC4; n=6 ORC6; n=9 CDT1; n=1 CDC6; n=10 no defi nitive molecular diagnosis.
Intrauterine growth retardation (weight for gestational age <-1.3 SDs)25 was established 
in 32 out of 33 individuals (97%) with mutations in one of the fi ve known genes. Birth 
weight ranged from 1580 g after 40 weeks of gestation, to 3260 g after 41 weeks 
of gestation. One individual had a normal birth weight and mutations in CDT1. The 
birth weight of two individuals was unknown. IUGR was present in all ten individuals 
without defi nitive molecular diagnosis.
Postnatal growth was delayed (height for age <-2 SDs)24 in 31 out of 35 individuals (89%) 
with mutations and in nine out of ten individuals (90%) clinically diagnosed with MGS.
Microcephaly (OFC <-3 SDs)24 at birth was present in three out of 14 individuals (21%) 
with mutations (1/1 with mutations in ORC1, 1/4 in ORC4 and 1/1 in CDC6). Postnatally, 
microcephaly was present in 13 out of 30 individuals (43%) with mutations (8/8 ORC1; 
2/5 ORC4; 1/6 ORC6; 2/9 CDT1). Microcephaly was reported in three out of ten individuals 
(30%) clinically diagnosed with MGS.
Growth hormone treatment was initiated in eight individuals with mutations in all 
fi ve genes and pubertal development was delayed with a gonadotropin-releasing 
hormone analog in one individual with ORC4 mutations. Positive results of growth 
hormone treatment were reported in one individual with mutations in ORC4 and one 
with mutations in CDC6. The latter received treatment from age 2.5 years till age 7 years 
and from age 7.5 years till age 15.5 years. His height improved from -5 to -3 SDs during 
the fi rst 4 years, but showed no further improvement afterwards.
The former received growth hormone treatment from the age of 3 years till the age of 
9 years. Initially, her growth velocity increased, but the positive effect wore off and the 
treatment was stopped.
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Growth hormone therapy, with positive effects, was initiated in two males without 
mutations. One received growth hormone from the age of 3 years and 1 month. His 
height increased from -6.9 to -3.1 SDs at 12 years and 7 months of age. The other male 
was treated with growth hormone from the age of 5 years and 5 months. His height 
increased from -5.8 to -4.1 SDs at the age of 6 years and 9 months.
Neurological features
Most individuals with MGS had normal intellect (39/41; 95%) and showed normal motor 
and speech development (31/42; 74%). A mild intellectual disability was reported in one 
individual with mutations in ORC1 and one individual without mutations. Moderate 
learning difficulties were recorded in an individual with homozygous missense 
mutations in ORC1 who suffered from intraventricular hemorrhage due to prematurity. 
The delay in motor development in one individual with mutations in CDT1 might be 
related to congenital limb anomalies (club feet and genu recurvatum). Besides the 
anomalies in the individual with mutations in ORC1 described above, structural brain 
anomalies were rarely observed in MGS.
Facial features
All individuals with MGS (both molecularly and clinically diagnosed) had a 
recognizable facial appearance with microtia (44/45; 98%), microstomia (27/39; 69%), 
full lips (30/40; 75%) and retro-/micrognathia (35/39; 90%) (Figure 1). The profile of the 
nose was less consistent, but often convex (13/23; 57%) and narrow (12/26; 46%) with 
a high nasal bridge (17/27; 63%) and appeared to become more prominent with age 
(Figure 1). Less frequent findings were strabismus (3/23; 13%), a bifid uvula (2/45; 4%) 
and cleft palate (1/45; 2%). 
Respiratory tract
Pulmonary emphysema may be a serious complication in individuals with MGS. It was 
present in 12 out of 28 individuals (43%) with mutations in ORC1 (3), ORC4 (1), CDT1 
(7) and CDC6 (1) and one out of ten individuals (10%) without molecular diagnosis. 
None of the seven individuals with ORC6 mutations had pulmonary emphysema. 
Emphysema was congenital in most individuals, except for two, in whom the diagnosis 
was made at 4 and 7 years of age, respectively.
Structural abnormalities of the respiratory tract, comprising laryngomalacia, 
tracheomalacia and bronchomalacia are a relatively frequent finding in individuals with 
MGS. They were reported in ten out of 24 individuals (42%) with mutations and three 
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out of ten individuals (30%) without a known molecular cause. One individual with 
mutations in ORC4 had a tracheoesophageal fistula with trachea- and bronchomalacia. 
She developed secondary aspiration pneumonia and required nocturnal mechanical 
ventilation. Ten out of 25 individuals (40%) suffered from recurrent respiratory tract 
infections without apparent structural malformations during infancy and young 
childhood, improving with aging.
Cardiovascular tract
Congenital heart defects were rarely observed in MGS. They were present in 2 out of 
30 individuals (7%) with mutations. One individual with mutations in ORC4 had a 
perimembranous ventricular septal defect causing congestive heart failure, which 
closed spontaneously. 
The other individual had mutations in CDT1 and a patent ductus arteriosus (PDA), 
which required interventional coiling.
Gastrointestinal tract
Feeding problems in infancy and young childhood were very common in individuals 
with MGS, with a prevalence of 81% (26/32) in individuals with mutations and 100% 
(10/10) in individuals without a known molecular cause. They may, however, partially 
be triggered by anxiety about the growth deficiency in these individuals. Feeding 
problems ranged from a small appetite (17/40; 43%) to gastroesophageal reflux (15/41; 
37%) and failure to thrive (13/41; 32%). Of 41 individuals, 17 (41%) had tube feeding or 
gastrostomy interventions.
Urogenital tract
Minor genital anomalies were frequently described in individuals with MGS. In our 
cohort of 35 individuals with mutations in one of the five genes underlying MGS, 15 
(43%) had genital anomalies (10/14 (71%) males, 5/21 (24%) females; mutations in all 
five genes). The genital anomalies in males encompassed small testes (2/14; 14%) and 
cryptorchidism (7/14; 50%), accompanied by a micropenis in two (14%). One individual 
had hypospadias (7%). In females, hypoplastic labia majora were present in four (19%). 
Two had clitoromegaly in addition, one also had hypoplastic labia minora. Hypoplastic 
labia minora alone was reported in one individual (5%). The same genital anomalies 
were seen in individuals without a molecular diagnosis: cryptorchidism (1/3; 33%), 
small testes (1/3; 33%) and hypoplastic labia majora (2/7; 29%).
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Structural renal anomalies were uncommon in individuals with MGS: unilateral kidney 
aplasia was reported in two individuals (6%) with mutations in CDT1. Kidney stones 
were detected in one individual (3%) with mutations in ORC1.
Secondary sexual characteristics
Mammary hypoplasia was invariably present in all 13 post-pubertal females (100%; 10 
with mutations in ORC1, ORC4, ORC6 and CDT1; three without molecular diagnosis). 
Exogenous estrogen treatment in two siblings with ORC4 mutations had a positive 
effect on breast development. Menarche and menstrual cycles were normal in all. 
Hypoplastic nipples were seen in one male with mutations in CDT1. Sparse or absent 
axillary hair was reported in nine post-pubertal individuals (75%; three males, six 
females; seven with mutations in all five genes, one with one mutation in CDT1 and one 
without mutations). One individual with ORC6 mutations also had sparse pubic hair.
Musculoskeletal features
In addition to the cardinal patellar malformation, various skeletal anomalies 
accompanied MGS, including a delayed bone age (14/22; 64%), slender long bones 
(13/20; 65%), hooked clavicles (1/15; 7%), genu recurvatum (9/28; 32%), club feet or other 
joint contractures (5/27; 19%) and joint subluxations (3/30; 10%). One individual with 
mutations in ORC1 required craniosynostosis surgery. Another individual with CDT1 
mutations required surgery for scoliosis. One individual with mutations in CDC6 had 
a mandibular osteochondroma. Three out of ten individuals (30%) without molecular 
diagnosis had a delayed bone age, one (10%) had contractures of the knees, one (10%) 
joint subluxations and five (50%) showed muscle weakness at physical examination. 
One individual (10%) had craniosynostosis.
Discussion
We performed genotype–phenotype studies on 35 individuals from 26 families with 
mutations in one of the five known pre-replication genes for Meier–Gorlin syndrome 
(ORC1, ORC4, ORC6, CDT1 and CDC6) and ten individuals from nine families without a 
definitive molecular diagnosis.13–15
Our clinical data of the 35 individuals with MGS show that all individuals but 
one had at least two of the three main classical characteristics (microtia, absent/
hypoplastic patellae and short stature). In the one individual with short stature only, 
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it is questionable whether the diagnosis MGS could be made solely on a clinical basis, 
indicating a broader range of phenotypes in MGS than previously expected.
In an infant with short stature or microtia, the diagnosis MGS should be considered 
and the patellae should be assessed with care, as hypoplasia of the patellae can be 
mild. In infants and young children, ultrasound investigations are preferred over 
radiographic investigations for demonstrating patellar aplasia, as the patella is 
completely cartilaginous and therefore radiolucent in the first few years of life.30
Follow-up of growth and development is recommended. Growth hormone treatment 
may be worthwhile considering, as there has been apparent benefit to some MGS 
individuals, however further studies need to be undertaken to determine growth 
trajectories and the effect of growth hormone treatment in MGS. Finally, clinicians 
and families should be aware that mammary hypoplasia is present in all postpubertal 
females with MGS. Exogenous estrogen treatment may be beneficial to breast 
development, but the effects need to be studied further.
All 35 individuals had mutations in one of the five known pre-replication complex 
genes. Ten individuals had mutations in ORC1 (29%), seven in ORC4 (20%), seven in 
ORC6 (20%), ten in CDT1 (29%) and one in CDC6 (3%).
We show that individuals with ORC1 mutations have a significantly shorter stature and 
smaller head circumference than individuals with mutations in the other four genes 
and individuals without definitive molecular diagnosis.
No other clear genotype–phenotype correlation was detected between the different 
gene categories. Moreover, no distinct intra- and interfamilial variation was observed. 
However, our data suggest that compound heterozygous missense and loss-of-function 
mutations have a more severe effect on the phenotype, compared with homozygous 
and compound heterozygous missense mutations. For instance, two individuals with 
compound heterozygous missense and loss-of-function ORC1 mutations had a severe 
lethal phenotype with multiple congenital anomalies. Three individuals with each 
one missense and one loss-of-function mutation in ORC4 had more severe growth 
retardation than the other four individuals with homozygous missense mutations 
in ORC4 (-6.4 to -3.5 compared with -5.4 to -1.8). One of these three individuals had 
pulmonary emphysema, another had a congenital cardiac anomaly and two had severe 
feeding problems for which they required tube feeding and gastrostomy interventions 
(one individual with homozygous missense ORC4 mutations also required tube 
feeding). Furthermore, congenital pulmonary emphysema was reported in seven out 
of nine individuals with compound heterozygous missense and loss-of-function CDT1 
mutations. Two of these individuals had a lethal phenotype. The only individual with 
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homozygous missense mutations in CDT1 did not have pulmonary emphysema.
So far, no homozygous or compound heterozygous null mutations were identified, 
suggesting that these mutations cause a lethal phenotype. Two siblings with a recurrent 
missense mutation (p.Arg105Gln) and frameshift mutation (p.Val667fsX24) in ORC1 had 
a lethal phenotype. A lethal phenotype was also seen in two siblings with compound 
heterozygous nonsense and missense mutations in CDT1 (pGlu278X + p.Arg462Gln). 
We hypothesize that the presence of two null mutations or a combination of certain 
mutations has a disadvantage at conception or leads to early miscarriages, because 
of a severe effect of these mutations during embryological development. Results from 
studies in Drosophila of the gene double parked (dup), the Drosophila ortholog of CDT1, 
support this theory.31 Strong mutations in this gene cause embryonic lethality preceded 
by a failure to undergo S phase during division.
The clinical features of zebrafish with ORC1 mutations and yeast with ORC4 mutations 
show an overlap with the clinical features of individuals with MGS. Both zebrafish and 
yeast show a reduction in overall size.13–15 A slight hypoplasia of jaw cartilage, reduction 
in number or fusion of otolith organs and smaller eye size was present in over 80% 
of zebrafish with a depletion of ORC1. The remaining zebrafish, with a more severe 
depletion of ORC1, had a more severe reduction in growth with an abnormal body 
curvature and reduced viability.13
However, individuals with MGS show additional clinical features, such as 
underdevelopment of the patellae and structural anomalies, such as pulmonary 
emphysema, brain malformations and genitourinary anomalies. Mouse models for 
MGS may contribute in determining the effects of the different mutations in the pre-
replication complex on embryological development.
A mutation detection rate of 78% (35 out of 45 individuals) was established. The 
detection rate would have been lower (70%; 35 out of 50 individuals), if a clinical 
diagnosis of MGS could have been made in the five individuals who were excluded 
from the study because of insufficient clinical information.
Individuals without a molecular diagnosis had a similar phenotype to individuals 
with mutations. Further molecular studies, for instance parallel sequencing of pre-
replication complex genes and next-generation sequencing, may be useful to diagnose 
MGS earlier. We suppose that the individuals without mutations in ORC1, ORC4, ORC6, 
CDT1 and CDC6 have mutations in other genes of the pre-replication complex or 
pathways linked to the pre-replication complex. Another possibility is the presence 
of intragenic deletions or duplications in one of the five known pre-replication genes 
underlying MGS.
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In conclusion, MGS is a recognizable clinical phenotype, characterized by microtia, 
patellar aplasia/hypoplasia and a short stature, frequently accompanied by 
specific facial features, respiratory and gastrointestinal problems and skeletal and 
genitourinary anomalies. In three quarters of individuals with a clinical diagnosis of 
MGS, the diagnosis can now be confirmed by molecular analysis of ORC1, ORC4, ORC6, 
CDT1 and CDC6.
Individuals with ORC1 mutations have the most severe growth retardation in MGS. 
Therefore, testing of ORC1 first should be considered in individuals with a severe 
growth retardation and microcephaly. No other clear genotype–phenotype correlation 
was established, although compound heterozygous mutations appear to have a more 
severe effect on phenotype than homozygous missense mutations.
Longitudinal studies on growth/phenotype in an extended series of patients are 
important to investigate the effect of growth hormone and estrogen treatment on 
growth and mammary development, respectively.
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Abstract
Meier–Gorlin syndrome (MGS) is a rare autosomal recessive disorder characterized by 
primordial dwarfism, microtia and patellar aplasia/hypoplasia. Recently, mutations 
in the ORC1, ORC4, ORC6, CDT1 and CDC6 genes, encoding components of the pre-
replication complex, have been identified. This complex is essential for DNA replication 
and therefore mutations are expected to impair cell proliferation and consequently 
could globally reduce growth. However, detailed growth characteristics of MGS 
patients have not been reported and so this is addressed here through study of 45 MGS 
patients, the largest cohort worldwide. Here, we report that growth velocity (length) 
is impaired in MGS during pregnancy and first year of life, but, thereafter, height 
increases in paralleled normal reference centiles, resulting in a mean adult height of 
-4.5 standard deviation score (SDs). Height is dependent on ethnic background and 
underlying molecular cause, with ORC1 and ORC4 mutations causing more severe short 
stature and microcephaly. Growth hormone therapy (n=9) was generally ineffective, 
though in two patients with significantly reduced IGF1 levels, growth was substantially 
improved by GH treatment, with 2 SDs and 3.8 SDs improvement in height. Growth 
parameters for monitoring growth in future MGS patients are provided and as well 
we highlight that growth is disproportionately affected in certain structures, with 
growth related minor genital abnormalities (42%) and mammary hypoplasia (100%) 
frequently present, in addition to established effects on ears and patellar growth.
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Introduction
Meier–Gorlin syndrome (MGS; ear patella short stature syndrome; OMIM #224690) is 
defi ned by the triad of microtia, patellar aplasia/hypoplasia and short stature. Other 
frequent fi ndings include pulmonary emphysema and typical facial characteristics 
(Figure 1). 
MGS is part of a group of autosomal recessive disorders called microcephalic primordial 
dwarfi sm, characterized by severe proportionate pre- and postnatal growth defi ciency 
and microcephaly.1
Figure 1. Facial characteristics of three patients with Meier–Gorlin syndrome. Note the characteristic face with 
small, abnormally shaped ears, beaked nose, small mouth with full lips and retrognathia. Patient 13 was previously 
described by Lacombe et al. and Bicknell et al. (Case 3 and Patient 8, respectively).7,21 Patients 20 and 43 were 
previously described by Bongers et al. (patients 4 and 2, respectively).13
Sixty-three cases of MGS have been described in literature, thus far.2-23 Recently, 
mutations in fi ve different pre-replication complex genes (ORC1, ORC4, ORC6, CDT1 and 
CDC6) were identifi ed in 67% (31/46) of patients with MGS described in literature.20-22 
The pre-replication complex consists of the origin recognition complex (subunits ORC1–
ORC6), two regulatory proteins (CDT1 and CDC6) and the MCM helicase complex. The 
complex forms at origins of DNA replication and is essential for initiation of genome 
replication, a crucial step in cell cycle and cellular growth.24,25 Growth is globally 
reduced in MGS, presumably as a consequence of mutations slowing cell proliferation, 
with reported mean adult height in females of 131.6 cm (-5.6 standard deviation score 
(SDs) according to Prader et al.; range 127–148 cm, n=5) and 147.8 cm in males (-3.3 SDs 
according to Prader et al.; range 132–157.5 cm; n=3).9,16,17,20,21,26 Growth did not improve 
during growth hormone (GH) therapy performed in six patients, thus far.7,14,18,20,22
Reductions in growth of specifi c tissues are also evident, most notably affecting the 
patella and ear, given that microtia and patellar aplasia/hypoplasia are defi ning 
features of MGS. Microtia can vary profoundly, ranging from slightly small and 
normally positioned to abnormally shaped and positioned ears. Only one patient was 
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reported to have normal sized and shaped ears.22 Additionally, genital growth may be 
specifically affected both evident at birth, resulting in minor genital anomalies and 
during secondary sexual development, resulting in mammary hypoplasia.3,7,8,10,12,13,16,20,21
Detailed longitudinal growth and endocrinological studies in patients with MGS have 
not been described and no reference curves for height, weight and head circumference 
have been established. Here, we provide an overview of growth in a unique cohort of 
45 MGS patients, the largest worldwide. Moreover, we describe the beneficial effect 
of GH treatment in two MGS patients with additional growth hormone insufficiency. 
Finally, we provide an overview of genital anomalies, secondary sexual characteristics 
and disrupted growth of the ears in MGS.
Materials and methods
Patients
Pre- and postnatal growth measurements, endocrinological findings and data regarding 
development of genitalia, secondary sexual characteristics and ears of 45 patients with 
MGS were collected retrospectively by sending clinical questionnaires to the referring 
physicians and prospectively by physical examination and laboratory investigations. 
The cohort comprised 28 females (62%) and 17 males (38%), aged between 3 months 
and 47 years. Twenty patients had reached postpubertal or adult age (44%; 6 males, 
14 females). Gynecologic examination, including a transvaginal ultrasound, was 
performed in five females. The demographic data of our cohort are summarized in 
Tables 1a and 1b. All patients were previously described in literature.3,5,7,11,12,13,15,16,20-23
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Table 1a. Demographic data and data on growth and sexual development of a cohort of 45 patients with Meier-
Gorlin syndrome. 
Demographic data Meier-Gorlin syndrome  (% or range)
Total number of patients  45
Number of females/males  28 /17  (62%/38%)
Age range in years  0.3 to 4.7
Region of descent 
    Europe  21            (47%)
    North America  14          (31%)
    North Africa  4  (9%)
    Middle East  3  (7%)
    Asia  1          (2%)
    Middle east/North America  1      (2%)
    Oceania  1           (2%)
Gene mutated  
    ORC1  10          (22%)
    ORC4  7            (16%)
    ORC6  7            (16%)
    CDT1  10          (22%)
    CDC6  1            (2%)
    No known molecular cause  10          (22%)
- Monoallelic mutation ORC1  1
- Monoallelic mutation CDT1  2
- No mutation  7
Intrauterine growth retardation  42/43     (98%)
    Mean birth weight in SDsI  -3.4  (-6.5 to -0.3)
    Mean birth length in SDsI  -3.9  ( -13.2 to 0.0)
    Mean birth head circumference in SDs1  -2.1  (-5.4 to 1.5)
Number of postpubertal/adult patients (14 F/6 M)  20           (44%)
Adult height (≥ 18y)
    Mean female height in cm (7 females)  137.7  (127.0 to 150.8)
    Mean male height in cm (2 males)  147.0    (136.5 to 157.5 )
    Mean in SDsII for both sexes  -4.5   (-6.4 to -2.3)
Adult BMI
   Mean female BMI (5 females)  16.8   (14.3 to 19.8)
   Mean BMI in SDsII (5 females, 1 male)  -3.1   (-4.9 to -0.8)
Adult head circumference (≥ 15y)
   Mean female head circumference in cm (12 females)  50.3    (45.6 to 53.0)
   Mean male head circumference in cm (5 males)  51.9    (44.2 to 57.4)
   Mean in SDsII for both sexes  -2.4   (-5.8 to +1.3)
ISDs calculated using the growth charts of Niklasson et al.27  
IISDs calculated using growth charts of Prader et al.26 
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Anthropometric measurements at birth (length, weight and head circumference 
for gestational age) were standardized using the growth charts from Niklasson and 
Albertsson-Wikland.27 Postnatal growth measurements (height, body mass index 
(BMI) and head circumference for age) were standardized according to the growth 
charts from Prader et al., as used by Ranke et al. in their international evaluation of 
growth and growth hormone therapy.26,28
Endocrinological data (IGF1, stimulated GH, LH, FSH, estrogen and testosterone 
levels) of 15 patients were available and standardized according to Rikken et al.29 GH 
treatment was initiated in nine patients. Two of these patients (P43 and P44, Table 2) 
were prospectively followed, seven were retrospectively analyzed.
In addition to a short stature and small head circumference, microtia is one of the 
most characteristic features of MGS. The ear length of 20 patients was compared to the 
normal values provided by Hall et al.30 The ear morphology of 10 patients is shown in 
Figure 4. A detailed description of the ear morphology of 20 patients according to the 
terminology of Hunter et al. is provided in Supplementary Table 1.31
Statistical analysis
A linear mixed model with random factor patient was used to analyze the standardized 
height and head circumference according to Prader et al. (random intercept model).26,32 
Independent fixed factors were sex, molecular cause and region of descent. Age and 
age x age were included as fixed covariates. When the coefficient of age x age was not 
significant, that is, when there was no indication of a non-linear age trend, the analysis 
was repeated without age x age. In case of non-linearity, the relationships between 
age and growth during the first years and later years were estimated separately 
by including the variables age- and max (0, age-1; the latter variable represents the 
difference between the growth in the first year and second year). Growth data after the 
age of 20 years or after start of GH treatment were excluded from growth analysis. Five 
patients were completely excluded from analysis (three were treated with GH for an 
unknown duration; of one, no measurements before the age of 47 years were available; 
of one, no measurements were available after 17 weeks of gestation). Six patients were 
excluded from growth analysis after GH treatment was initiated. Four hundred fifty two 
measurements of 40 patients were obtained on different ages from birth throughout 
their childhood. Of six patients, only one measurement was available. Of 19 patients, 
five or more measurements were available.
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Results
Pre- and postnatal growth
At birth, mean length was -3.9 SDs, with a mean weight of -3.4 SDs and mean head 
circumference of -2.4 SDs according to Niklasson and Albertsson-Wikland.27 Mean 
birth length was -3.5 SDs according to Prader et al.26 In the first year after birth, length 
dropped significant with 1.7 SDs (P < 0.0001) to -5.2 SDs, relative to the general 
population. In other words, infants with MGS are small at birth, but become even 
smaller in the first year of life, compared to the general population. Thereafter, height 
remained below, but increased in parallel with the population centiles (nonsignificant 
gain of 0.08 SDs/year, until age 15 years (P > 0.05)). Afterwards, (between age 15 and 18 
years) no reliable trend could be calculated. Mean adult height (≥18 years of age) was 
-4.5 SDs (females 137.7 cm, males 147.0 cm), with a BMI of -3.1 SDs (females 16.8 kg/m2, 
one male 15.0 kg/m2) and head circumference of -2.4 SDs (females 50.3 cm, males 51.9 
cm). Stature was proportionate, except in two previously described adult females (P21 
and P22) without known molecular cause.12 One of these females had a span of 136 cm 
and a height of 149 cm, the other had a span of 134 cm and a height of 143.6 cm.
Height appeared to be significantly affected by ethnic origin (P < 0.0001): patients 
from the Middle East were shortest, followed by patients from North America, Europe 
and North Africa. In contrast, BMI and head circumference were not significantly 
influenced by age or ethnic background compared to normal (P > 0.05).
Height and head circumference were significantly influenced by the underlying 
molecular cause (P < 0.0001). Patients with mutations in ORC1 or ORC4 had a 
significantly shorter stature and smaller head circumference than patients with 
mutations in other genes (ORC6, CDT1, CDC6 or unknown genes), such that they were 
4.7 SDs (ORC1) and 3.1 SDs (ORC4) shorter than the others (after adjustment for ethnic 
origin). For head circumference, the differences were 5.0 SDs and 1.6 SDs, respectively.
Prenatal and postnatal growth data are summarized in Table 1a. The trends for height, 
BMI and head circumference for age, using the standardized growth charts according 
to Prader et al., are illustrated in Figure 2a.26 In Figure 2b, the proposed reference 
growth chart for height of MGS patients, derived from this data analysis, is shown. The 
difference between the reference growth curve and the normal curve corresponds to 
the average difference for our patient population. For individual patients the difference 
may depend on ethnic background, gender and mutated gene. However, the slope of 
the curve (growth velocity) is independent of these factors.
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Figure 2. (A) Trends for height, body mass index and head circumference of 33 patients with Meier–Gorlin 
syndrome. Growth measurements for both sexes were standardized according to the growth charts of Prader et al. 
Height dropped significantly with 1.7 SDs in the first year after birth (P < 0.0001) and increased with an average of 
0.08 SDs per year afterwards, until age 15 years (P > 0.05).26 Between age 15 and 18, insufficient data were available 
for statistical analysis. Head circumference and BMI were not significantly influenced by age (P > 0.05). There were 
no differences in growth patterns between males and females. 
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(B) Proposed growth charts for patients with Meier–Gorlin syndrome. This growth chart is based on the trends in 
a cohort of 33 patients with Meier–Gorlin syndrome. Here, the growth pattern (height for age) is shown in 
comparison to the growth charts for boys of Prader et al.26 This growth pattern is the same for males and females. 
After 15 years of age, insuffi cient data were available to calculate a reliable statistical trend. These data can be 
applied to predict height in an individual MGS patient: the growth chart of an individual patient will differ from 
this chart in actual height (i.e., in distance relative to the normal growth chart), but follow the same pattern of 
growth velocity (i.e., shape) as our proposed chart.
0-15 
months 
Growth hormone levels and growth hormone treatment
GH status, assessed by IGF1 and/or stimulated GH measurements, was normal in 12 
out of 15 (80%) patients tested. Low IGF1 levels were detected in one female (-2.3 SDs; 
P21) and two males (-4.6 and -3.3 SDs; P43 and P44, respectively, described below). The 
female was never treated with growth hormone.
GH therapy was initiated in 9 out of 45 patients (20%). An overview of their GH status, 
skeletal age, the period of GH treatment and effect on height is presented in Table 2. 
GH status was normal in seven patients, but abnormal in two (P43 and P44). Skeletal 
age according to Greulich and Pyle was delayed in four patients and unknown in fi ve.33 
A positive effect of GH treatment was seen in the two prospectively followed male 
patients (22%; P43 and P44, Figure 3a,b, Table 2). In both patients, height continued 
to decrease, even after the infancy period, up to the age of 1.5 years and to standard 
deviations of -7 and -6.5. In both, strikingly low IGF1 levels were detected, up to -4.6 SDs, 
with stimulated GH levels of 11.4 and 26 mIU/L. Growth hormone treatment resulted 
in an increase of height velocity in the fi rst year of treatment from approximately 5 cm/
year to more than 10 cm/year, with a total gain of 2 SDs and 3.8 SDs within 2 years after 
the start of treatment, respectively.
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Figure 3. Growth charts of two patients with Meier–Gorlin syndrome showing a positive response to growth 
hormone treatment. Height for age is compared to the growth charts of Prader et al.26 The green highlighted areas 
represent the period of GH treatment. The black/gray dots and arrows represent the bone age at that age. (A) 
Growth chart of Patient 43 (Table 2; Bongers et al. Patient 3)13, height improved 3.8 SDs during GH therapy. (B) 
Growth chart of Patient 44 (Table 2; de Munnik et al. individual i)23 height improved 2 SDs during GH therapy.
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Abnormalities of genital and secondary sexual development
Minor anomalies of external genitalia were present in 19 out of 45 patients (42%). 
Cryptorchidism was seen in 11 out of 17 males (65%; 3 bilateral, 1 unilateral, 5 unknown), 
micropenis was present in two out of 17 males (12%), hypospadias in one (6%). 
Hypoplastic labia majora or minora were present in seven out of 28 females (25%).
Transvaginal ultrasound investigations were performed in five out of 14 postpubertal 
females. A small uterus and polycystic ovaries were observed in two females, while 
no abnormalities were detected in two others. In the fifth female (P22), ultrasound 
investigations, which were performed after premature delivery, showed a shortened 
uterus with a probe length of 4–5 cm. This female had two miscarriages after 17 and 18 
weeks, respectively. No fetal anomalies were detected by ultrasound investigation and 
autopsy. These were the first two pregnancies in a patient with MGS.
Secondary sexual development was affected in 17 out of 20 patients (85%, males 
and females). Axillary hair was sparse or absent in 9 out of 12 patients (75%; 3 males, 
6 females; 8 unknown), pubic hair was sparse in 1 out of 10 patients (10%; male; 10 
unknown). Mammary hypoplasia was present in all 14 postpubertal females. However, 
menarche had occurred at a normal age (before age 14.5 years) and menstrual cycles 
were regular in these females. Though endogenous hormonal levels were normal, 
exogenous estrogen treatment was initiated in five females. An increase in breast size 
was reported in two females. A very mild increase was observed in a third female, after 
treatment with 100 μg ethinylestradiol between 16 and 18 years of age. In contrast, no 
increase in breast size was seen in two other females treated with 20 μg ethinylestradiol 
between 13.5 and 16 years of age. Hypoplastic nipples were reported in one male, but 
nipples were not hypoplastic in six postpubertal females (unknown in the other eight 
females).
Ears
Microtia (ear length <-2 SDs) was present in 44 out of 45 MGS patients (98%). The 
mean right ear length was -5.8 SDs (20 patients, range -7.3 to -3.1 SDs), the mean left 
ear length -5.3 SDs (20 patients, range -7.9 to -3.2 SDs). Most ears were small, with a 
shelved antihelix, prominent crus and small or absent ear lobes. The ear anomalies 
of 10 MGS patients are shown in Figure 4. A detailed description according to the 
morphology of Hunter et al. of the ear malformations of 20 patients is provided in 
Supplementary Table 1.31
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Figure 4. The ear morphology of 10 patients with Meier–Gorlin syndrome. The ears are arranged from most (P38) 
to least underdeveloped (P18, only microtia). Common features were microtia (10; 100%), a shelved antihelix (4; 
40%), prominent crus helix (5; 50%) and small or absent ear lobes (6; 60%). A detailed description of the ear 
anomalies in 20 MGS patients is provided in Supplementary Table 1. IPatients 38, 37 and 18 were previously 
described by Bicknell et al. (patients 10, 11 and 17).21 IIPatients 43 and 20 were previously described by Bongers et al. 
(patients 4 and 2, respectively).13 IIIPatient 42 was previously described by Bicknell et al. (patient 18) and Bongers et 
al. (Patient 3).13,21 IVPatients 36 and 13 were previously described by Bicknell et al. (patients 8 and 9) and Lacombe et 
al. (patients 2 and 3).7,21 VPatients 44 and 45 were previously described by de Munnik et al. (individual i).23
Discussion
In this first retrospective and partially prospective study of growth in patients with MGS, 
we show that the growth retardation in MGS predominantly arises prenatally and in 
early infancy. Mean birth length was -3.5 SDs.26 In the first year of life, relative length 
further decreased to -5.2 SDs. In the following years, growth velocity stayed normal 
with a height curve nearly parallel to normal and a mean adult height of -4.5 SDs. This 
pattern is consistent with an intrinsic growth problem of reduced cellular proliferation, 
though, surprisingly, growth velocity post infancy is not perturbed. Alternatively, 
placental dysfunction could potentially cause growth impairment in MGS prenatally, 
while feeding problems, present in almost all MGS patients during the first year of life, 
might contribute to the growth retardation. 
Global growth, as reflected by both height and head circumference, was influenced 
by the underlying molecular cause: ORC1 mutations caused the most severe growth 
retardation, followed by ORC4 mutations. This might represent a differential 
sensitivity to efficient DNA replication, of mutations in different pre-replication 
complex subunits, or simply reflect the strength of specific mutations, of which there 
are a limited number in each subunit so far reported. However, the limited number 
of patients with a mutation in one of the five pre-replication complex genes and the 
inclusion of patients with all features of the classical triad of clinical characteristics 
might have introduced ascertainment bias in these results. Centile charts for height, 
weight and head circumference cannot be established given the rarity of this condition, 
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the restricted size of our cohort and the lack of measurements at standardized ages.
Our data have clinical utility and will be useful in predicting the growth pattern during 
different stages of life of future patients with MGS. Our data can be used to predict the 
height of a patient, since height decreases with 1.7 SDs during the first year of life and the 
growth velocity is nearly equal to the normal growth velocity thereafter (Figure 2b). The 
actual height of the proposed growth chart of Figure 2b corresponds to the average height 
of our patient group. Corresponding curves for individual patients with different gender, 
ethnic background or mutated gene, would lie closer to or further away from the normal 
curve according to Prader et al., but the growth velocity is independent of these factors, so 
they would all run parallel to our proposed growth chart of Figure 2b.26 This is in contrast 
to growth curves in other syndromes, such as achondroplasia or Turner’s syndrome.34,35
In two MGS patients, growth hormone treatment turned out to be successful in 
improving height. Growth patterns in these patients differed from the general pattern 
in our cohort, because growth velocity continued to be reduced after early infancy and 
in particular, extremely low IGF1 levels were found (Table 2). Notably though, these 
two patients had a classic MGS phenotype with microtia and patellar aplasia and the 
underlying molecular cause is currently unknown for both of them. It is tempting to 
speculate that the gene causing MGS in these two patients might play an important 
role in the growth hormone axis. Furthermore, this suggests that IGF1 measurements 
can be used to target treatment to a subset of MGS patients that will respond to GH 
therapy, in contrast to those with mutations in the pre-replication complex, who 
appear unlikely to benefit from GH therapy.
Mammary hypoplasia was present in all postpubertal females. Besides an early 
disturbance of embryonic development, (partial) insensitivity to estrogen as a cause of 
secondary sexual underdevelopment may be considered. This would explain the lack of 
response to estrogen treatment in two patients with mammary hypoplasia. However, 
the presence of normal menstrual cycles in these patients contradicts this theory.
In the future, further prospective growth studies would be useful to confirm our results 
and establish more detailed growth charts, as well as more systematically assessing 
the effect of GH treatment in MGS patients. Further studies of an increased number of 
MGS patients with a known molecular cause and elucidation of the genetic defect in 
MGS patients with a yet unknown molecular cause will further define the phenotypic 
spectrum of MGS, including growth.
Finally, animal studies (mouse models) might contribute to gain insight into the 
embryonic development of MGS patients and unravel pathogenic mechanisms 
underlying the growth retardation and underdevelopment of genitalia, secondary 
sexual characteristics and ears in MGS.
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Supplementary Table 1. Overview of ear anomalies in 20 patients with Meier-Gorlin syndrome. The ear with the 
most severe anomalies is described first (P38), that of the patient with the least severe ear anomalies last (P18). The 
description follows the alphabetical order as in the article from Hunter et al.31
Patient 38II Patient 43IV Patient 42III Patient 36I Patient 13I Patient 37II Patient 44V Patient 45V Patient 20V Patient 18II Patients
2, 6, 9-12
23, 24, 33, 
342, 5, 6
Total
Mutated Gene CDT1 U CDC6 ORC6 ORC6 ORC6 U U U: ORC1
Monoallelic
CDT1 U, ORC1 
ORC4,
ORC6
Sex M M M M F M M M F F 8F/2M 11F/9M
Mutations [c.1385G>A] 
[c1560C>A]
- [c.968C>G]
[c.968C>G]
[c.257_
258delTT] 
[c.695A>C]
[c.257_
258delTT] 
[c.695A>C]
[c.257_
258delTT] 
[c.695A>C]
- - [c.1721C>T] [c.1081C>T] 
[c.1357C>T]
Microtia + + + + + + + + + + 10/10 20 (100%)
Antihelix stem
  Prominent + - + + - - - - - - 0/10 3  (15%)
  Shelfed - - - + - + + + - - 5/10 9  (45%)
Tragus
  Underdeveloped - + + - - - - - + - 1/10 4  (20%)
  Prominent - - - - - - - + - - 0/10 1  (5%)
Antitragus
  Underdeveloped + - - - - - - + - - 3/10 5  (25%)
  Prominent - - - - - + + - - - 1/10 3  (15%)
Protruding ears - + - - - - - + - - 1/15 3  (15%)
Superior crus
  Underdeveloped - + - - + - - + - - 1/10 4  (20%)
  Prominent + - + + - - - - - - 1/10 4  (20%)
Crus helix
  Underdeveloped - - - - - - + + - - 2/10 4  (20%)
  Prominent + - + + + - - - + - 5/10 10 (50%)
  Expanded terminal
  portion
+ - - + - - - - - - 1/10 3  (15%)
Helix
  Darwinian notch + - - + + - - - - - 0/10 3  (15%)
  Darwinian tubercle  + - - - + - - - + - 0/10 3  (15%)
  Underfolded - + - - - - - + - - 0/10 2  (10%)
  Overfolded - - - - + - - - - - 3/10 1  (15%)
Ear lobe
  Absent/small + + + - + - + + - - 4/10 10 (50%)
  Forward facing - + + - - - - - - - 0/10 2  (10%)
  Attached + - - - - - - - - - 1/10 2  (10%)
U = Unknown. 
IPatients 13 and 36 were previously described by Bicknell et al. (patients 8 and 9) and Lacombe et al. (patients 2 and 
3).7,21
IIPatients 9, 18, 37 and 38 were previously described by Bicknell et al. (patients 5, 10, 11, and 17).21 
IIIPatient 42 was previously described by Bicknell et al. (patient 18) and Bongers et al. (patient 3).13,21
IVPatient 20 and 43 were previously described by Bongers et al. (patient 4 and 2, respectively).13
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VPatients 12, 33, 34, 44 and 45 were not previously described.
VIPatient 2 was previously described by Bicknell et al.(patient 3);22 patients 10 and 11 were previously described 
by Bicknell et al. (patients 6 and 7), Bongers et al. (patients 5 and 6) and Guernsey et al., 2011 (patients 1768 en 
1769);13,20,21 Patient 6 was previously described by Guernsey et al. (patient1882);20 patients 23 and 24 were previously 
described by Cohen et al.5
Supplementary Table 1. Overview of ear anomalies in 20 patients with Meier-Gorlin syndrome. The ear with the 
most severe anomalies is described first (P38), that of the patient with the least severe ear anomalies last (P18). The 
description follows the alphabetical order as in the article from Hunter et al.31
Patient 38II Patient 43IV Patient 42III Patient 36I Patient 13I Patient 37II Patient 44V Patient 45V Patient 20V Patient 18II Patients
2, 6, 9-12
23, 24, 33, 
342, 5, 6
Total
Mutated Gene CDT1 U CDC6 ORC6 ORC6 ORC6 U U U: ORC1
Monoallelic
CDT1 U, ORC1 
ORC4,
ORC6
Sex M M M M F M M M F F 8F/2M 11F/9M
Mutations [c.1385G>A] 
[c1560C>A]
- [c.968C>G]
[c.968C>G]
[c.257_
258delTT] 
[c.695A>C]
[c.257_
258delTT] 
[c.695A>C]
[c.257_
258delTT] 
[c.695A>C]
- - [c.1721C>T] [c.1081C>T] 
[c.1357C>T]
Microtia + + + + + + + + + + 10/10 20 (100%)
Antihelix stem
  Prominent + - + + - - - - - - 0/10 3  (15%)
  Shelfed - - - + - + + + - - 5/10 9  (45%)
Tragus
  Underdeveloped - + + - - - - - + - 1/10 4  (20%)
  Prominent - - - - - - - + - - 0/10 1  (5%)
Antitragus
  Underdeveloped + - - - - - - + - - 3/10 5  (25%)
  Prominent - - - - - + + - - - 1/10 3  (15%)
Protruding ears - + - - - - - + - - 1/15 3  (15%)
Superior crus
  Underdeveloped - + - - + - - + - - 1/10 4  (20%)
  Prominent + - + + - - - - - - 1/10 4  (20%)
Crus helix
  Underdeveloped - - - - - - + + - - 2/10 4  (20%)
  Prominent + - + + + - - - + - 5/10 10 (50%)
  Expanded terminal
  portion
+ - - + - - - - - - 1/10 3  (15%)
Helix
  Darwinian notch + - - + + - - - - - 0/10 3  (15%)
  Darwinian tubercle  + - - - + - - - + - 0/10 3  (15%)
  Underfolded - + - - - - - + - - 0/10 2  (10%)
  Overfolded - - - - + - - - - - 3/10 1  (15%)
Ear lobe
  Absent/small + + + - + - + + - - 4/10 10 (50%)
  Forward facing - + + - - - - - - - 0/10 2  (10%)
  Attached + - - - - - - - - - 1/10 2  (10%)
U = Unknown. 
IPatients 13 and 36 were previously described by Bicknell et al. (patients 8 and 9) and Lacombe et al. (patients 2 and 
3).7,21
IIPatients 9, 18, 37 and 38 were previously described by Bicknell et al. (patients 5, 10, 11, and 17).21 
IIIPatient 42 was previously described by Bicknell et al. (patient 18) and Bongers et al. (patient 3).13,21
IVPatient 20 and 43 were previously described by Bongers et al. (patient 4 and 2, respectively).13
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Abstract
Meier-Gorlin syndrome (MGS) is a rare autosomal recessive primordial dwarfism 
disorder, characterized by microtia, patellar aplasia/hypoplasia and a proportionate 
short stature. Associated clinical features encompass feeding problems, congenital 
pulmonary emphysema, mammary hypoplasia in females and urogenital anomalies, 
such as cryptorchidism and hypoplastic labia minora and majora. Typical facial 
characteristics during childhood comprise a small mouth with full lips and micro-
retrognathia. During ageing, a narrow, convex nose becomes more prominent. The 
diagnosis MGS should be considered in patients with at least two of the three features 
of the clinical triad of microtia, patellar anomalies and pre- and postnatal growth 
retardation. In patients with short stature and/or microtia, the patellae should be 
assessed with care by ultrasonography before age 6 or radiography thereafter. 
Mutations in one of five genes (ORC1, ORC4, ORC6, CDT1 and CDC6) of the pre-
replication complex, involved in DNA-replication, are detected in approximately 67-
78% of patients with MGS. Patients with ORC1 and ORC4 mutations appear to have the 
most severe short stature and microcephaly.
Management should be directed towards in-depth investigation, treatment and 
prevention of associated problems, such as growth retardation, feeding problems, 
hearing loss, luxating patellae, knee pain, gonarthrosis and possible pulmonary 
complications due to congenital pulmonary emphysema with or without broncho- or 
laryngomalacia.
Growth hormone treatment is ineffective in most patients with MGS, but may be 
effective in patients in whom growth continues to decrease after the first year of life 
(usually growth velocity normalizes after the first year) and with low levels of IGF1. At 
present, few data is available about reproduction of females with MGS, but the risk of 
premature labor might be increased.
Here, we propose experience-based guidelines for the regular care and treatment of 
MGS patients.
40970 Munnik, Sonja de.indd   80 04-07-16   14:02
Meier-Gorlin syndrome
81
2.3
Review
In this review, we outline the clinical symptoms of MGS and propose experience-based 
guidelines for care and treatment of MGS patients. The reported percentages of clinical 
symptoms are calculated from the frequency of these symptoms in the 38 patients 
with bi-allelic mutations in one of the five causative pre-replication complex genes 
(ORC1, ORC4, ORC6, CDT1 and CDC6) described in literature.1-5 Clinical symptoms that 
may affect management and that are present only in patients with clinically diagnosed 
MGS (in whom the molecular defect is unknown) are mentioned as well.
Disease name and synonyms
Meier-Gorlin syndrome (MGS; MIM#224690, ORPHA 2554).
Ear patella short stature syndrome (EPS).
Definition
Meier-Gorlin syndrome (MGS) is characterized by the triad of microtia, absent or small 
patellae and short stature. At least two of these three clinical features are present in 
97% (32/33) of patients with MGS, the combination of patellar a-/hypoplasia and 
microtia being the most prevalent. Microtia, however, can be mild. One patient was 
described with short stature, but without microtia or patellar anomalies, indicating 
that the clinical phenotype might be more variable than previously suspected.3,4
Epidemiology
Until now, 67 patients with MGS have been described since the first reported patients 
by Meier in 1959 and Gorlin in 1975 (30 males; 36 females; 1 of unknown sex; age range 
0.3-55 years).1-22 The underlying molecular defect is known in 38 of these patients.1-5
The exact prevalence of MGS has not been determined, but is estimated to be less than 
1-9/1,000,000 based on the number of cases described in literature. However, this 
might be an underestimation, due to underreporting and missed diagnoses.
Clinical description
Patients with MGS present with a recognizable phenotype. The classical triad of clinical 
features comprises microtia, patellar aplasia or hypoplasia and pre- and postnatal 
growth retardation.
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Microtia is present in almost all patients with MGS (34/36; 94%). Severity ranges from 
mild to severe microtia, where the ears appear underdeveloped and low-set. Narrow 
ear canals and conductive hearing loss may accompany microtia.
Patellar anomalies are among the most frequent findings in MGS (31/33; 94%). In most 
patients, patellae are absent, but they may be hypoplastic.
Prenatal growth is delayed in the majority of patients with MGS. Intra uterine growth 
retardation (IUGR) was present in 97% (35/36), with a mean birth weight of −3.8 
SDs (range < −6.5 SDs to −0.3 SDs), five infants were born prematurely (5/30; 17%; 
terms ranging from 28 to 36 weeks of gestation).2-4 In three cases, the pregnancy was 
terminated because of severe IUGR, in combination with congenital anomalies.5
We studied growth extensively in our cohort of 45 MGS patients (35 patients with a 
known and 10 with an unknown molecular defect).23 Postnatal growth was delayed 
during the first year of life. Growth velocity was almost normal thereafter, with patients 
growing parallel to the normal growth charts without significant catch up growth. In 
this cohort, height varied considerably between MGS patients and ranged from −9.6 
SDs to −0.4 SDs. The average adult height in the MGS patients with a known underlying 
molecular defect was −5.5 SDs (five patients).
Microcephaly (head circumference < −3 SDs) was present in 43% (13/30) of patients, with 
a head-circumference ranging from −9.8 SDs to +1.7 SDs. Height differed significantly
between the gene mutated, ethnic background and gender. Patients with mutations 
in ORC1 and ORC4 had a significantly shorter stature (a difference of 4.7 SDs and 3.1 
SDs, respectively) and smaller head circumference (a difference of 5.0 SDs and 1.6 SDs, 
respectively), than patients with mutations in ORC6, CDT1 or CDC6.4,23
Growth hormone therapy was unsuccessful in MGS patients with a known molecular 
defect. However, growth hormone therapy was successful in two patients with a clinical 
diagnosis of MGS, whose growth velocity continued to be low after the first year and 
who had low levels of IGF1 (−3.3 SDs and −4.6 SDs).23
All postpubertal females (10/10; 100%) had mammary hypoplasia. Transvaginal 
ultrasound investigations were performed in five adult females (clinically diagnosed 
with MGS). A small uterus was reported in three of them and polycystic ovaries were 
reported in two of these five females.23
Axillary hair is often sparse or absent, while pubic hair generally is normal in both 
males and females.
Furthermore, patients with MGS have a recognizable facial phenotype with 
microstomia, full lips and retro-/micrognathia at young age (Figure 1). The nose can be 
narrow and convex with a high nasal bridge. These characteristics of the nose become 
more prominent with age.
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Figure 1. Facial features of Meier-Gorlin syndrome. (A) A girl aged 7 years and 9 months with two mutations in 
ORC4. (B) A 14 year old girl, who carries one mutation in ORC1. Both show the characteristic facial features of MGS, 
including microtia, a prominent nose with a convex nasal profile, a small mouth with full lips and retro-/
micrognathia.
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Intellect is normal in the majority of patients with MGS (30/31; 97%), although delayed 
motor development and/or speech development without intellectual disability (ID) 
were present in 19% (6/32) and 16% (5/32) of patients, respectively. A mild ID was 
present in one patient (3%).
Respiratory tract anomalies are relatively frequent. Congenital pulmonary emphysema 
was reported in 43% (12/28) of patients with MGS. Congenital pulmonary emphysema 
is usually detected in the neonatal period or early in childhood (10/12; 83%), but can be 
diagnosed late in childhood. Bronchomalacia, laryngomalacia and/or tracheomalacia 
are reported in 42% (10/24) of subjects. Recurrent respiratory tract infections occur 
often during childhood, but disappear thereafter.
Congenital cardiac anomalies appear to be rare: they have been described in two 
patients (2/30; 7%: one ventricular septal defect, one patent ductus arteriosus).
Feeding problems are seen in approximately 80% (26/32) of patients with MGS 
during infancy and young childhood. Problems range from a small appetite (which 
may correlate with the short stature of infants), to gastroesophageal reflux with 
administration of tube feeding or gastrostomy interventions in 35% (11/31).
Anomalies of the urogenital tract are frequently reported, especially cryptorchidism in 
males (9/14; 64%) and hypoplastic labiae in females (5/21; 24%).
A delayed bone age and genu recurvatum are often seen in patients with MGS. Joint 
contractures, including club feet, were present in 23% (7/30) of patients.
Not much is known about the reproduction of patients with MGS. Recently, a previously 
described woman clinically diagnosed with MGS gave birth prematurely twice after 17 
and 18 weeks of gestation, respectively.23
Aetiology
MGS is an autosomal recessive disorder. Mutations in five genes of the pre-replication 
complex (ORC1, ORC4, ORC6, CDT1 and CDC6), were detected in patients with MGS. 
Mutation detection rate was approximately 78% in a cohort of 45 patients with MGS.4 
The pre-replication complex (PRC) assembles on genomic DNA at origins of replication.
The exact underlying mechanism for the clinical features of MGS remains to be 
elucidated. The impaired function of the PRC is presumed to reduce the G1 phase of 
DNA replication and to limit the available time for origin licensing. This limitation is 
hypothesized to become rate-limiting, thereby impeding cellular proliferation. This 
would result in a reduction of the total cell number and thereby diminish overall 
growth.24,25 Another possible mechanism affecting cell cycle progression was identified 
in ORC1 depleted cells, where a defect in the rate of formation of primary cilia was 
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demonstrated to influence cell cycle progression.26 Alternatively, the ORC1 subunit 
of the PRC contains distinctive domains that regulate centriole and centrosome copy 
number. It is suggested that mutations in these domains alter centrosome duplication 
and thereby contribute to the growth retardation and microcephaly in MGS.27
Mutations in ORC1 and ORC4 appear to cause a more severe short stature and 
microcephaly than mutations in other genes. Furthermore, compound heterozygous 
missense- and loss of function mutations appear to have a more severe effect on the 
phenotype than homozygous or compound heterozygous missense mutations.4 No 
patients are known with homozygous or compound heterozygous loss of function 
mutations, suggesting that these mutations cause a lethal phenotype. No additional 
genotype-phenotype correlations were recognized.
Diagnostic methods
The clinical diagnosis of MGS can be established in the presence of microtia, patellar 
aplasia or hypoplasia and proportionate short stature. However, about 18% (6/33) of 
patients show only two out of three cardinal features and one patient was described 
with short stature only. 
The diagnosis MGS should be considered in patients with short stature or microtia and 
the presence of these features necessitates comprehensive examination of the patellae. 
In infants, ultrasound investigations are advised, since patellae are radiolucent in the 
first 5–6 years of life and will not be visible by conventional radiography.
Furthermore, the characteristic facial features and mammary hypoplasia are specific 
findings for MGS and will assist in diagnosing MGS.
In a patient clinically suspected to have MGS, the diagnosis can be confirmed by 
detecting compound heterozygous or homozygous mutations in one of the five pre-
replication complex genes (ORC1, ORC4, ORC6, CDT1 and CDC6). Mutations were 
detected in approximately 78% of patients clinically suspect for MGS.4 In patients with 
a severe short stature and/or microcephaly, starting with the analysis of ORC1 and 
ORC4 should be considered, since mutations in these two genes are associated with 
a significantly shorter stature and smaller head circumference than mutations in the 
other genes.4,23
40970 Munnik, Sonja de.indd   85 04-07-16   14:02
Chapter 2
86
Differential diagnosis
The association of microtia, patellar anomalies and short stature as such has not been 
described in other syndromes.
MGS is a part of the primordial dwarfism spectrum. These disorders are characterized 
by microcephaly and prenatal short stature. Other primordial dwarfism disorders 
include Seckel syndrome and Microcephalic Osteodysplastic Primordial Dwarfism 
(MOPD) type I, II and III. However, even though these syndromes show considerable 
overlap with MGS, they are clinically distinct disorders. In Seckel syndrome, short 
stature is proportionate, as in MGS. However, height and head circumference are 
generally much smaller in Seckel syndrome than in MGS (average −7.1 SDs and −8.7 
SDs, respectively)28, the facial appearance differs from MGS and patients generally 
have ID. These patients can have patellar anomalies and microtia, but these findings 
are not frequently present, contrary to MGS, where they are mandatory features.
Patients with MOPD type 1 and 2 have a disproportionate short stature and a skeletal 
dysplasia, clearly distinguishing these disorder from MGS. MOPD type 3 is rare and it 
is suggested this is the same disorder as MOPD type 1. Stature in patients with MOPD 
type 3 was proportionate, though.
Patellar anomalies and short stature are cardinal features of RAPADILINO and 
genitopatellar syndrome. However, these syndromes differ from MGS in the lack of 
microtia (both), the presence of radial ray defects (RAPADILINO) and developmental 
delay and agenesis of the corpus callosum (genitopatellar syndrome).
If patellar anomalies are present and microtia and short stature are absent, nail 
patella syndrome should be considered. In nail patella syndrome, familial patellar a-/
hypoplasia is almost always accompanied by nail dysplasia, including the pathognomic 
tri-angular lunulae.
An overview of other syndromes with patellar anomalies, such as small patella syndrome, 
patella aplasia-hypoplasia and trisomy 8 mosaicism is provided by Bongers et al.29
In patients with microtia, other diagnoses to contemplate are branchio oto renal 
syndrome, Townes-Brocks syndrome, Treacher-Collins syndrome, Nager syndrome, 
Miller syndrome and CHARGE association.
Genetic counselling
MGS is an autosomal recessive disorder. The recurrence risk for a couple with an affected 
child is 25%. Parents are obligate heterozygotes. Heterozygotes are asymptomatic.
In literature, three patients with a classic MGS phenotype and mono-allelic mutations 
(one in ORC1, two in CDT1) were described. However, their healthy fathers carried the 
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same mutation. Therefore, it is expected that these patients either carry a second 
mutation in ORC1 or CDT1 that cannot be detected with the current molecular 
techniques, or that their symptoms were caused by a different molecular defect.
To our knowledge, so far, no patients with MGS have had any children. However, future 
reports are expected. Offspring of a patient with MGS are obligate heterozygotes.
The risk of having an affected child with MGS is low (<1%), since carrier frequencies and 
thus the risk of a partner being a carrier are low.
Antenatal diagnosis
When the underlying molecular defect is known, prenatal diagnosis by chorionic villus 
sampling or amniocentesis is possible. If no causative gene defects are identified, 
prenatal ultrasound investigations at 18–20 weeks of gestation may contribute to the 
recognition of MGS. However, it is unknown whether overall growth is already delayed 
at this term. Microtia and congenital pulmonary emphysema can be seen and certain 
facial features, such as micrognathia may be detected. Nonetheless, because of the 
variable expression of the disorder and the lack of structural congenital anomalies, 
ultrasound abnormalities may be absent or mild and difficult to interpret. The ethical 
issues of prenatal diagnosis and possible termination of a pregnancy for a disorder 
with a variable expression and a relatively low chance of life-threatening complications 
or intellectual disability, should be discussed.
Management
Especially during childhood, multidisciplinary care is needed.
Here, we propose guidelines for regular care and treatment, based on clinical 
experience. An overview of the proposed guidelines for diagnostic evaluation and 
management of patients with MGS is presented in Supplementary Table 1.
Ears
Microtia can be associated with narrow ear canals and conductive hearing loss. 
Therefore, at the time of diagnosis, a patient suspected to have MGS should be 
examined by an ear-nose-throat specialist. Afterwards, examinations are indicated 
when hearing loss appears to be present.
Patellae
Patellar aplasia or hypoplasia may lead to instability of the knee joint, pain and early 
gonarthrosis. A multidisciplinary approach, including examination by an orthopedic
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surgeon and rehabilitation physician is advised. Special shoes and advise about 
strength enhancing exercises and sports, may be provided, especially since patients 
with MGS often have hypermobile joints and are more prone to develop pes planus.
Growth and growth hormone treatment
Growth hormone treatment was effective in only four patients, one with ORC4 
mutations, one with CDC6 mutations and two without mutations.4,23 In one patient 
with CDC6 mutations, height improved from −5 SDs to −3 SDs during the first 4 years. 
In two patients without mutations, height improved from −6.8 SDs to −3.0 SDs and 
from −5.7 SDs tot −3.7 SDs.
In a child with MGS, endocrinological evaluation (IGF1 and stimulated growth hormone 
measurements) is advised. Growth hormone treatment should be considered in a 
patient with low IGF1 levels and further delay of growth after the first year.
Feeding problems
Feeding problems can be severe, necessitating tube feeding and a gastrostomy to 
optimize nutrition. Gastroesophageal reflux as a cause should be considered.
Congenital pulmonary emphysema
Surgical resection can be performed when respiratory distress is life-threatening 
or debilitating. In older patients with MGS and congenital pulmonary emphysema 
treatment with selective Beta2-antagonists can be considered. 
Congenital cardiac anomalies
Since 7% of the reported MGS patients had a congenital cardiac anomaly, we advise 
cardiac screening (physical examination, ECG and ultrasound investigations) at the 
time of diagnosis.
Mammary hypoplasia
Treatment of mammary hypoplasia with exogenous estrogen can be debated in 
females with MGS. Estrogen therapy was reported to be successful in two females with 
MGS. In a third female, minor effects were reported. In two other females, no effect was 
seen.4,23 Breast augmentation surgery can be considered.
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Reproduction
Males born with cryptorchidism may have fertility problems. One female with MGS had 
two consecutive miscarriages. Her uterus was described to be small. No information 
about other pregnancies is available, but preconception gynaecologic examinations 
should be considered and possible preterm labor should be a point of attention in 
obstetric care of females with MGS, especially since gynecologic evaluation in four 
other females with MGS revealed a small uterus and polycystic ovaries in two of them.23
Prognosis
Life span is expected to be normal for most individuals with MGS. Osteoarthritis of the 
knees, secondary to patellar anomalies, may occur at a younger age than usual.
Life threatening complications that may accompany MGS are severe congenital 
pulmonary emphysema and cortical malformations. When severe congenital 
anomalies and/or severe respiratory problems are absent, however, there is no reason 
to expect an abnormal life span.
Four reported patients with MGS were deceased (11%) and three pregnancies were 
terminated because of ultrasound abnormalities, including severe IUGR (8%).3-5,16
One patient (with ORC1 mutations) passed away after 3.5 months. He had a severe 
cortical dysplasia, pachygyria and ventricular enlargement, cranial suture stenosis, 
congenital emphysema of the lung and his pancreatic tail was absent. His brother 
died in utero after 17 weeks of gestation. Both patients exhibited microtia and a severe 
growth retardation. A third patient (with CDT1 mutations) deceased after a sudden 
cardiac arrest. He had congenital pulmonary emphysema for which he required 
surgery. His sister passed away after 3 months. She had severe respiratory problems 
due to a tracheobronchomalacia with progressive pulmonary emphysema. 
Unresolved questions
The long-term risks of congenital pulmonary emphysema in patients with MGS need 
to be evaluated through long-term follow-up. Furthermore, future reports about 
reproduction in patients with MGS have to be awaited to assess the exact reproductive 
risks.
Approximately 22% of patients with a classical clinical phenotype of MGS lacked 
mutations in one of the five known genes of the pre-replication complex.4 These 
patients might have mutations in one of the five known genes we are unable to detect 
with current sequencing techniques, or their symptoms may be caused by mutations in 
other genes of the pre-replication complex or in pathways connected to this complex.
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It is currently unknown why patients with ORC1 and ORC4 mutations appear to have 
shorter stature and smaller head circumference compared to patients with mutations 
in other genes. Further understanding of the role of the different genes of the pre-
replication complex during growth and development might contribute to gain insight 
in these differences.
Conclusions
Here, we provide an overview of the clinical features of Meier-Gorlin syndrome and 
guidelines for management and treatment of associated problems in this rare disorder.
MGS is an autosomal recessive primordial dwarfism disorder characterized by microtia, 
patellar a-/hypoplasia and short stature and often accompanied by feeding problems,
respiratory problems, mammary hypoplasia and urogenital anomalies.
Multidisciplinary care, directed towards diagnosis and treatment of ear anomalies and/
or hearing loss, patellar anomalies, feeding problems, respiratory problems and possible 
reproductive issues, is necessary to assure optimal medical care. Endocrinologic testing 
should be routinely performed in all children with MGS, although growth hormone 
treatment is not beneficial in most patients with MGS.
Molecular analysis of the five known genes for MGS (ORC1, ORC4, ORC6, CDT1 and CDC6) 
is important in genetic counseling. A molecular diagnosis assists in determining the 
exact recurrence risk and enables future reproductive options, such as preimplantation 
genetic diagnosis and invasive diagnostic testing during pregnancy.
Since a molecular diagnosis cannot be established in 20-35% of patients with MGS, 
further studies are necessary to identify the underlying genetic defects in these 
patients.
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Abstract
Background Floating-Harbor syndrome (FHS) is a rare condition characterized by short 
stature, delays in expressive language and a distinctive facial appearance. Recently, 
heterozygous truncating mutations in SRCAP were determined to be disease-causing. 
With the availability of a DNA based confirmatory test, we set forth to define the 
clinical features of this syndrome.
Methods and results Clinical information on fifty-two individuals with SRCAP mutations 
was collected using standardized questionnaires. Twenty-four males and twenty-eight 
females were studied with ages ranging from 2 to 52 years. The facial phenotype and 
expressive language impairments were defining features within the group. Height 
measurements were typically between minus two and minus four standard deviations, 
with occipitofrontal circumferences usually within the average range. Thirty-three of 
the subjects (63%) had at least one major anomaly requiring medical intervention. We 
did not observe any specific phenotype-genotype correlations.
Conclusions This large cohort of individuals with molecularly confirmed FHS has 
allowed us to better delineate the clinical features of this rare but classic genetic 
syndrome, thereby facilitating the development of management protocols.
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Background
Floating-Harbor syndrome (FHS; MIM 136140) is a rare disorder characterized by short 
stature with delayed bone age, deficits in expressive language and a distinctive facial 
appearance. The name of the syndrome is derived from the two hospitals where the 
first patients were reported over 35 years ago.1,2 Recently, we used exome sequencing 
to investigate a cohort of 13 unrelated individuals with classic features of FHS and 
identified heterozygous mutations in SRCAP (MIM 611421) as causative of this disorder.3 
All reported mutations were truncating and occurred between codons 2,407 and 2,517 
in exon 34 resulting in loss of three C-terminal AT-hook motifs. SRCAP encodes a SNF2-
related chromatin-remodeling ATPase that serves as a coactivator for CREB-binding 
protein, better known as CBP, the major cause of Rubinstein-Taybi syndrome (RTS). The 
disrupted interaction between these two proteins likely explains some of the clinical 
overlap between FHS and RTS.4 The mechanism of disease in FHS is suspected to be 
dominant-negative due to the non-random clustering of truncating mutations in the 
final exon that results in the loss of the major transactivation function of SRCAP located 
in a 655 residue C-terminal fragment, evidence that expression of a construct solely 
consisting of the CBP interaction domain of SRCAP strongly inhibits CREB-mediated 
transactivation in a dominant-negative fashion and the existence of patients with 
haploinsufficiency of SRCAP who do not have features of FHS.3,5
Many of the features of FHS are non-specific (short stature, delayed bone age and 
language delays) and if the distinctive facial features are not recognized, this diagnosis 
can be difficult. Several years ago, Feingold provided a thirty-two year follow-up on the 
first reported patient accompanied by a review of the literature.6 He suggested that 
some of the patients reported to have FHS did not fit the classical description and likely 
had a different condition. With the availability of a molecular test, we are now able to 
further delineate the distinctive and recognizable features of this syndrome.
Methods
Subjects and clinical data
Individuals with a presumptive clinical diagnosis of FHS were invited to be part of 
this study. Clinical data was collated from three sources: FORGE Canada Consortium 
(Finding of Rare Disease Genes in Canada), based at the Children’s Hospital of 
Eastern Ontario, the Manton Center for Orphan Disease Research at Boston Children’s 
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Hospital and the Radboud University Nijmegen Medical Centre. All samples that 
were referred for analysis were accepted for the study. Approval of the study design 
was in compliance with the Helsinki Declaration and was obtained from each of the 
participating institutions’ research boards. Free and informed consent was obtained 
from each study subject (or guardian, if appropriate) prior to enrollment. Recruitment 
e-mails were sent to all members of the Floating-Harbor syndrome support group. 
Interested families or physicians contacted the genetic counselor at the Manton 
Center. A medical history questionnaire was administered to the family or physician via 
telephone, which reviewed all pertinent medical and developmental history, as well 
as FHS-specific questions (Supplementary File 1). Referring providers who submitted 
cases directly to the above institutions completed the same questionnaire. In most 
cases, clinical photographs were available prior to molecular testing and the likelihood 
of finding a mutation was noted. Due to the diversity of the sample sources, there was 
wide pre-test probability of referred individuals actually having FHS, as this is a rare 
condition and most clinicians do not have familiarity with it. The clinical information 
from the first 13 subjects described by Hood et al. was also included.3
Molecular analysis
Sanger sequencing of exons 31–34 of SRCAP was performed using DNA samples 
from individuals with suspected FHS (Supplementary Table 1). When available, 
parental studies were performed to determine de novo or inherited status. The clinical 
information, from twenty-seven individuals who did not carry a mutation in exons 
31–34 of SRCAP, was used to help clarify key diagnostic features. For three individuals, 
who most closely resembled the FHS phenotype and for which no mutations were 
identified in exon 34, complete sequencing of the SRCAP gene was performed (primer 
sequences available on request).
Results and discussion
Molecular
In total, 24 males and 28 females were identified with mutations in SRCAP; 39 new 
individuals and 13 previously reported.3 Ages at time of data collection ranged from 
two years to 52 years of age. The average age of diagnosis was 8 years. Two mother/
daughter pairs and a number of the other subjects have been previously reported 
in the literature.1,3,6,7,9-11 All the mutations identified in our cohort were truncating 
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(nonsense or frameshift) alleles (Table 1). Two mutations are recurrent; the Arg2444* 
mutation was observed in about half (24/52) (including the original patient described 
by Pelletier and Feingold)1, while the Arg2435* mutation was present in approximately 
one quarter (13/52) of the individuals with FHS. In our original cohort of 13 patients with 
FHS we delineated the boundaries of the critical region to between codons 2407 and 
2517. The extended cohort of molecularly-defined patients we present here extends the 
critical region to between codons 2389 and 2748, a further 249 amino acids in exon 
34. Interestingly, the boundaries of this critical region are delineated by mutations 
observed in our two mother-daughter pairs (Table 1), however, the significance of this 
finding is unclear.
Table 1. Mutations detected in exon 34 of SRCAP in individuals with FHS.
c.DNA Frequency (52) Comments
Glu2389* c.7165G>T 2 Mother/Daughter8
Gln2407* c.7219C>T 1
Gln2407fs*35 c.7218_7219delTC 1
Asn2410fs*32 c.7230insA 1
Thr2425fs*17 c.7274insC 1
Arg2435* c.7303C>T 13 2nd Recurrent mutation
Ala2440fs*3 c.7316dupC 1
Arg2444* c.7330C>T 24 Most frequent recurrent 
mutation
Pro2459fs*125 c.7374dupT 2
Pro2459fs*16 c.7376delC 1
Thr2512fs*5 c.7533_7534insAA 1
Gln2517fs*5 c.7549delC 1 
Asn2618fs*11 c.7852insC 1
Arg2748* c.8242C>T 2 Mother/Daughter7
Facial gestalt
The face of FHS is the most distinctive aspect of this syndrome (Figures 1, 2 and 3) and 
although there are changes with age, the cardinal features, as originally described, 
remain constant.1,2,4 The overall facial shape is triangular. The nose is narrow at the 
root and broadens to the tip. The columella is low hanging, nares are large and the 
philtrum is often short. The upper vermillion is typically thin and the lower lip is often 
everted. The lips tend to be in a horizontal plane at rest or when smiling. The eyes are 
frequently deep set and the eyelashes tend to be long. The ears can be low set and large 
in appearance. As seen in the photos, the FHS phenotype is more difficult to recognize 
in infancy.
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Figure 1. Facial photographs of 6 females with FHS with the common Arg2444* mutation.
Figure 2. Facial photographs of 4 individuals with FHS of varying ages with the Arg 2435* mutation.
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Figure 3. Facial photographs of 7 individuals with FHS as examples of the other mutations. (A) A female with the 
Gln2407* mutation. (B) A male with the Ala2440fs*3 mutation. (C) A female with the Asn2618fs*11 mutation. (D) 
A female and male with the Pro2459fs*125 mutation. (E) A mother and daughter with the Arg2748* mutation.
Skeletal
Of the 17 individuals where thumb morphology was formally assessed, broad thumbs 
were only seen in 10 individuals indicating that they are a frequent but not mandatory 
finding in FHS. The differential diagnosis of broad thumbs includes Rubinstein-Taybi 
syndrome, where they are a cardinal feature. FHS is also in the differential, which is 
logical as SRCAP interacts with CBP. Other skeletal findings include broad first toes and 
brachydactyly. Broad fingertips are seen frequently and the fingers are often described 
as being clubbed, although would be more accurately classified as having broad 
fingertips (Figure 4). Leisti et al. reported a right-sided pseudoarthrosis-type anomaly 
of the clavicle noted at age two in one of their patients.2 Four individuals in our series 
have uni- or bilateral clavicular anomalies including pseudoarthroses or hypoplasia. 
Two individuals have 11 pairs of ribs and four have hip dysplasia.
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Figure 4. Hands and feet of individuals with FHS. Clinical photos demonstrating the variability of features 
ranging from unremarkable to brachydactyly, short broad thumbs and big toes, broad fingertips.
Growth
Where available, growth parameters were plotted on aggregate graphs. Thirteen of 49 
individuals had birth weights less than the third percentile (Figure 5). For females, the 
maximum height was at the 20th percentile, with most data points between minus 
two and minus four standard deviations (SDs) (Figure 6). For the males, the height 
measurements varied more widely, with maximum height at the 25th percentile and 
two adult heights below 4 SDs (Figure 7). Occipito-frontal circumferences (OFC) were 
more variable, with most being well within the average range (Figures 8 and 9). Seven 
individuals had OFCs less than 2 standard deviations and only one measurement 
was less than minus 3 SDs. This suggests relative sparing of head size in relation to 
stature. Body weights were not consistent to suggest a particular body habitus for this 
syndrome and probably reflect the variability seen in the general population.
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Figure 5. Birth weights of individuals with FHS. Male birth weights - blue dots; Female birth weights – pink dots. 
The mean, 5th and 95th confidence intervals are indicated.
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Figure 6. Height and weight of female individuals with FHS. Each point represents a single individual’s 
measurements at the time of data collection.
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Figure 7. Height and weight of male individuals with FHS. Each point represents a single individual’s 
measurements at the time of data collection.
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Figure 8. OFCs of females with FHS. Each point represents a single individual’s measurements at the time of data 
collection. The mean, 5th and 95th confidence intervals are indicated.
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Figure 9. OFCs of males with FHS. Each point represents a single individual’s measurements at the time of data 
collection. The mean, 5th and 95th confidence intervals are indicated.
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Bone age and endocrine
Bone age values were plotted against chronological age (Figure 10) and all values in 
subjects less than 8 years old showed significant delays. There were no data values 
between ages 8–10 years, however, the bone ages approached the chronological age 
or became advanced after age 10 years. A number of participants in this study have 
been on growth hormone (GH) therapy, which may alter the natural history of growth 
in this population. Two of our subjects have been assessed in more detail regarding 
this issue.9,10 Some GH treated individuals with FHS had documented GH deficiency, 
while others had modest responses to treatment despite normal levels of GH.9,10,12 Early 
puberty has previously been reported in FHS and was documented in four individuals 
in our study.13 Some of our subjects are currently pre-pubertal, while others could 
not accurately report pubertal timing, rendering the data incomplete. However, early 
puberty could explain the advanced bone age seen in teenage individuals with FHS as 
well as contributing to shorter adult heights.
Figure 10. Bone age values plotted against chronological age for 25 individuals with FHS.
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Structural anomalies
A number of structural anomalies were detected in our cohort (Table 2), but no 
particular finding was seen with enough frequency to consider it a distinguishing 
feature of this syndrome. However, as some anomalies may affect clinical management, 
comprehensive screening is necessary in this population.
Table 2. Frequency of different clinical features in individuals with FHS.
Clinical features Frequency reported 
Eyes
   Strabismus 7/43
   Hyperopia 5/43
   Nystagmus 1/43
Ears
   Recurrent otitis media/T-tube placement 6/52
   Hearing loss 9/52
   Cochlear anomaly 1/UI
Other ENT
   Cleft lip and pseudocleft lip 2/52
   Velopharyngeal insufficiency 2/U
   Choanal atresia 1/U
Dental issues
   Small teeth/increased spacing 13/38
   Cavities 6/38
   Malocclusion/underbite 3/38
Cardiac malformationII 3/52
Gastrointestinal
   Motility issues (reflux/constipation) 13/52
   Colonic stricture 1/U
   Celiac disease 2/52
Genitourinary
   Cryptorchidism 5/24
   Renal/collecting system anomalies 7/U
Seizures 6/52
Hypothyroidism 2/52
IU denominator unknown
IIMild aortic coarctation, atrial septal defect, Tetralogy of Fallot.
Voice quality and language
A high-pitched voice is often commented upon in individuals with FHS and was 
reported in 8/11 individuals. Others noted a nasal quality to the voice. An additional 
individual had documented velopharyngeal insufficiency (VPI), which may indicate 
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that VPI is under-recognized. Expressive language delay is a cardinal feature of this 
syndrome and was reported in all subjects. There was significant variability in severity 
with one individual who was bilingual, while another could only speak a few words as 
an adult. However, language development could potentially be hampered by the high 
frequency of recurrent otitis media and conductive hearing loss found in our cohort.
Cognition
The cognitive abilities in individuals with FHS range from average (IQ of 104) to 
significant intellectual impairment in a few instances. Most individuals had some 
modifications of their schooling (37/41). Obtaining full psychoeducational assessments 
on this cohort was beyond the scope of this study. However, when assessing global 
cognition in an individual with FHS, one must consider the language impairments, and 
in some instances sensory impairments and adjust accordingly.
Behaviour
The caregivers, in comparison to physicians, who filled out the questionnaires, often 
commented upon behavioral issues for their children (5/25). It is likely that these issues
are under-recognized in this population. Rigid mannerisms were observed (7/25), 
as were some obsessive tendencies (e.g. skin picking). Parents often described their 
children as anxious individuals and attention deficit hyperactivity disorder (ADD or 
ADHD) was common (9/32).
We acknowledge that the data collection in our study was incomplete as data was 
obtained from a number of sources without a centralized clinical assessment. We also 
recognize that the ethnic backgrounds of the study subjects were mostly Caucasian 
and that FHS may be more difficult to diagnose in other populations. However, three 
individuals of Chinese origin were clinically diagnosed and identified to have mutations 
in SRCAP. In addition to growth and developmental issues, all of these subjects had 
classical FHS facial features, which were distinct from those of their family members.
Lastly, we evaluated for the presence of a genotype-phenotype correlation in FHS. Upon 
review of the clinical data, no clinical features were identified which discriminated 
between the different mutations. Given that all mutations cause truncation in a very 
defined area of the gene, this observation was not entirely unexpected.
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Development of diagnostic criteria
The indication for analysis of the SRCAP gene was a presumptive diagnosis of FHS. 
The majority of those who underwent testing had short stature, delayed bone age, 
language delays and a distinctive facial appearance, usually with a prominent nose. 
Clinicians very familiar with FHS were able to distinguish those who ultimately carried 
a mutation in SRCAP, by his/her clinical information and facial photographs, from those 
who did not have a mutation. Those individuals who were referred who did not have a 
mutation detected often had dysmorphic facial features, but these were distinct from 
the classical FHS gestalt, making facial features the defining characteristic of FHS. The 
nose is quite distinctive in FHS with its overall triangular appearance, the orientation 
and size of the nares and the low hanging columella. The linear orientation of the 
mouth, at rest or when smiling, is also an important defining feature.
Additional consistent features of those who tested negative were a formal diagnosis of 
autism or head circumferences at a comparatively smaller OFC percentile than that for
height. Russell-Silver syndrome and 3-M syndrome are included in the differential 
diagnosis for FHS, but we do not believe any of the patients in our negative group had 
either of these diagnoses.
Three individuals, whose phenotype most closely resembled FHS, had sequencing of 
the entire SRCAP gene to explore the possibility of mutations outside of exons 31–34. 
However, no mutations were detected. It is plausible that their phenotypes could be 
due to a mutation in another gene that codes for a protein, which interacts with SRCAP 
and CBP. Further research is needed to elucidate this possibility. Given that we have no 
evidence of genetic heterogeneity within our cohort, we conclude that the detection 
of a truncating mutation in exon 34 of SRCAP is a mandatory feature for a diagnosis of 
FHS. This is contrary to the report put forth by Le Goff et al.14 Six of their nine subjects 
were found to have mutations in exon 34 within the boundaries we describe and they 
proposed that their three mutation-negative individuals indicate genetic heterogeneity 
for FHS. However, we reviewed the two photographs of their SRCAP-negative patients 
and did not believe their facial features were consistent with a diagnosis of FHS.
A high frequency of associated anomalies was seen in this study (33/52 had at least one 
major anomaly requiring medical intervention); however, none are pathognomonic for 
FHS. This large cohort of FHS individuals clarifies which clinical features are observed 
frequently and informs patient management guideline development. For example, 
celiac disease was initially thought to be more common in FHS, however, only 2 of 
52 subjects had this finding. Although this is more than expected in comparison to 
the general population, the numbers are not such to suggest generalized screening. 
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In comparison, genitourinary, ocular and dental issues were seen often enough to 
warrant investigations.
Suggestions for management
Based on our clinical data, we suggest the following guidelines for the care of 
individuals with FHS:
1.   Sequencing of SRCAP exons 31–34 in all suspected cases to confirm the 
diagnosis
2.  Complete assessments of auditory and visual systems
3.  Renal and urinary tract ultrasound
4.  Neurologic assessment if there is a suspicion of seizures
5.  Dental hygiene to prevent cavities and to monitor for malocclusion
6.   Evaluation for growth hormone deficiency at baseline, to be repeated if 
loss of growth velocity occurs
7.    Monitoring of bone age and pubertal timing. In cases of precocious 
puberty, referral to a pediatric endocrinologist
8.    Psychoeducational assessments corrected for deficiencies in expressive 
language and sensory issues
9.    Monitoring of behavioral disturbances and provision of early intervention
10.   Counseling for families regarding recurrence risk (extremely low) and to 
offspring of individuals with FHS (50% chance).
Conclusions
We have assembled the largest cohort of individuals with Floating-Harbor syndrome; 
documenting pathogenic mutations in SRCAP in 52 affected individuals. Characteristic
clinical findings include short stature, delayed bone age, distinctive facial features, 
expressive language delay and broad thumbs. If the characteristic facial gestalt is not
present, the likelihood of finding a mutation in SRCAP is very low. It is not uncommon 
for an individual with FHS to have additional anomalies and health complications 
that require medical intervention and thus comprehensive baseline screening and 
surveillance is warranted. In general, individuals with FHS are healthy and despite 
some impairments, enjoy a good quality of life.
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Supplementary File 1.Floating-Harbor questionnaire
Patient
Sex
Ethnicity
Paternal age (years)
Gestation (weeks)
Birth weight (g)
Age at diagnosis
Age at last assessment (ALAI)
Head circumference (cm) ALA
Weight (kg) ALA
Height (cm) ALA
Age at puberty
Pre-pubertal height 
Bone age years versus chronological age 
Triangular face
Distinctive nose
Low-hanging columella
Short philtrum
Thin upper vermilion
Wide mouth
Low set ears
Broad thumbs
Broad fingertips
Brachydactyly
Clinodactyly
Other skeletal
Dental issues
Gastrointestinal problems 
Seizures
Other health issues/serious illnesses/hospitalizations
Behaviour issues 
Attention Deficit/Hyperactivity
Psychiatric issues/Anxiety/Depression
High pitched voice
Speech delay
Intellectual development/Developmental Delay/
Mental Retardation
IALA – at last assessment
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Supplementary Table 1.
FHS Primers
1 SRCAP.exon34_A.F TGACCTGCTGGCCTTAACTT 381
2 SRCAP.exon34_A.R GGCGGATATGACAGGAGTGT
3 SRCAP.exon34_B.F CACCGGCGCAGTAAAAAG 400
4 SRCAP.exon34_B.R TATGAGCTGGTGGAGGGGTA
5 SRCAP.exon34_C.F TCAGCCCCAAATCCAATAAC 374
6 SRCAP.exon34_C.R AGGATCTCCACAGCAACTGG
7 SRCAP.exon34_D.F GCATTGGCATCTCCAGAGTC 368
8 SRCAP.exon34_D.R TCTGTCAGCTCTTCCGAGGT
9 SRCAP.exon34_E.F GTGAGGAGTTGCCCCTGT 499
10 SRCAP.exon34_E.R ATGGGAGGGGAGGATTCTG
11 SRCAP.exon34_F.F GGCTGGTAACTGTGGTAGAGGA 488
12 SRCAP.exon34_F.R CCCAGGAATAAGCTGTGGTTC
13 SRCAP.exon34_G.F ACCTTGAAGGGAAAAACCAATG 457
14 SRCAP.exon34_G.R AGCTCTCGAGAACAGAAGTGCT
15 SRCAP.exon34_H.F CCTCCCAAGAATCCTCCATC 500
16 SRCAP.exon34_H.R GCTTCAGCCTCAGACTCCTCTA
17 SRCAP.exon34_I.F TGCGTCCAGGGTCTCTAGTC 494
18 SRCAP.exon34_I.R TGACAACCAGTTGCCTACCC
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Abstract
The phenotype of patients with a chromosome 1q43q44 microdeletion (OMIM 612337) 
is characterized by intellectual disability with no or very limited speech, microcephaly, 
growth retardation, a recognizable facial phenotype, seizures and agenesis of the 
corpus callosum. Comparison of patients with different microdeletions has previously 
identified ZBTB18 (ZNF238) as a candidate gene for the 1q43q44 microdeletion 
syndrome. Mutations in this gene have not yet been described. We performed exome 
sequencing in a patient with features of the 1q43q44 microdeletion syndrome that 
included short stature, microcephaly, global developmental delay, pronounced 
speech delay and dysmorphic facial features. A single de novo nonsense mutation was 
detected, which was located in ZBTB18. This finding is consistent with an important 
role for haploinsufficiency of ZBTB18 in the phenotype of chromosome 1q43q44 
microdeletions. The corpus callosum is abnormal in mice with a brain-specific knock-
out of ZBTB18. Similarly, most (but not all) patients with the 1q43q44 microdeletion 
syndrome have agenesis or hypoplasia of the corpus callosum. In contrast, the patient 
with a ZBTB18 point mutation reported here had a structurally normal corpus callosum 
on brain MRI. Incomplete penetrance or haploinsufficiency of other genes from the 
critical region may explain the absence of callosum agenesis in this patient with a 
ZBTB18 point mutation. The findings in this patient with a mutation in ZBTB18 will 
contribute to our understanding of the 1q43q44 microdeletion syndrome.
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Introduction
The phenotype of patients with a submicroscopic deletion of chromosome 1q43q44 
(OMIM 612337) is characterized by intellectual disability, microcephaly, growth 
restriction, dysmorphic features, agenesis of the corpus callosum (ACC) and cardiac, 
gastroesophageal and urogenital anomalies.1–8 Even for patients with an overlapping 
deletion, the phenotype varies considerably. So far, no direct association has been 
identified between the phenotype and the deleted genes. On the basis of overlapping 
microdeletions, a number of candidate genes have previously been suggested for 
microcephaly and corpus callosum agenesis. These include AKT3, ADSS, CEP170, 
Clorf100, Clorf101, Clorf121, Clorf199, EFCAB2, FAM36A, HNRNPU, HNRNPU-AS1, PLD5, 
PNAS-4 and SDCCAG8.1,3,8–14 Specifically, ZBTB18 has repeatedly been identified as 
a strong candidate gene for microcephaly and/or ACC.7,9,11,14,15 ZBTB18 is particularly 
compelling since a brain-specific knock-out of this gene in mice causes microcephaly 
and callosal anomalies.16 However, other studies suggest critical regions that do not 
include ZBTB18.8,10,12
To our knowledge, no point mutations in ZBTB18 have been described so far. Here, we 
describe a patient with a de novo nonsense mutation in ZBTB18 and phenotypic features 
of the 1q43q44 microdeletion syndrome.
Materials and methods
Clinical features
This female was the first child of healthy, non-consanguineous parents. The 
pregnancy was established through in vitro fertilization, because of subfertility due to 
oligospermia. Amniocentesis, performed because of raised maternal serum markers, 
revealed a normal female karyotype. On ultrasound at 20 weeks of gestation bilateral 
pyelectasia and choroid plexus cysts were noted. Labor was induced at 36 weeks of 
gestation because of intra-uterine growth restriction.
Birth length was 45.5cm (-2.3 SDs), with a weight of 2.15 kg (-2.3 SDs) and a head 
circumference of 30 cm (-2 SDs). Neonatal examination was unremarkable. Ultrasound 
investigations of the brain and the abdomen showed no abnormalities.
The girl developed feeding problems after the introduction of formula milk and 
weight gain was poor. After elimination of cow’s milk from the diet, her weight gain 
remained delayed. Gastroenterological examinations (including biochemistry, 
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endoscopy, small bowel biopsy and abdominal ultrasound and upper GI tract X-rays) 
revealed gastroesophageal reflux, but no other explanation for her growth restriction. 
Because of developmental delay and suspected absence seizures associated with 
vomiting episodes, neurological assessment was performed which was unremarkable. 
Additional investigations included a cerebral MRI, EEG, metabolic screen and hearing 
tests. All results were normal (Figure 1c).
Figure 1. Female with a de novo nonsense mutation in ZBTB18: c.397G>T (p.(Glu133*))
(A) Patient at age 16 months. Dysmorphic features include arched eyebrows with telecanthus, short palpebral 
fissures, a long nose with a prominent tip, short philtrum and micrognathia; (B) Patient at age 34 months. 
Dysmorphic features are similar to those at age 16 months, however, the nasal tip is less prominent, the philtrum 
is longer and the upper lip is thinner; (C) Lateral view of the brain at age 15 months. Note the presence of a normal 
corpus callosum (white arrow).
At the age of 16 months, she was referred to the genetics clinic for further assessment. 
At this time, all growth parameters were below -2.5 SDs. Her height was 70.5 cm, weight 
7 kg and head circumference 41.5 cm. On clinical examination, she had proportionate 
short stature, mild facial dysmorphic features (Figure 1a and b) and slightly broad first 
fingers and toes. At later reviews, her delay became more evident and more marked in 
the speech domain. She walked unsupported at 26 months. At 34 months, her cognitive 
development was at the level of 2 years old with prominent speech delay. Her speech 
was hyper nasal. Her height was 79 cm (-4.5 SDs), with a weight of 7.9 kg (-4.6 SDs) and 
a head circumference of 43 cm (-4.1 SDs).
At this time, a diagnosis of possible Floating-Harbor syndrome was considered.
Subsequent mutation analysis of the SRCAP gene revealed no abnormalities. MLPA 
assays for telomeric and recurrent genomic rearrangements (MRC-Holland kits) were 
also normal, as was a genomic microarray.
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Molecular analysis
Exome sequencing was performed in a female patient from a cohort of patients with 
short stature, developmental delay, predominantly speech delay, with or without facial 
dysmorphic features. Exome sequencing was done on DNA from the female and both 
parents as described previously.17,18 In brief, genomic DNA was isolated from blood 
with the use of a QIAgen DNA mini kit (QIAgen, Venlo, The Netherlands). Exomes were 
enriched using a SOLiD-optimized SureSelect human exome kit (Agilent v2, 50Mb, 
Agilent Technologies Inc., Santa Clara, CA, USA), followed by sequencing performed 
using the 5500xl platform (Life Technologies, Carlsbad, CA, USA). After sequencing the 
trio, candidate de novo events were selected by excluding variants seen in either parent, 
whereas recessive models were evaluated using bi-allelic variants inherited from both 
parents. Candidate mutations were validated by conventional Sanger sequencing 
methods in DNAs of the patient and her parents (Supplementary Tables 1–3) and 
annotated according to HGVS recommendations. After publication, the variant will be 
submitted to the Human Gene Mutation Database (HGMD; URL: http://www.hgmd.
cf.ac.uk/ac/index.php).
Results
Exome sequencing detected three de novo variants. Two de novo missense variants were 
not confirmed with Sanger sequencing (Supplementary Table 3). Sanger sequencing 
confirmed the presence of a single de novo nonsense mutation located in ZBTB18: 
c.397 G>T (p.(Glu133*)) (NM_205768; UCSC, hg19). This mutation is predicted to cause 
a premature stop codon and may lead to nonsense mediated decay. No additional 
mutations in ZBTB18 were detected through Sanger sequencing in nine patients with an 
overlapping phenotype. Furthermore, neither stop mutation nor any other truncating 
event (stop-loss, frameshift mutation) in ZBTB18 was identified in 6500 individuals 
from the exome variant server (Exome Variant Server, NLHBI GO Exome Sequencing 
Project (ESP), Seattle, WA (URL: http://evs.gs.washington.edu/EVS/) (accessed July 
2013)).
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Discussion
We report a de novo nonsense mutation in ZBTB18 in a patient with global 
developmental delay, prominent speech delay, microcephaly, short stature and discrete 
facial dysmorphisms. These clinical features are consistent with the phenotype of 
patients with microdeletions of chromosome 1q43q44 (Table 1). Overlapping clinical 
features include microcephaly (97%), developmental delay (100%), intra-uterine 
growth retardation (62%) and postnatal growth retardation (45%). We suggest that 
haploinsufficiency of ZBTB18 contributes to these features of the chromosome 1q43q44 
microdeletion syndrome.
Table 1. Comparison of the clinical features of a patient with a de novo nonsense mutation in ZBTB18, c.397G>T 
(p.(Glu133*)) and the phenotype of patients with a chromosome 1q43q44 microdeletion including ZBTB18 
described in literature.
Features
Patient with ZBTB18 
mutation 
Patients with 1q43q44 microdeletion 
described in literature (N= 29) 1,8-12
Deletion size (range in Mb) NAI 1.26 - 4.9
Mutation 397G>T (p.(Glu133*)) NA
Sex F 16F/12M  (57%/43%)
Growth parameters
   Intra-uterine growth retardation + 6/15   (40%)
   Postnatal growth delay + 11/26  (42%)
   Microcephaly (OFC < -2 SDs) + 28/29  (97%)
Neurology
   Developmental delay + 18/18  (100%)
   Speech delay + 3/3   (100%)
   Corpus callosum anomalies - 23/28  (82%)
   Hypotonia - 14/18  (78%)
   Seizures - 19/29  (66%)
Facial dysmorphic features
   Hypertelorism - 5/19   (26%)
   Strabismus - 2/18   (11%)
   Prominent nasal tip/Bulbous nose + 10/19  (53%)
   Abnormal philtrum + 6/19   (32%)
   Abnormal lips + 8/19   (42%)
   Micro-/retrognathia + 1/19   (5%)
   Abnormal ears - 4/19   (21%)
   Abnormal fingers/toes + 8/19   (42%)
Cardiac anomalies - 7/19   (37%)
Urogenital anomalies - 6/19   (32%)
Gastrointestinal problems + 8/17   (47%)
INA = Not Applicable
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There are a number of reports on patients with deletions of 1q43q44 not including 
ZBTB18.1,8–12 Out of 27 patients with deletions distal or proximal (including the AKT3 
gene) to ZBTB18, only 5 (19%) showed corpus callosum abnormalities and 10 (37%) 
had microcephaly, compared with 82 and 97%, respectively, of patients with deletions 
including ZBTB18.1,8–12 Furthermore, IUGR was seen in 3 out of 14 of these patients (21%) 
and postnatal growth retardation was seen in 7 out of 23 patients (30%). Collectively, 
these results support a crucial role for ZBTB18, but with contributions to the phenotype 
of other genes in patients with larger deletions.
ZBTB18, also known as ZNF238 or RP58, acts as a transcriptional repressor of key 
proneurogenic genes such as Neurogenin2 and NeuroD1.16 ZBTB18 is activated during 
neuronal differentiation in pin-like cells of the ventricular zone and in migrating 
multipolar cells.19 ZBTB18 participates in neuron and astrocyte differentiation by 
mediating cell-cycle control of neural stem cells.20 Mice with loss of ZBTB18/RP58 
die at birth with neocortical defects. CNS-specific loss of ZBTB18 is associated with 
microcephaly, ACC and cerebellar hypoplasia.16 ZBTB18-mutant brains maintain 
precursor pools, but have reduced neuronal and increased glial differentiation. This 
is consistent with a role for ZBTB18 in favoring neuronal differentiation and brain 
growth by repressing multiple proneurogenic genes in a timely manner. On the basis 
of the phenotypes observed in mutant mice, Xiang et al16 proposed ZBTB18 as a strong 
candidate gene for the 1qter deletion syndrome. Our finding of intellectual disability 
and microcephaly in a female with a de novo nonsense mutation in ZBTB18 strongly 
supports this hypothesis.
Dysmorphic features in our female were mild, whereas variable facial features have 
been previously reported with 1q43q44 microdeletions of different sizes and gene 
content. Clearly, other genes from the 1q43q44 region may still contribute to the 
phenotypic outcome in patient cases with the 1q43q44 microdeletion syndrome. Most 
(24 out of 29) previously reported patients with a 1q43q44 microdeletion including 
ZBTB18 had corpus callosum abnormalities on brain imaging. The majority (66%) 
developed seizures.1,8–12,15 Incomplete penetrance is a possible explanation for the 
absence of ACC in this girl, given that the corpus callosum was apparently normal in 
at least five patients with 1q43q44 microdeletions that included ZBTB18 as described 
previously.1,9,12 We note that brain-specific loss of ZBTB18 in mice leads to a small brain 
phenotype with ACC and cerebellar hypoplasia.16
In conclusion, we describe the first patient with a de novo nonsense mutation in ZBTB18. 
The phenotype of the patient reported here suggests that ZBTB18 haploinsufficiency 
contributes to the microcephaly and global developmental delay that are core features 
of the 1q43q44 microdeletion syndrome.
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Supplementary Table 1. Exome mapping statistics for a female patient with global developmental delay, 
prominent speech delay, microcephaly, short stature and mild dysmorphic features, and her parents. 
Enrichment was performed with Agilent’s v2 (50Mb) exome; sequencing was performed using Life Technologie’s 
5500xl platform; mapping and variant calling was done using Life Technologie’s LifeScope v2.1.
Child Mother Father
Total mapped bases [hg19] 5.245.459.026 4.984.680.534 5.788.453.725 
Bases on target 80.6% 81.7% 81.4%
Bases near target (+/- 50nt) 7.3% 7.1% 7.2%
Bases off target 12.1% 11.2% 11.4%
Median target coverage 64.5 60.7 71.8
Average target coverage 81.4 78.0 91.2
Supplementary Table 2. Variant filtering of exome data for a female patient with global developmental delay, 
prominent speech delay, microcephaly, short stature and mild dysmorphic features. Trio - de novo analysis, 
similar to Vissers et al. 2010; de Ligt et al. 2013.1,2
All variants 45803
coding and splice site variants 19863
of which privateI 314
non synonymous 217
high quality de novo candidatesII 3
I Variant not present in dbSNP132 nor in 1051 in-house exomes.
II Variant not present in maternal or paternal exome data, ≥5 unique variant reads, ≥20% variant reads.
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In this exciting new era of genomics, the introduction of next generation sequencing 
(NGS) has precipitated the development of ‘next generation phenotyping’. In the 
field of clinical genetics, new syndromes can be recognized by integrating the clinical 
phenotype of patients with molecular variants detected by whole exome sequencing. 
Furthermore, through whole exome sequencing, the molecular cause of many known 
syndromes has been identified, enabling genotype-phenotype studies for these 
syndromes (Chapter 1).
In this thesis, we have put next generation phenotyping into practice: we performed 
genotype-phenotype studies in two syndromes accompanied by short stature after 
their molecular causes had been identified through NGS: Meier-Gorlin syndrome (MGS) 
and Floating-Harbor syndrome (FHS). We provided clinically based management 
advice for these conditions (Chapters 2 and 3) and we used the results of whole exome 
sequencing to establish a new syndrome (Chapter 4). Consequently, we increased the 
knowledge and awareness of these conditions.
Chapter 2. Meier-Gorlin syndrome
The discovery of ORC1, ORC4, ORC6, CDT1 and CDC6 mutations as the underlying cause 
of MGS in 2011 enabled us to perform the genotype-phenotype studies described in 
Chapter 2.1.1-3 
We performed these studies in a cohort of 35 MGS patients with biallelic mutations 
in one of the five above mentioned genes of the pre-replication complex and in ten 
additional MGS patients in whom the diagnosis of MGS was based exclusively on the 
clinical findings, since no underlying genetic defect was detected.
The classical triad of microtia, patellar a-/hypoplasia and short stature was present 
in 83% of patients with a clinical and molecular diagnosis of MGS. Four patients (one 
with ORC1 mutations, one with ORC6 mutations and two with CDT1 mutations) had 
microtia and patellar aplasia with a normal stature. One patient with ORC1 mutations 
had microtia and short stature, without patellar a-/hypoplasia. Finally, one individual 
with ORC1 mutations had short stature, but the ears and patellae were of normal size.
These findings show the variability of the phenotypic spectrum of MGS and should 
prompt clinicians to consider the diagnosis of MGS more often, since MGS can be 
present in patients with just one of the three cardinal features.
Other frequent clinical findings in our cohort were typical facial features (including 
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a small mouth with full lips and retro-/micrognathia and a narrow nose with broad 
nasal bridge and convex nasal profile), respiratory problems (including congenital 
pulmonary emphysema and trachea-, laryngo- and/or bronchomalacia) and feeding 
problems during infancy, mammary hypoplasia and genital anomalies.
Our studies revealed that patients with ORC1 mutations show the most severe growth 
retardation, reflected by the fact that these patients are shortest in height and have the 
smallest head circumference, with mean standard deviation scores of -7.1 SDs (range 
-9.6 to -5.2 SDs) and -6.7 SDs (range -9.8 to -4 SDs) respectively.
Furthermore, our data suggest that compound heterozygous nonsense and missense 
mutations have a more severe effect on the phenotype than homozygous missense 
mutations. Growth was more delayed in three patients with one missense and one 
null mutation in ORC4 and these patients had more congenital anomalies (congenital 
pulmonary emphysema, congenital heart defect and severe feeding problems) in 
comparison with four patients with two missense mutations in ORC4. Furthermore, 
the only individual with homozygous missense mutations in CDT1 had no congenital 
pulmonary emphysema, while all seven patients with one missense and one null 
mutation in this gene were diagnosed with congenital pulmonary emphysema. 
Moreover, four patients with compound heterozygous null and missense mutations had 
a lethal phenotype: one boy with one frameshift and one missense mutation in ORC1 
had a severe cortical dysplasia with pachygyria and ventriculomegaly, craniosynostosis, 
congenital pulmonary emphysema and pancreatic tail agenesis. He passed away at the 
age of 3.5 months. His brother deceased after 17 weeks of gestation. A boy with one 
nonsense and one missense mutation in CDT1 passed away due to a sudden cardiac 
arrest, his sister died of severe respiratory problems due to a tracheobronchomalacia 
with progressive congenital pulmonary emphysema.
Thus far, no patients with MGS and homozygous or compound heterozygous null 
mutations have been described, suggesting that the effect of these mutations is not 
compatible with life. This hypothesis is supported by results from Drosophila studies 
described in literature, in which null mutations in ORC6 and CDT1 cause embryonic 
lethality.4,5
In Chapter 2.2, in depth studies were performed in our cohort of 45 MGS patients in 
order to establish a specific growth pattern, enabling us to predict growth in patients 
with MGS.
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Trend analyses of growth showed that the growth retardation in MGS predominantly 
arises prenatally. Prenatal growth retardation was present in 98% of patients with MGS, 
with a mean birth weight of -3.9 SDs and a mean length of -3.4 SDs. In the first year 
of life, height decreased further to -5.2 SDs. In the subsequent years, growth velocity 
remained normal to slightly increased, resulting in a mean adult height of  -4.5 SDs. 
These growth studies showed the growth pattern of MGS patients: height decreases 
with an average of 1.7 SDs in the first year of life and growth velocity is near to normal 
thereafter.
Height was significantly influenced by ethnic origin and the underlying molecular cause. 
These findings confirmed and expanded our previous findings described in Chapter 
2.1. We showed that patients with mutations in ORC1 and ORC4 were significantly 
shorter (4.7 SDs and 3.1 SDs shorter, respectively) than patients with mutations in 
ORC6, CDT1 and CDC6 or without molecular diagnosis. Their head circumferences were 
5.0 SDs (ORC1) and 1.6 SDs (ORC4) smaller than the head circumference of patients 
with mutations in ORC6, CDT1 and CDC6.
Growth hormone treatment was successful in two patients with a clinical diagnosis of 
MGS. In these patients, growth hormone treatment was initiated when growth velocity 
continued to be decreased after the first year of life and extremely low levels of IGF1 
were detected. These findings suggest that IGF1 measurements can be used to predict 
the success of growth hormone treatment in a subset of patients with MGS.
Recent clinical findings have shown the presence of congenital pulmonary emphysema 
in two MGS patients diagnosed with asthma/asthmatic symptoms (unpublished 
data). Although future studies are necessary to assess its exact incidence and long-
term effects, the presence of congenital pulmonary emphysema should be considered 
in all patients with MGS who present with airway problems resembling asthma.
The results of our molecular and longitudinal clinical studies (with follow-up data of 
over 15 years) in patients with MGS have led us to propose experience based advice for 
diagnostic evaluation and management of patients with MGS in Chapter 2.3. Medical 
care should be directed towards growth and secondary sexual development, motor 
and speech development, respiratory and skeletal problems.
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Chapter 3. Floating-Harbor syndrome
After the identification of heterozygous truncating mutations of the SRCAP gene as 
the underlying molecular cause of FHS in 2012, we performed genotype-phenotype 
studies in 52 patients with FHS. The results of these studies are described in Chapter 3.6
In these 52 patients, we reported 14 different mutations in the SRCAP gene. All 14 
detected mutations were truncating mutations between codons 2389 and 2748 in exon 
34. Two mutations were recurrent: Arg2444* and Arg2435*, present in 50% and 25% of 
patients, respectively. Only one instance of parent-to-child submission was observed.
We further delineated the clinical spectrum of FHS and identified expressive language 
delay and the facial phenotype as the core, mandatory features of FHS. In patients with 
these cardinal features, mutation detection rate was 95%. The likelihood of detecting a 
mutation in SRCAP in patients without distinctive facial features was very low. 
The characteristic facial features include a triangular face with deep-set eyes and long 
eyelashes, a narrow nasal root that broadens towards the tip, a low columella, large 
nares, short philtrum and thin upper vermillion with everted lower lip. A key feature is 
the horizontal lineage of the lips at rest or when smiling.
The expressive language delay was present in all patients, but varied considerably, 
since one patient was bilingual, while other adults with FHS could only speak a few 
words. Cognitive development varied from normal to profound intellectual disability.
Other frequent, non-obligatory findings included broad thumbs and first toes and 
brachydactyly with broad fingertips.
Growth analysis showed that prenatal growth retardation (birth weight below -2 SDs) 
was present in approximately 25% of FHS patients and that growth velocity decreased 
after birth, with a postnatal growth retardation (height below -2.5 SDs) present in 92% 
of patients. Bone age was significantly delayed before the age of eight. 
Microcephaly (head circumference below -2 SDs) was present in only a minority of 
patients and only one patient had a head circumference below -3 SDs, indicating that 
growth of the brain is relatively spared in FHS.
At least one major anomaly was present in 63% of patients. However, none of them 
was present frequently enough to be distinguishing. Gastro-intestinal (motility issues, 
colonic stricture, celiac disease), genitourinary (cryptorchidism, abnormalities of the 
renal/collecting system) and eye anomalies (strabismus, hyperopia, nystagmus) were 
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described relatively frequently, as well as seizures, hearing loss and dental issues (small 
teeth, cavities, malocclusion). Cardiac malformations (mild aortic coarctation, atrial 
septal defect, Tetralogy of Fallot) and hypothyroidism were seen less frequently. 
Based on our genotype-phenotype studies, we suggested that management of FHS 
patients should be directed towards auditory and visual problems, genitourinary 
malformations, dental issues, growth, bone age and possible precocious puberty, 
psychomotor and speech development, possible seizures and behavioral problems.
FHS is a highly recognizable, monogenic disorder, indicating that patients without 
mutations in SRCAP either were misdiagnosed with FHS in the past, or have mutations 
in a second FHS gene harboring a broader clinical spectrum.
Chapter 4. ZBTB18
As described in Chapter 3, Floating-Harbor syndrome is characterized by short stature, 
a typical facial phenotype and expressive language delay.
In 2011, we saw five patients with a clinical diagnosis/suspicion of FHS. A molecularly 
confirmed diagnosis of FHS could be made in only two of the five patients. Whole 
exome sequencing led to the identification of a novel disease gene in one of the three 
remaining patients. 
We reported this case in Chapter 4: the first patient with a de novo nonsense mutation 
in ZBTBT18 and a phenotype including short stature, microcephaly, a developmental 
delay (especially of the speech) and facial dysmorphic features (arched eyebrows, 
telecanthus, short palpebral fissures, a long nose with a prominent tip, short philtrum, 
thin upper lip and micrognathia), showing some resemblance to FHS.
ZBTB18 (also known as ZNF238) is located on chromosome 1q44, within the chromosome 
1q43q44 microdeletion region.7 It encodes a C2H2-type zinc finger protein that acts as 
a transcriptional repressor of genes involved in neuronal development.8 
The phenotype of patients with 1q43q44 microdeletions and a smallest region of overlap 
including ZBTB18 suggested this gene as a strong candidate gene for microcephaly 
and/or agenesis of the corpus callosum.9-13
Clinical findings in patients with microdeletions of chromosome 1q43q44 may 
resemble the FHS phenotype. Overlapping features include short stature and language 
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deficits. Additionally, structural defects such as cardiac, gastro-intestinal and urogenital 
anomalies have been described in both syndromes. Dysmorphic features of patients 
with 1q43q44 microdeletions include a round face with deep set eyes, epicanthic folds, 
low set ears, a prominent metopic ridge, short nose with prominent/broad nasal tip, a 
thin upper lip, wide spaced teeth and retro-/micrognathia.
The absence of facial features distinctive for FHS and the presence of microcephaly and 
corpus callosum abnormalities in patients with 1q43q44 microdeletions distinguish 
these patients from patients with FHS.
The clinical features of our patient have all been described in patients with 1q43q44 
microdeletions that include the ZBTB18 gene. However, our patient did not have corpus 
callosum abnormalities, even though these are seen in 82% of patients with deletions. 
Furthermore, the facial features of our patient overlapped only partially with those 
of the 1q43q44 microdeletion syndrome (prominent nasal tip, smooth philtrum, thin 
upper lip and micrognathia).
The absence of corpus callosum abnormalities in our patient could be attributed to 
incomplete penetrance or to a contribution of other genes in the 1q43q44 region to 
corpus callosum development.
Our study suggests that ZBTB18 haploinsufficiency contributes to the phenotype of 
the 1q43q44 microdeletion syndrome: the non-mandatory pre- and postnatal growth 
retardation (present in 40% and 42% of patients) and the core features, particularly 
microcephaly and developmental delay, present in 97% and 100% of patients with this 
syndrome, respectively. A lethal phenotype with neocortical defects is seen in Zbtb18 
knockout mice and ZBTB18-mutant brains show reduced neuronal and increased glial 
differentiation.
Furthermore, central nervous system-specific loss of ZBTB18 causes microcephaly, 
agenesis of the corpus callosum and cerebellar hypoplasia, providing supportive 
evidence for this hypothesis.8 
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In this thesis, we have put next generation phenotyping into practice. We performed 
genotype-phenotype studies in three syndromes with short stature as a cardinal 
feature, after the elucidation of their underlying genetic causes through whole exome 
sequencing: Meier-Gorlin syndrome (MGS) and Floating-Harbor syndrome (FHS) 
(Chapters 2 and 3).1-3,6 
Furthermore, through whole exome sequencing, we identified a de novo ZBTB18 
mutation in a patient previously suspected to have FHS and proposed ZBTB18 as a 
candidate gene for (a part of) the phenotype of the 1q43q44 microdeletion syndrome 
(Chapter 4).
Implications for medical care
Our findings illustrate the relevance of next generation phenotyping, including 
genotype-phenotype studies in rare disorders and the importance of a correct and 
molecularly confirmed diagnosis in individual patients. 
In an individual with a syndrome accompanied by a short stature, it can be very 
challenging to identify a definitive molecular diagnosis. When next generation 
techniques are used as a first tier diagnostic tool, knowledge of the phenotypic 
spectrum of genetic disorders is essential to assess the relevance of detected variants. 
For this purpose, next-generation phenotyping, including genotype-phenotype 
studies, is of crucial importance in daily clinical practice.
MGS and FHS syndrome
We have further delineated the phenotypic spectrum of MGS and FHS syndrome, 
thereby facilitating the assessment of health risks for patients with these syndromes. 
In addition, we have developed experience-based guidelines for the management of 
these patients, enabling appropriate medical follow-up for individual patients who are 
diagnosed with MGS and FHS syndrome. 
Our genotype-phenotype studies and overview of the frequencies of clinical features of 
patients with MGS and FHS syndrome will assist physicians to clinically recognize these 
syndromes and should prompt them to examine these specific features in patients with 
MGS and FHS syndrome. Moreover, our data can help physicians to determine whether 
these syndromes should be part of the differential diagnosis of an individual patient.
Our genotype-phenotype studies increase the likelihood of making a correct clinical 
and molecular diagnosis in patients with clinical features in the spectrum of MGS or 
FHS syndrome, thereby reducing the number of misdiagnoses.
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Currently, next generation sequencing techniques are still (largely) unavailable in many 
countries. In these countries, clinicians still depend on targeted DNA analysis following 
a clinical suspicion/diagnosis of a genetic disorder. However, many syndromes are 
accompanied by short stature: a search for proportionate short stature in the Winter-
Baraitser London Dysmorphology Database (version 1.0.36) reveals 960 hits at present.14 
It can be challenging and difficult to clinically distinguish between these syndromes, 
especially when clinical features are similar, when the disorders lack pathognomonic 
features or when certain features can only be recognized after a certain age. 
The molecular cause of many syndromes remains unknown, enabling only clinical 
diagnoses at present. Erroneous clinical diagnoses are regularly made, even by 
experienced clinical geneticists.15-17
The parents of the three patients previously diagnosed with FHS, in whom the 
diagnosis of FHS was discarded after SRCAP analysis, had focused on the wrong 
disorder and management of these patients was incorrectly directed towards FHS. One 
of the patients who displayed behavioral problems turned out to have KBG syndrome 
(KBG after the initials of surnames of the first three patients described).18 Even though 
behavioral problems have been described in patients with FHS, they are a cardinal 
feature in KBG syndrome.19-22 After the patient was diagnosed with KBG syndrome, his 
problems could be attributed to this syndrome and parents were brought in contact 
with the parents of other patients with KBG syndrome.
After a patient is diagnosed with a syndrome, questions of parents may arise: will our 
child survive? Will he or she develop significant other health problems? Will my child 
have a normal intellect?
 The findings of this thesis can be shared with the families of patients with MGS or FHS 
syndrome and thereby help to answer their questions and obtain the best medical care.
In syndromes with a short stature, parents also wonder how tall their child will become.
Often, little is known about the expected growth and adult height of patients with rare 
syndromes. We successfully used a new method to perform in depth growth studies 
in a cohort of 45 MGS patients (Chapter 2.2). The usual methods based on statistical 
analyses of large groups of children could not be applied to our small cohort of MGS 
patients, since there was insufficient power to perform the statistical analyses necessary 
to create classic growth charts.23 
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We therefore developed a linear mixed model with random factor patient. This model 
can be extrapolated to predict the growth pattern and adult height in other rare 
syndromes with short stature as well.
ZBTB18 mutations
We reported the first de novo nonsense mutation in ZBTB18, detected in the second 
of our three patient, who were previously diagnosed with FHS (Chapter 4). Her 
phenotype consisted of a developmental delay, especially of the speech, short stature, 
microcephaly and facial dysmorphic features including a round face with deep set eyes, 
epicanthic folds, low set ears, a prominent metopic ridge, short nose with prominent/
broad nasal tip, a thin upper lip, wide spaced teeth and retro-/micrognathia. Since we 
described only a single patient, studies to establish the phenotypic spectrum of ZBTB18 
mutations and genotype-phenotype correlations could not be performed at the time.
However, recently, a second patient with a de novo mutation in ZBTB18 was reported.24 
This 4-year old infant had a developmental delay, hypotonia, spastic diplegia with 
hyperreflexia and dystonia, stereotyped behaviors and a thin corpus callosum and 
cerebellar vermis hypoplasia. Furthermore, whole exome sequencing revealed a de novo 
ZBTB18 mutation in a third patient, with a severe developmental delay with marked 
speech delay, seizures in infancy and facial dysmorphic features including deep set 
eyes, full arched eyebrows, a full nasal tip, broad mouth with full lips and a pointed 
chin (unpublished data).
Even though a cohort of three patients is still insufficient to perform genotype-
phenotype studies, these patients confirm our hypothesis that ZBTB18 mutations 
cause a syndromic form of intellectual disability/ global developmental delay and that 
ZBTB18 haploinsufficiency contributes to the phenotype of the chromosome 1q43q44 
microdeletion syndrome.
Genetic counseling
One of my main reasons to engage in research is to help patients and their families by 
increasing the knowledge of rare genetic disorders, not only to improve medical care 
for these disorders, but to optimize genetic counseling as well. 
Diagnosing a child with a specific syndrome can help parents to come to term with the 
problems of their child. In many cases, the search for a classifying diagnosis is a process 
that extends over numerous years. Parents often feel guilty and wonder if there was 
anything they could have done to prevent the disorder in their child, especially during 
pregnancy. Once a diagnosis is made, genetic counseling is important to support 
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patients and their parents to “understand and adapt to the medical, psychological and 
familial implications of genetic contributions to disease”.25
Establishing the molecular diagnosis of MGS or FHS syndrome proves to parents that 
they could not have averted the disorder of their child and that they are not to blame. 
Furthermore, insight into the definitive diagnosis helps patients and their parents in 
the process of accepting their problems and can be of benefit in obtaining support for 
special education and adaptations at home. 
However, feelings of sorrow that the condition is incurable can be present and, 
unfortunately, any feelings of guilt do not always abate with this understanding.26,27 
Discussing these emotional aspects is an important facet of genetic counseling.
Following the molecular confirmation of the diagnosis and mutation specific testing 
in both parents, the exact recurrence risk can be determined, providing parents 
and patients (and sometimes other family members) with more options for family 
planning, either through reassurance in the case of a de novo mutation, or through DNA 
analysis in chorionic villi or preimplantation diagnosis (PGD) in the case of inherited 
variants.28,29 In the future, non-invasive prenatal testing, in which DNA analysis of the 
fetus can be performed in maternal blood without risk of fetal loss, may be available for 
many syndromes in which the molecular diagnosis is established.30-32
Implications for molecular diagnostics
Next to the implications for medical care, the results of our genotype-phenotype 
studies influence the molecular diagnostic process.
We established that FHS is a highly recognizable, monogenic (homogeneous) disorder, 
indicating that patients without mutations in SRCAP likely were misdiagnosed with 
FHS in the past or have a disorder similar to FHS that is caused by mutations in a 
separate gene.
MGS, on the other hand, is a heterogeneous disorder. We detected mutations in one of 
the five known genes (ORC1, ORC4, ORC6, CDT1, CDC6) in approximately 70% of MGS 
patients. In 22% of patients with a classical phenotype of MGS, no mutation could be 
identified. 
Recently, however, we performed WES in four MGS patients and recognized a de novo 
heterozygous mutation in GMNN in one patientA. Simultaneously, another group 
detected a de novo GMNN mutation in another MGS patient. Afterwards, we performed 
Sanger sequencing of the GMNN gene in seven MGS patients and detected a de novo 
mutation in a third patient.33 
A  This patient is described in this thesis as individual j (Chapter 2.1) and patient 43 (Chapter 2.2). In these chapters, 
he is included as a patient in whom no definitive diagnosis could be made.
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The GMNN gene encodes the DNA replication inhibitor Geminin. Geminin interacts 
with CDT1, a DNA replication factor involved in the regulation of cell cycle progression 
and replication (Figure 1).34-36
Figure 1. Model illustrating how Cdt1 and geminin limit DNA replication to exactly one round per cell cycle.90 
The origin-recognition complex (ORC) remains bound throughout the cell cycle. During mitosis Cdt1 is sequestered 
by geminin; upon exit from metaphase, geminin is degraded, releasing Cdt1. Cdt1 and Cdc6 bind to DNA, allowing 
the mini-chromosome maintenance (MCM) complex to bind to DNA during G1 phase, thereby ‘licencing’ DNA for 
a single round of replication. The MCM complex, Cdt1 and possibly Cdc6 are displaced from DNA during S phase. 
Newly synthesized geminin binds to displaced Cdt1 during S, G2 and M phases, preventing re-licencing of DNA 
within the same cell cycle. (published with permission of Nature Cell Biology) 
These are the first three patients with an autosomal dominant form of MGS. All three 
mutations were de novo, reducing the recurrence risk from 25% to less than 1% for 
parents, while increasing the recurrence risk for the offspring of patients from less than 
1% to 50%. 
The classical triad of microtia, patellar anomalies and short stature was present in all 
three patients. Compared to our cohort of MGS patients with mutations in ORC1, ORC4, 
ORC6, CDT1 and CDC6, however, the patients with mutations in GMNN are at the severe 
end of the spectrum, with heights ranging from -3.9 to -6.8 SDs.
In addition, the patients with GMNN mutations have certain clinical features that 
are rare in MGS: one of the patients was previously described as one of two patients 
with extremely low IGF1 levels and a positive response to growth hormone treatment. 
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Furthermore, two of the three patients have marked lumbar lordosis and developmental 
delay and/or cognitive impairment. Moreover, two patients share fullness of the peri-
orbital region, a feature not previously recognized in MGS. Even though these three 
patients fulfill the clinical criteria of MGS, the clinical data of more patients needs to be 
analyzed to determine whether these patients really have MGS or a clinical phenotype 
resembling MGS.
GMNN mutations (and ORC1 mutations) may perturb DNA replication to a greater 
extent than mutations in the other MGS associated genes. Furthermore, GMNN 
mutations may have a more profound effect on the replicative burst and cell growth 
required for brain development and head size expansion and height. Lack of geminin 
in mice resulted in preimplantation mortality.37
In three other MGS patientsB, we were able to identify two recurrent mutations in ORC6 
through whole exome sequencing. Previously, these mutations were not detected after 
whole exome sequencing on a different platform that did not cover the entire protein 
coding region of known genes at sufficient read depth, a well recognized restriction of 
whole exome sequencing.38
In the five remaining patients of our cohort, including three patients with mono-allelic 
mutations in ORC1 and CDT1, the molecular defect remains to be elucidated. These 
remaining patients could have syndromes resembling MGS and have been diagnosed 
with MGS unjustly. Mutations could also be located in one of the regulatory elements 
present in the remaining 98-99% of our DNA which we are unable to sequence with 
current molecular techniques such as whole exome sequencing. 
The introduction of whole genome sequencing may lead to the identification of the 
molecular cause in these patients: in whole genome sequencing, the entire genome is 
sequenced, enabling the detection of mutations in non-coding regions. Furthermore, 
whole genome sequencing is more effective in detecting variants in the coding regions 
of our DNA, due to an increased coverage of these regions.39 The introduction of whole 
genome sequencing is expected to further increase the diagnostic yield in MGS, as was 
shown for severe early-onset epilepsy and intellectual disability.40,41 
Moreover, the discovery of de novo dominant mutations in GMNN has altered our belief 
that MGS is solely an autosomal recessive disorder.
B  All three patients are included in Chapter 2.1 and Chapter 2.2 as patients without definitive molecular 
diagnosis. One of these patients is described as individual i (Chapter 2.1) and patient 44 (Chapter 2.2). The other 
two patients were not specified.
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To unravel the genetics of MGS (and other syndromes in which the underlying 
molecular defect is unknown) we may benefit from animal studies as well. The 
phenotype of animals with mutations in an orthologous gene may help to select 
candidate genes (both before and after exome sequencing) and to establish or support 
the pathogenicity of mutations in novel genes detected with WES.1,42 Moreover, clinical 
features seen in animal studies may be relevant to our human patients and thereby 
influence diagnostic management and follow-up of these patients.
Insights into pathophysiology and developmental pathways
Establishing the molecular defect in rare genetic syndromes followed by thorough 
genotype-phenotype studies can provide valuable insights in the pathophysiology 
of these disorders. Knowledge of the mechanisms through which mutations in the 
concerning genes cause these syndromes is crucial. It can help to order genes in 
developmental pathways and provide clues for possible therapeutic strategies.
The other way around, identification of genes involved in specific developmental 
pathways may lead to the selection of candidate genes for specific syndromes with a 
phenotype likely to be caused by disturbance of that pathway or in which mutations in 
other genes from that pathway have already been described.
For instance, mutations in genes from intracellular signaling pathways influencing 
growth, including the RAS-MAPK/ERK and PI3K-mTOR pathways, can cause several 
syndromes in which growth is affected, such as Noonan-syndrome, FGFR3-related 
skeletal dysplasias (the RAS-MAPK/ERK pathway) and PTEN-hamartoma tumor 
syndrome (the PI3K-mTOR pathway). Especially in the RAS-MAPK/ERK pathway, 
knowledge of the genes involved in this pathway has enabled researchers to identify 
new ‘Rasopathies’.43-66
The pre-replication genes ORC1, ORC4, ORC6, CDT1 and CDC6, that are known to cause 
MGS, are all part of the pre-replication complex (preRC), a complex that is essential 
for DNA replication.67,68 GMNN, our recently identified MGS gene, interacts with this 
complex through interaction with CDT1 (Figure 1). The precise pathogenic mechanism 
of MGS is yet to be unraveled, but several mechanisms have been proposed. Mutations 
in these genes are presumed to delay cell cycle progression and may become rate 
limiting during very rapid cell cycles, slowing cell cycle progression and subsequently 
reduce total cell number and thereby organ size.69,70 
A second possible mechanism affecting cell cycle progression is a defect in the rate of 
formation of primary cilia, which was demonstrated in ORC1 depleted cells.71 Finally, 
mutations in distinctive domains of the ORC1 subunit of the preRC, that regulate 
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centriole and centrosome copy number, are suggested to alter centrosome duplication 
and thereby contribute to the growth retardation and microcephaly in MGS.72
The mutations in the SRCAP gene that cause FHS are clustered in the C-terminal region 
of the gene.6 SRCAP encodes a SNF2-related chromatin remodeling ATP-ase, a co-
activator of CREB-binding protein. Mutations in SRCAP may lead to an altered protein 
that interferes with normal activation of the CREBBP gene. CREBBP plays an important 
role in regulating cell growth and division. Studies have linked CREBBP to the RAS-
MAPK pathway by demonstrating that mitogen-activated protein kinase (MAPK) 
phosphorylation of Ets-1 and Ets-2 resulted in enhanced transactivation by preferential 
recruitment of the co-activators CREBBP and p300.73
So far, the ZBTB18 gene could not be linked directly to any of the known pathways for 
growth. 
Further functional studies of the genes that cause MGS and FHS syndrome and the 
ZBTB18 gene are necessary to determine their exact role in embryological development 
and the pathophysiologic mechanism of mutations in these genes. Again, animal 
studies may help in providing these insights and may assist in developing future 
therapies, as was the case in Leber congenital amaurosis, where studying animal 
models eventually led to RPE65 gene therapy.74-77
Future studies: a molecular diagnosis and data sharing are fundamental
We intend to carry our next generation phenotyping studies forward and further 
delineate the phenotypic spectrum of MGS, FHS syndrome, ZBTB18 mutations and 
disorders resembling these syndromes by additional longitudinal genotype-phenotype 
studies in extended cohorts of patients with these syndromes. We aim to incorporate 
our mixed linear growth model to study growth in these disorders. These studies will 
further assist physicians in interpreting results from next generation sequencing and 
accommodate them in establishing a clinical diagnosis in countries where the use of 
whole exome sequencing in a diagnostic setting is not standard.
Genotype-phenotype studies can only be performed when the underlying molecular 
defect is known. However, in OMIM (Online Mendeliance in Man; http://omim.org/), 
there are over 1600 phenotypic descriptions (entities) of patients or groups of patients 
in whom the molecular diagnosis remains to be elucidated.78
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Current molecular tests (e.g. linkage studies, genome-wide SNP-array studies 
including homozygosity mapping and whole exome sequencing) are used to detect the 
underlying molecular cause in syndromes of which the cause is yet to be established.
As clinical geneticists, we play a key role in this process by recognizing clinical syndromes, 
selecting cohorts of patients and interpreting results of molecular investigations. 
Furthermore, we assist in the unraveling of new syndromes caused by mutations in 
novel genes by proper phenotyping, recognizing patients with overlapping phenotypes 
and performing segregation analysis in families.
A more widespread use of whole exome sequencing can increase the number 
of established correct diagnoses and further reduce the number of phenotypic 
descriptions with an unknown molecular defect. New techniques, such as whole 
genome sequencing, are expected to contribute to this process even further.40,41,79
A prerequisite for next generation phenotyping is data sharing. When the underlying 
molecular defect of a rare syndrome is identified, the formation of a cohort of patients 
with the same genetic defect is essential to perform genotype-phenotype studies. 
Due to the low prevalence of many genetic syndromes, however, it can be very difficult 
to obtain sufficient data and perform these studies. (Inter)national cooperation 
to establish large scale data sharing is crucial to form cohorts of patients with rare 
disorders. 
The same accounts for the unraveling of molecular defects in patients with rare genetic 
syndromes: in daily practice, it is often difficult to find a second patient with a mutation 
in the same gene or to collect more patients with the same phenotype in whom you 
can perform WES simultaneously in order to detect the underlying genetic defect in 
these patients. In our studies, we encountered these difficulties when we detected a de 
novo ZBTB18 mutation in a single patient (Chapter 4). Identification of more patients 
with mutations in this gene is essential to enhance the knowledge of this disorder and 
improve patient care.
This problem is recognized by professionals, patients and politicians. 
At present, the European Union ‘helps to pool scarce resources that are currently 
fragmented across individual EU countries and helps patients and professionals 
share expertise and information across borders’ by enabling the formation of national 
centers of reference for rare diseases that join together to form European networks of 
reference (http://ec.europa.eu/health/rare_diseases/european_reference_networks/).
Professional driven initiatives have led to the development of programmes for 
secured data sharing between clinicians and scientists. They aim to facilitate in 
40970 Munnik, Sonja de.indd   154 04-07-16   14:03
General discussion and future prospects
155
 5.2
establishing a correct diagnosis by indicating overlapping clinical features between a 
patient and known syndromes or between two patients without a known diagnosis, 
thereby enabling us to learn more about known rare disorders and to unravel new 
genetic syndromes. An example of such a platform is Matchmaker Exchange (http://
matchmakerexchange.org), which aims to ‘facilitate the matching of cases with 
similar phenotypic and genotypic profiles (matchmaking) through standardized 
application programming interfaces (APIs) and procedural conventions’. These APIs 
enable submitters to search for overlapping genetic variants and phenotypes in 
multiple databases with just one query. Phenome Central (https://phenomecentral.
org), Leiden Open Variation Database (http://www.lovd.nl), GeneMatcher (http://
www.genematcher.org), Cafe Variome (www.cafevariome.org) and Decipher (https://
decipher.sanger.ac.uk) are examples of databases that are part of the Matchmaker 
Exchange platform.80-83
A patient participation portal is Genomeconnect, part of the clinical genome resource 
(http://www.clinicalgenome.org). It aims to ‘connect people who are interested in 
sharing de-identified genetic and health information to improve the understanding of 
genetics and health’ and is associated with the Matchmaker Exchange platform.
An example of the successful use of these databases is the identification of de novo 
HNRNPK mutations in two patients with ID, specific facial dysmorphic features and 
skeletal and connective tissue abnormalities.84
The matchmaking process can be challenging, though. To increase the chances of 
successful matchmaking, the use of standardized measures for capturing phenotypic 
abnormalities is of major importance.85 The Human Phenotype Ontology project 
(http://www.human-phenotype-ontology.org) aims to ‘provide a standardized 
vocabulary of phenotypic abnormalities encountered in human disease’.86 So far, it 
‘provides a structured, comprehensive and well-defined set of 10,088 classes (terms) 
describing human phenotypic abnormalities and 13,326 subclass relations between 
the HPO classes’.87
HPO has assisted in unraveling genetic defects in 707 cases with unexplained bleeding 
and platelet disorders, demonstrating the power of this standardized vocabulary.88
 Another initiative to increase the chance of successful matchmaking is a computational 
tool called ‘Phenolyzer’.89 This tool prioritizes Mendelian and complex disease genes, 
based on disease or phenotype terms entered as free text, thereby utilizing existing 
disease nomenclature systems to interpret the user input, sometimes including 
multiple diseases or phenotype terms.
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Thus, the widespread use of HPO-terms in daily practice and data sharing programmes 
could accommodate physicians in making a correct diagnosis, enable genotype-
phenotype studies by forming cohorts of patients with rare disorders and assist in 
elucidating new genetic syndromes by connecting the phenotypes of patients without 
a diagnosis.
Next to professional-based initiatives, patient organizations play an upcoming, 
important role in data sharing and educating patients and their surroundings, by 
providing them with information about their disorder. Moreover, they keep patients 
and their parents informed about new developments (i.e. potential therapies, DNA-
investigations) and stimulate research participation.
Nowadays, patients often organize themselves through social media, such as facebook 
or patient organization websites. Patients or parents of patients with the same disorder 
form their own groups, enabling contact between people who live on other sides of 
the world. Social media are a good platform for patients to increase the awareness of 
their condition and to help collect data from other patients with the same disorder for 
research purposes. A good example of a patient organization that is active on social 
media and aims to ‘educate, increase awareness and promote research for the support 
and enrichment of individuals living with Koolen-de Vries Syndrome and their families’, 
is ‘Supporting Families with Koolen-de Vries Syndrome Mission’: www.supportingkdvs.
com and https://ww.facebook.com/supportingkdvs.
To our knowledge, no active patient organizations exist for MGS and FHS syndrome 
(the information on the Floating Harbor syndrome support group dates back to 2013 
(www.floatingharborsyndromesupport.com)) and our research groups. These patients 
could also benefit from patient organizations that remain up to date.
For future studies, sharing DNA or other tissues is equally important as sharing clinical 
data. Biobanks store biological samples of patients for research purposes. Scientists 
can obtain DNA or other tissues from several patients with the same disorder, to search 
for the underlying molecular cause of a syndrome or to perform functional studies to 
acquire more insight in the pathophysiology of disorders.
Two examples of such biobanks are AGORA (Aetiologic research into Genetic 
and Occupational/environmental Risk factors for Anomalies in children) of the 
Radboud university medical center, a data- and biobank of patients with congenital 
malformations (such as malformations of the kidneys and urinary tract, intestines and 
anus, lip and palate and the heart, but also childhood cancers; www.agoraproject.nl) 
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and the ‘Dutch Parelsnoer initiative’, a collaboration of the eight Dutch Universities to 
collect clinical data and biological samples from patients with chronic diseases (www.
parelsnoer.nl).
All initiatives are important steps towards proper worldwide data sharing. In an 
ideal world, all clinical and molecular information would be shared in one database 
accessible to physicians, scientists and patients worldwide and DNA of all patients 
would be stored in biobanks and be available for researchers worldwide through a 
single coordination centre. 
In conclusion
In this thesis, we performed genotype-phenotype studies in Meier-Gorlin syndrome 
(MGS) and Floating-Harbor syndrome (FHS) syndrome and proposed experience 
based management advice after the molecular cause for these disorders was 
identified through whole exome sequencing. We have increased the knowledge of the 
phenotypic spectrum of these syndromes and improved clinical care for these patients. 
Additionally, we established a de novo nonsense mutation in ZBTB18 in a girl with 
features resembling FHS syndrome through whole exome sequencing.
To take next generation phenotyping to a higher level, sharing of clinical and 
molecular data is essential. For example, data sharing will enable us to form a cohort 
of patients with ZBTB18 mutations and even larger cohorts of patients with MGS and 
FHS syndrome in whom we can perform genotype-phenotype and follow-up studies to 
further improve diagnosis and management of these patients. Furthermore, functional 
studies aimed to increase our knowledge about the underlying molecular mechanism 
of these disorders may assist us to select new candidate genes for MGS and disorders 
resembling MGS and FHS syndrome and may contribute to explain the phenotypic 
variability of these syndromes and potentially provide valuable clues for therapeutic 
strategies.
Overall, the era of genomics provided valuable new techniques with a tremendously 
increased diagnostic yield, leading to the identification of the molecular genetic defect 
in patients with clinically well-known disorders and many new genetic syndromes. In 
this era, clinical genetic practice is slowly shifting from a phenotype-first approach to a 
predominantly genotype-first approach. 
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Major challenges still to overcome comprise genotype and phenotype data sharing of 
patients and interpretation of the clinical significance of genetic variants by integrating 
clinical and molecular data, combined with knowledge from model systems and 
biological network data.
Phenotyping of each individual remains of the utmost importance to interpret detected 
genetic variants, make the correct diagnosis and ensure optimal medical care.
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Op dit moment leven we in het ‘Genomics’ tijdperk. Dit tijdperk wordt gekenmerkt 
door een nieuwe generatie genetische onderzoeken (‘next generation sequencing’ 
(NGS)), waarbij veel genen tegelijkertijd onderzocht kunnen worden, terwijl het 
voorheen slechts mogelijk was om één gen per test te onderzoeken. Met behulp 
van deze nieuwe technieken zijn we veel vaker in staat om een diagnose te stellen, 
maar komen we ook voor nieuwe uitdagingen te staan. De introductie van NGS 
heeft tot een nieuwe werkwijze binnen de klinische genetica geleid: ‘next generation 
fenotypering’. Met deze werkwijze worden diagnoses gesteld en nieuwe syndromen 
ontdekt door het associëren van de overeenkomstige klinische kenmerken (‘fenotype’) 
van patiënten met DNA-afwijkingen (‘mutaties’) in genen die gevonden zijn met NGS. 
Bij kinderen met een verstandelijke beperking bijvoorbeeld, worden tussen de 0 en 
7 DNA-varianten per individu gevonden, die bij het kind nieuw zijn ontstaan en dus 
niet bij beide ouders worden teruggevonden. Om te kunnen bepalen welke van deze 
varianten daadwerkelijk de oorzaak is van de verstandelijke beperking, is het belangrijk 
om de klinische kenmerken van een patiënt gedetailleerd in kaart te brengen. Deze 
vergelijken we vervolgens met het fenotype van andere patiënten (of dieren) met DNA-
afwijkingen (mutaties) in dezelfde genen.
Daarnaast zijn we er in geslaagd om met behulp van NGS de onderliggende genetische 
oorzaak voor veel bekende syndromen te identificeren, waardoor genotype-fenotype 
studies voor deze syndromen mogelijk zijn geworden. Om nieuwe syndromen te 
ontdekken en meer kennis over deze syndromen te vergaren, is het belangrijk om 
het fenotype van een patiënt zo goed mogelijk in kaart te brengen. Door middel van 
(inter)nationale samenwerking en het delen van data in internationale databases is 
het mogelijk om de kenmerken van meerdere patiënten met mutaties in hetzelfde 
gen te bestuderen en zo meer inzichten te krijgen in nieuwe syndromen. Het inzicht 
in het klinische spectrum van deze aandoeningen wordt hierdoor vergroot, waardoor 
patiënten met deze aandoeningen en hun ouders en behandelend artsen weten welke 
gezondheidsproblemen zouden kunnen optreden. Bovendien kunnen we op deze 
manier patiënten met hetzelfde zeldzame fenotype vinden en de resultaten van hun 
genetisch onderzoek vergelijken om de onderliggende oorzaak voor hun syndroom op 
te sporen.
In dit proefschrift hebben we, nadat de onderliggende genetische oorzaak met behulp 
van NGS was vastgesteld, genotype-fenotype studies verricht voor twee syndromen, 
die beiden onder andere gekenmerkt worden door een kleine lengte: Meier-Gorlin 
syndroom (MGS) en Floating-Harbor syndroom (FHS). Op basis van deze studies 
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presenteerden we als eerste adviezen voor de medische zorg van patiënten met deze 
syndromen (hoofdstukken 2 en 3). Doordat artsen nu de klinische kenmerken van MGS 
en FHS beter met die van hun patiënt kunnen vergelijken, wordt het makkelijker om 
een klinische (waarschijnlijkheids)diagnose te stellen en te bepalen welk aanvullend 
genetisch onderzoek aangewezen is. Tenslotte hebben we met NGS een nieuw 
ontstane mutatie in ZBTB18 gevonden bij een patiënt bij wie in eerste instantie gedacht 
werd aan FHS (hoofdstuk 4). Vervolgens hebben we de medische gegevens van andere 
patiënten met ZBTB18 in kaart gebracht (ongepubliceerde data) en hiermee een nieuw 
syndroom geïdentificeerd.
Hoofdstuk 2. Meier-Gorlin syndroom
Het Meier-Gorlin syndroom (MGS) is voor het eerst beschreven in 1959. In 2011 werd 
ontdekt dat MGS wordt veroorzaakt door mutaties in de ORC1, ORC4, ORC6, CDT1 en 
CDC6 genen in ongeveer 70% van de patiënten. Deze vijf genen maken onderdeel uit 
van het pre-replicatie complex, een complex dat betrokken is bij het kopiëren van het 
DNA (‘DNA-replicatie’), dat een cruciale stap in de celdeling is. 
Deze ontdekking stelde ons in staat om de genotype-fenotype studies te verrichten, 
die zijn beschreven in hoofdstuk 2.1.
We hebben genotype-fenotype studies verricht in een cohort van 35 MGS patiënten 
met twee mutaties in één van de vijf bekende genen van het pre-replicatie complex en 
10 MGS patiënten bij wie de onderliggende genetische afwijking onbekend was. De 
diagnose MGS werd bij deze 10 patiënten gesteld op basis van klinische kenmerken.
De klassieke trias van klinische kenmerken van MGS omvat kleine oren (‘microtie’), 
te kleine/afwezige knieschijven (‘patella a-/hypoplasie’) en een kleine lengte. Deze 
klassieke trias werd gezien in 29 van de 35 MGS patiënten met mutaties in een van de 
vijf bekende genen. Vier patiënten (één met ORC1 mutaties, één met ORC6 mutaties 
en twee met CDT1 mutaties) hadden microtie en patella aplasie, maar een normale 
lengte. Één patiënt met ORC1 mutatie had microtie en een kleine lengte, maar normale 
patellae. Een andere patiënt met ORC1 mutaties had een kleine lengte, zonder microtie 
en patella afwijkingen.
Deze bevindingen tonen aan dat het fenotypische spectrum van MGS breder is dan 
werd gedacht voordat genetische diagnostiek mogelijk was. Aangezien na moleculaire 
40970 Munnik, Sonja de.indd   169 04-07-16   14:03
Appendix
170
diagnostiek van patiënten is gebleken dat bij een klein deel van de patiënten met MGS 
slechts één van de drie klassieke kenmerken van MGS aanwezig is, wordt aan artsen 
geadviseerd de diagnose MGS vaker in hun differentiaal diagnostische overwegingen 
mee te nemen.
Andere frequente klinische kenmerken in ons cohort van patiënten met MGS 
waren een typisch gelaat (o.a. een klein mond met volle lippen en een smalle neus 
met een brede neusrug), ademhalingsproblemen tijdens de vroege kinderleeftijd 
(inclusief aangeboren long emfyseem, en trachea-, laryngo- en/of bronchomalacie), 
voedingsproblemen tijdens de kinderleeftijd, onderontwikkelde borsten (‘mamma 
hypoplasie’) en afwijkingen van het genitaal.
Door het fenotype van MGS patiënten met mutaties in de vijf verschillende genen 
onderling te vergelijken, kwam aan het licht dat patiënten met ORC1 mutaties de 
meest ernstige groeiachterstand hadden: zij waren het kleinst en hadden de kleinste 
schedelomtrek, met een gemiddelde standaard deviatie score van respectievelijk -7.1 
SDs (range -9.6 tot -5.2 SDs) en -6.7 SDs (range -9.8 tot -4 SDs).
Daarnaast hebben we het fenotype van patiënten met verschillende types mutaties 
(met een verschillend effect op de vorming van het eiwit) in hetzelfde gen met 
elkaar vergeleken. Deze data suggereerde dat compound heterozygote nonsense 
en missense mutaties een ernstiger effect op het fenotype hebben dan homozygote 
missense mutaties. Drie patiënten met een missense mutatie en een nonsense mutatie 
in ORC4 hadden een meer uitgesproken groeiachterstand en meer aangeboren 
afwijkingen (aangeboren long emfyseem, een aangeboren hartafwijking en ernstige 
voedingsproblemen) dan vier patiënten met twee missense mutaties in ORC4. 
Daarnaast had de enige patiënt met een homozygote missense mutatie in CDT1 geen 
aangeboren long emfyseem, terwijl dit bij alle zeven patiënten met een missense en 
een nonsense mutatie in CDT1 wel vastgesteld was.
Vier patiënten met compound heterozygote nonsense en missense mutaties zijn 
overleden: een jongen met een nonsense en een missense mutatie in CDT1 is 
overleden ten gevolge van een plotse hartstilstand, terwijl zijn zus op de leeftijd van 
drie maanden overleed aan ernstige ademhalingsproblemen veroorzaakt door een 
tracheobronchomalacie met progressief aangeboren long emfyseem. Een jongen met 
een frameshift mutatie en een missense mutatie in ORC1 overleed na 3.5 maanden. 
Hij had een ernstige corticale dysplasia met pachygyrie en ventriculomegalie, 
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craniosynostose, aangeboren long emfyseem en een agenesie van de pancreasstaart. 
Zijn broer overleed na 17 weken zwangerschap. Hij had een ernstige groeiachterstand 
en microtie.
Vooralsnog zijn er geen MGS patiënten beschreven met homozygote of compound 
heterozygote nonsense mutaties, hetgeen suggereert dat het effect van deze mutaties 
dusdanig ernstig is, dat dit niet verenigbaar is met het leven. Deze hypothese wordt 
ondersteund door de uitkomsten van diermodel studies met Drosophila-vliegen: 
vliegen met nonsense mutaties in ORC6 en CDT1 overlijden tijdens de embryologische 
fase.
In hoofdstuk 2.2 beschreven we de resultaten van een groei studie die we hebben 
verricht in ons cohort van 45 MGS patiënten om een specifiek groei patroon te kunnen 
herkennen. Dit met als doel de groei en het groeipatroon van MGS patiënten te kunnen 
voorspellen. 
Trend analyses van de groei toonden aan dat de groei achterstand van MGS patiënten 
voornamelijk tijdens de zwangerschap optreedt. Een intra-uteriene groei achterstand 
werd gezien bij 98% van de MGS patiënten. Het gemiddelde geboortegewicht lag op 
de -3.9 SDs, met een gemiddelde lengte van -3.4 SDs. In het eerste levensjaar boog de 
lengte verder af tot -5.2 SDs, maar in de jaren daarna was de groeisnelheid normaal tot 
licht verhoogd in vergelijking met kinderen zonder MGS. Dit laatste resulteerde in een 
gemiddelde volwassen lengte van -4.5 SDs. Deze studie resultaten maken het mogelijk 
om het groeipatroon van MGS patiënten te voorspellen: de lengte neemt in het eerste 
levensjaar af met gemiddeld 1.7 SDs, waarna de groeisnelheid nagenoeg normaal 
wordt.
De groei werd significant beïnvloed door etniciteit en de onderliggende moleculaire 
oorzaak. 
Dit bevestigde onze bevindingen die beschreven zijn in hoofdstuk 2.1 en gaf ons 
verder inzicht in de groei. We toonden aan dat patiënten met ORC1 en ORC4 mutaties 
significant kleiner waren (respectievelijk 4.7 SDs en 3.1 SDs kleiner) dan patiënten met 
mutaties in ORC6, CDT1 en CDC6 of MGS patiënten zonder moleculaire diagnose. 
De schedelomtrek van patiënten met ORC1 en ORC4 mutaties was 5.0 SDs (ORC1) en 1.6 
SDs (ORC4) kleiner dan de schedelomtrek van patiënten met mutaties in ORC6, CDT1, 
CDC6 en patiënten zonder moleculaire diagnose.
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In ons cohort van MGS patiënten werden twee Nederlandse patiënten (bij wie de 
diagnose MGS werd gesteld op basis van klinische kenmerken) vanaf de leeftijd van 3 
en 5 jaar succesvol behandeld met groeihormoon (een inhaalgroei van 2 SDs of meer). 
Bij deze twee patiënten bleef de groeisnelheid na het eerste levensjaar vertraagd, 
waardoor de groei verder afboog van het gemiddelde. Ook hadden zij extreem lage 
IGF1 waarden. Deze bevindingen suggereren dat de IGF1 waarde bij een aantal MGS 
patiënten kan worden gebruikt om te voorspellen of behandeling met groeihormoon 
zinvol is.
Recent werd aangeboren long emfyseem vastgesteld bij twee MGS patiënten met 
astma/verschijnselen die op astma lijken (niet gepubliceerde data). 
Ofschoon meer onderzoek nodig is om vast te stellen hoe frequent aangeboren 
long emfyseem daadwerkelijk voor komt bij MGS patiënten, stellen we dat nader 
onderzoek naar aangeboren long emfyseem altijd geïndiceerd is bij MGS patiënten 
met luchtwegklachten die lijken op astma.
Op basis van de resultaten van onze moleculaire en longitudinale klinische studies van 
MGS patiënten (met follow-up data van meer dan 15 jaar) hebben we in hoofdstuk 
2.3 een voorstel gedaan voor de diagnostiek, controles en behandeling van patiënten 
met MGS. De belangrijkste aandachtspunten voor de medische zorg zijn de groei, 
de ontwikkeling van secundaire geslachtskenmerken, de motorische en spraak-taal 
ontwikkeling, luchtwegklachten en orthopedische problemen.
MGS is een heterogene aandoening, waarbij er behoudens de lengte en schedelomtrek, 
geen duidelijke verschillen in fenotype zijn tussen de vijf bekende genen.
Bij ongeveer 30% van de MGS patiënten werd met DNA-onderzoek tot recent geen 
onderliggende oorzaak gevonden. In 2015 werd bij drie MGS patiënten (waaronder 
twee Nederlandse patiënten) één nieuw ontstane mutatie in GMNN gevonden. Bij 
twee van de drie patiënten werd deze mutatie opgespoord met behulp van exoom 
sequencing. Hierna werd de mutatie bij de derde patiënt met behulp van Sanger 
sequencing opgespoord. Het GMNN gen codeert voor het eiwit geminin, dat door een 
interactie met het eiwit CDT1 een essentiële rol heeft in DNA replicatie. Opvallend is 
dat deze bevinding wijst op een autosomaal dominante overerving, terwijl tot nu toe 
alleen aanwijzingen werden gevonden voor een autosomaal recessieve overerving. De 
patiënten met GMNN mutaties presenteerden zich met de bekende klassieke trias 
van MGS, maar hun groeiachterstand leek ernstiger (lengte tussen de -3.9 en -6.8 SDs) 
40970 Munnik, Sonja de.indd   172 04-07-16   14:03
Nederlandse samenvatting
173
en zij hadden andere bijkomende kenmerken (bij twee van de drie patiënten): een 
evidente holle rug (versterkte ‘lumbale lordose’), een ontwikkelingsachterstand en/of 
verstandelijke beperking en prominent weefsel rond de ogen. Één van de patiënten 
was een van de twee Nederlandse patiënten die goed reageerde op de behandeling 
met groeihormoon.
Daarnaast waren we in staat om bij drie patiënten met exoom sequencing twee 
mutaties in ORC6 te vinden. Tot nu toe hadden we deze mutaties niet opgespoord na 
exoom sequencing met een ander platform.
Van ons cohort zijn er nog vijf patiënten bij wie het genetische defect nog niet 
opgehelderd is (waaronder twee patiënten met één mutatie in ORC1 en CDT1). Deze 
patiënten kunnen een syndroom hebben dat klinisch lijkt op MGS. Zij kunnen ook 
mutaties hebben die we met de huidige technieken nog niet kunnen detecteren.
Hoofdstuk 3. Floating-Harbor syndroom
Nadat in 2012 werd vastgesteld dat het Floating-Harbor syndroom (FHS) veroorzaakt 
wordt door truncerende mutaties in het SRCAP gen, hebben we genotype-fenotype 
studies verricht bij 52 FHS patiënten met 14 verschillende mutaties in dit gen. De 
resultaten van dit onderzoek zijn beschreven in hoofdstuk 3.
We stelden vast dat alle 14 beschreven mutaties in het SRCAP gen truncerende mutaties 
zijn, gelegen tussen codons 2389 en 2748 in exon 34. Er waren twee terugkerende 
mutaties: Arg2444* en Arg2435*, die bij respectievelijk 50% en 25% van de patiënten 
gevonden werden.
We hebben de klinische kenmerken van FHS verder in kaart gebracht. Karakteristieke 
kenmerken zijn een kleine lengte (92%; range -1 tot -4.5 SDs; met name postnataal), 
achterblijvende skeletleeftijd, karakteristieke gelaatskenmerken, brede duimen en 
een expressieve spraakachterstand. Het faciale fenotype was in ons cohort de beste 
voorspeller voor de aanwezigheid van een SRCAP mutatie. Wanneer de typische faciale 
kenmerken niet aanwezig waren, was de kans dat er een SRCAP mutatie werd gevonden 
erg klein.
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De karakteristieke faciale kenmerken zijn een driehoekig gelaat met diepliggende 
ogen, lange wimpers, een smalle neusbasis die breder wordt richting de neuspunt, een 
lage columella, grote neusgaten, een kort filtrum en een dunne bovenlip met een naar 
buiten gekeerde onderlip. Een typerend kenmerk is de horizontale lijn van de boven- 
en onderlip. 
De expressieve spraak-taal achterstand werd bij alle patiënten beschreven, maar 
varieerde in ernst: één patiënt sprak twee talen, terwijl andere volwassen FHS 
patiënten slechts enkele woorden spraken. De verstandelijke ontwikkeling varieerde 
van normaal (IQ 104) tot ernstig verstandelijke beperkt (enkele patiënten).
Microcefalie werd slechts bij een minderheid van de patiënten vastgesteld en slechts 
één patiënt had een schedelomtrek die onder de -3 SDs lag, hetgeen suggereerde dat 
de groei van de hersenen van FHS patiënten relatief gespaard wordt.
Ongeveer 63% van de FHS patiënten had ten minste één aangeboren afwijking, onder 
andere in het maag-darmstelsel (motiliteitsproblemen, een vernauwing van het 
colon, coeliakie), het urinewegstelsel (cryptorchidisme, nier-/nierbekken afwijkingen), 
het hart (milde coarctatie van de aorta, atrium septum defect, tetralogie van Fallot), 
de ogen (strabismus, hypermetropie, nystagmus) en het gebit (kleine tanden, cariës, 
malocclusie). Gehoorsverlies en epilepsie werden relatief frequent gezien.
Op basis van deze resultaten, pleiten we ervoor dat de zorg voor FHS patiënten gericht 
wordt op de herkenning en behandeling van gehoor- en visusproblemen, urogenitale 
malformaties, tandafwijkingen, vertraagde skeletleeftijd en groeiretardatie, mogelijke 
vervroegde puberteit, de psychomotore en spraak-taalontwikkelingsachterstand, 
epilepsie en gedragsproblemen.
FHS is een monogene aandoening met een klinisch goed herkenbaar fenotype. 
Patiënten met klinische kenmerken lijkend op FHS, maar zonder mutatie in SRCAP, 
hebben hoogstwaarschijnlijk geen FHS, maar een mutatie in een tweede ‘FHS gen’, 
waarbij het klinische spectrum breder is.
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Hoofdstuk 4. ZBTB18
Zoals beschreven in hoofdstuk 3, wordt Floating-Harbor syndroom (FHS) gekenmerkt 
door een kleine lengte, typische gelaatskenmerken en een expressieve spraak-taal 
achterstand.
Bij slechts twee van de vijf patiënten die we in 2011 in ons universitair medisch centrum 
zagen, kon de diagnose FHS moleculair bevestigd worden. In één van de overige drie 
patiënten heeft whole exome sequencing geleid tot de identificatie van een mutatie in 
een nieuw gen, ZBTB18. 
In hoofdstuk 4 beschrijven we de laatstgenoemde patiënt: de eerste patiënt met een de 
novo nonsense mutatie in ZBTB18 had als klinisch beeld een kleine lengte, microcefalie, 
een ontwikkelingsachterstand (voornamelijk van de spraak) en faciale dysmorfieën 
(gebogen wenkbrauwen, telecantus, korte palpebrale fissuren, een lange neus met 
een prominente punt, een dunne bovenlip en een kleine kin). Op een MRI scan van de 
hersenen werden geen afwijkingen gezien. De klinische kenmerken overlapten deels 
met het fenotype van FHS (o.a. kleine lengte, spraakontwikkelingsachterstand).
Het ZBTB18 gen (ook bekend als ZNF238) ligt op chromosoom 1q44, in de regio van 
het chromosoom 1q43q44 microdeletie syndroom. Het gen codeert voor een C2H2-
type zinc vinger eiwit dat de transcriptie remt van genen die betrokken zijn bij de 
ontwikkeling van het centrale zenuwstelsel. 
De klinische kenmerken van patiënten met microdeleties van chromosoom 1q43q44 
die in de literatuur beschreven zijn komen deels overeen met die van FHS patiënten. 
Overeenkomstige kenmerken zijn een kleine lengte en spraak-taalproblemen. Ook 
aangeboren afwijkingen, zoals hartafwijkingen, gastro-intestinale afwijkingen 
en urogenitale afwijkingen zijn beschreven bij beide syndromen. Typische 
gelaatskenmerken van patiënten met 1q43q44 microdeleties zijn onder andere 
een rond gelaat met diepliggende ogen, epicantusplooien, laagstaande oren, een 
prominente metopische naad, een korte neus met prominente/brede neuspunt, een 
dunne bovenlip, wijd uiteen staande tanden en retro-/micrognatie.
Het fenotype van FHS onderscheidt zich van het 1q43q44 microdeletie syndroom 
door de aanwezigheid van karakteristieke gelaatskenmerken en de afwezigheid van 
microcefalie en corpus callosum afwijkingen. Microcefalie en corpus callosum agenesie 
zijn wel aanwezig bij het grootste deel van de patiënten met 1q43q44 microdeleties. 
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Deze patiënten hebben vaak geen herkenbare, karakteristieke gelaatskenmerken.
In de literatuur zijn meerdere genotype-fenotype studies gepubliceerd van patiënten 
met 1q43q44 microdeleties inclusief het ZBTB18-gen, waarin wordt gesuggereerd 
dat ZBTB18 een belangrijk kandidaatgen is voor microcefalie en/of corpus callosum 
agenesie.
De aanwezigheid van een de novo nonsense mutatie in ZBTB18 in onze patiënt 
met een kleine lengte, microcefalie, een ontwikkelingsachterstand en opvallende 
gelaatskenmerken suggereerde dat haploinsufficiëntie van het ZBTB18-gen 
bijdraagt aan zowel de pre- en postnatale groeiachterstand (aanwezig bij 40% en 
42% van de patiënten), de microcefalie (aanwezig bij 97% van de patiënten) als de 
ontwikkelingsachterstand (aanwezig bij 100% van de patiënten) van het 1q43q44 
microdeletie syndroom.
Deze hypothese wordt ondersteund door het feit dat zbtb18 knockout muizen een 
lethaal fenotype met neocorticale afwijkingen hebben en dat verlies van zbtb18 in het 
centrale zenuwstelsel leidt tot microcefalie, corpus callosum agenesie en hypoplasie 
van het cerebellum. Bovendien laten zbtb18-gemuteerde hersenen een verminderde 
neuronale en toegenomen gliale differentiatie zien.
Alle klinische kenmerken van onze patiënt zijn beschreven bij patiënten met 1q43q44 
microdeleties, waarbij het ZBTB18-gen in het 1q43q44 deletie-gebied ligt. Onze patiënt 
had echter geen afwijkingen van het corpus callosum, terwijl deze bij 82% van de 
patiënten met deleties worden gezien. Bovendien kwamen de faciale kenmerken 
van onze patiënt slechts gedeeltelijk overeen met die van patiënten met het 1q43q44 
microdeletie syndroom (een prominente neuspunt, een vlak filtrum, een dunne 
bovenlip en een kleine kin).
De aanwezigheid van corpus callosum afwijkingen bij het 1q43q44 microdeletie 
syndroom zou verklaard kunnen worden door een variabele expressie, of door een 
bijdrage van andere genen in het microdeletie gebied.
We beschreven de eerste nieuw ontstane (nonsense) mutatie in ZBTB18. Aangezien 
dit slechts één patiënt betrof, waren we niet in staat om genotype-fenotype studies te 
verrichten.
Recent werd bij twee andere patiënten een ZBTB18 mutatie geïdentificeerd. Een 4 jaar 
oud meisje had een ontwikkelingsachterstand, een lage spierspanning, spasticiteit 
met dystonie, stereotype gedrag en een dun corpus callosum met onderontwikkeld 
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middendeel van de kleine hersenen (cerebellaire vermis hypoplasie). Een 15 jaar oude 
jongen had een ernstige ontwikkelingsachterstand met een uitgesproken spraak-
taalachterstand, epilepsie en opvallende gelaatskenmerken, waaronder diepliggende 
ogen, volle gebogen wenkbrauwen, een volle neuspunt, een brede mond met volle 
lippen en een puntige kin (niet gepubliceerde data).
Deze gegevens bevestigen onze hypothese dat ZBTB18 mutaties een syndromale vorm 
van een ontwikkelingsachterstand/verstandelijke beperking veroorzaken en dat verlies 
van ZBTB18 bijdraagt aan het fenotype van het chromosoom 1q43q44 microdeletie 
syndroom.
Het genomics tijdperk heeft ons waardevolle nieuwe technieken van genetisch 
onderzoek gebracht, waardoor de onderliggende genetische oorzaak voor veel 
patiënten met bekende en nieuwe syndromen geïdentificeerd is.
In dit tijdperk verschuift de klinisch genetische praktijk langzaam van een ‘fenotype-
eerst’ naar een voornamelijk ‘genotype-eerst’ benadering, wat vraagt om een nieuwe 
werkwijze, die aangeduid wordt als ‘next generation fenotypering’.
In dit proefschrift beschrijven we genotype-fenotype studies voor MGS en FHS en 
hebben we adviezen geformuleerd voor de behandeling en medische controles van 
patiënten met deze aandoeningen, nadat de genetische oorzaak voor deze syndromen 
was geïdentificeerd met behulp van exoom sequencing. We hebben de kennis van het 
fenotypisch spectrum van deze syndromen vergroot en hebben de medische zorg voor 
deze patiënten verbeterd. Daarnaast hebben we met behulp van exoom sequencing 
een nieuw ontstane mutatie in ZBTB18 aangetoond bij een meisje met een klinisch 
beeld lijkend op FHS.
Om next generation fenotypering verder te verbeteren, is het essentieel om de klinische 
en moleculaire data geanonimiseerd te delen in internationale databases die vrij 
toegankelijk zijn. Dit zal ons helpen om een cohort van patiënten met ZBTB18 mutaties 
te vormen en om de cohorten van patiënten met MGS en FHS te vergroten. Hierdoor 
wordt het mogelijk om (uitgebreidere) genotype-fenotype studies te verrichten, met 
als uiteindelijke doel de diagnostiek te verbeteren en gepersonaliseerde medische 
zorg voor deze patiënten te realiseren.
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Abbreviations
μg Micrograms
ACC Agenesis of the corpus callosum
ADD Attention deficit disorder
ADHD Attention deficit hyperactivity disorder
ADSS Homo sapiens Adenylosuccinate Synthase gene
AGORA Aetiologic research into genetic and occupational/environmental 
risk factors for anomalies in children
AKT3 Homo sapiens V-Akt Murine Thymoma Viral Oncogene Homolog 3 
gene
ALA At last assessment
ANKRD11 Homo sapiens Ankyrin repeat domain-containing protein 11 gene
APIs Application programming interfaces
ASD Autism spectrum disorder
ASHG American Society of Human Genetics
ATP Adenosinetriphosphate
ATRX Alpha-thalassemia X-linked intellectual disability syndrome
BMI Body mass index
BRAF Homo sapiens V-Raf Murine Sarcoma Viral Oncogene Homolog B1 
gene
BRWD3 Homo sapiens Bromodomain- and WD repeat-containing protein 3 
gene
CA Chronological age
C2H2 Acetylene
CBL Homo sapiens Cas-br-m murine ecotropic  retroviral transforming 
sequence homolog gene
CDC6 Homo sapiens Cell Division Cycle 6 gene
CDT1 Homo sapiens Chromatin licensing and DNA replication factor 1 gene
CEP170 Homo sapiens  Centrosomal Protein 170kDa gene
CIorf100 Homo sapiens Chromosome 1 open reading frame 100 gene
CIorf101 Homo sapiens Chromosome 1 open reading frame 101 gene
CIorf121 Homo sapiens Chromosome 1 open reading frame 121 gene
CIorf199 Homo sapiens Chromosome 1 open reading frame 199 gene
cm centimeters
CREB Homo sapiens cAMP Response Element-Binding Protein 1 gene
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CBP/CREBBP Homo sapiens CREB-Binding Protein gene
DMD Homo sapiens Dystrophin gene
DNA Desoxyribonucleïnezuur
ECG Electrocardiogram
EEG Electroencephalogram
EFCAB2 Homo sapiens EF-Hand Calcium Binding Domain 2 gene
e.g. Exempli gratia; for example
ENT Ear nose throat
EPS Ear patella short stature
ERK Extracellular signal-regulated kinases
ESHG European Society of Human Genetics
Ets-1 Protein C-ets-1
Ets-2 Protein C-ets-2
F Female
FAM36A Homo sapiens Family with sequence similarity 36, member A gene
FGFR3 Homo sapiens Fibroblast Growth Factor Receptor 3 gene
FGS FG syndrome, FG are the initials of the surnames of the first patients 
described
FHS Floating-Harbor syndrome
FISH Fluorescence in situ hibridization
FLNA Homo sapiens Filamin A gene
FSH Follicle-stimulating hormone
g grams
GERD Gastroesophageal reflux
GH Growth hormone
GI Gastrointestinal
GMNN Homo sapiens Geminin gene
HGMD Human gene mutation database
HGVS Human Genome Variation Society
HNRNPK Homo sapiens Heterogeneous Nuclear Ribonucleoprotein K gene
HNRNPU Homo sapiens Heterogeneous Nuclear Ribonucleoprotein U gene
HNRNPU-AS1 Homo sapiens Heterogeneous Nuclear Ribonucleoprotein U 
antisense RNA1 gene
HPO Human Phenotype Ontology
ID Intellectual disability
IGF1 Insulin-like Growth Factor 1
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IUGR Intra-uterine growth retardation
KANSL1 Homo sapiens Kat8 Regulatory NSL Complex, Subunit  1 gene
KBG The initials of the first three patients with KBG-syndrome described 
in literature 
KRAS Homo sapiens V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene 
Homolog gene
L Low
LH Luteinizing hormone
M Male
MAP2K1 Homo sapiens Mitogen Activated Protein Kinase Kinase 1 gene
MAPK Mitogen-activated protein kinase
Mb Mega base pairs (= 1.000.000 base pairs)
MCM Minichromosome maintenance
MED12 Homo sapiens Mediator Complex Subunit 12 gene
MGS Meier-Gorlin syndrome
MIM Mendelian Inheritance in Man
mIU Milli-international units
MLPA Multiplex ligation-dependent probe amplification
MOPD Microcephalic osteodysplastic primordial dwarfism
MRI Magnetic resonance imaging
mTOR Mammalian target of rapamycin
n number
N Normal
NA Not applicable
NGS Next generation sequencing
NRAS Homo sapiens Neuroblastoma Ras Viral Oncogene Homolog gene
OMIM Online Mendelian Inheritance in Man
OFC Occipitofrontal circumference 
ORC1 Homo sapiens Origin Recognition Complex subunit 1 gene
ORC4 Homo sapiens Origin Recognition Complex subunit 4 gene
ORC6 Homo sapiens Origin Recognition Complex subunit 6 gene
PCR Polymerase chain reaction
PGD Preimplantation genetic diagnosis
PI3K Phosphoinositide 3-kinase
PLD5 Homo sapiens Phospholipase D family, member 5 gene
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PNAS-4 Now known as DESI2: Homo sapiens Desumoylating Isopeptidase 2 
gene
PND Prenatal diagnosis
PreRC/PRC Pre-replication complex
PTPN11 Homo sapiens Protein-Tyrosine Phosphatase, Nonreceptor-Type, 11 
gene
PTEN Homo sapiens Phosphatase and Tensin Homolog gene
RAF1 Homo sapiens V-Raf-1 Murine Leukemia Viral Oncogene Homolog 
gene
RAS Rat Sarcoma
RIT1 Homo sapiens Ric-like Protein without Caax Motif 1 gene
RP58 Retinitis Pigmentosa Protein 58
RPE65 Retinal Pigment Epithelium-Specific 65 kDa Protein
RTS Rubinstein-Taybi syndrome
S Suboptimal
SA Skeletal age
SADDAN Severe achondroplasia with developmental delay and acanthosis 
nigricans
SDCCAG8 Homo sapiens  Serologically Defined Colon Cancer Antigen 8 gene
SDs Standard deviation score
SHOC2 Homo sapiens Soc-2 (Suppressor of Clear, C Elegans) Homolog gene
SNF2 Sucrose Non-Fermentable Protein 2
SNP Single Nucleotide Polymorphism
SOS1 Homo sapiens Son of Sevenless, Drosophila, Homolog 1 gene
SRCAP Homo sapiens Snf2-Related CREBBP Activator Protein gene
UK United Kingdom
USA United States of America
UPF3B Homo sapiens Up Phrameshift Suppressor 3 Homolog B gene
VKGN Vereniging Klinische Genetica Nederland
VPI Velopharyngeal insufficiency
WES Whole exome sequencing
ZBTB18 Homo sapiens Zinc Finger and BTB Domain Containing 18 gene
ZNF238 Homo sapiens Zinc Finger Protein 238 gene
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Dankwoord
En dan is daar opeens het laatste deel van mijn proefschrift: het dankwoord. Ik ben 
dankbaar dat ik de mogelijkheid heb gekregen om wetenschappelijk onderzoek 
te verrichten en dit proefschrift te schrijven. Ik heb de afgelopen jaren heel erg veel 
geleerd, dat neem ik mee in mijn werk als arts en bij het onderzoek dat ik in de toekomst 
nog wil verrichten.
In de eerste plaats wil ik de patiënten en hun families bedanken, omdat dit proefschrift 
zonder hen niet tot stand was gekomen. Daarnaast wil ik alle collega's bedanken met 
wie ik de afgelopen jaren heb samengewerkt en die ik helaas niet allemaal persoonlijk 
kan benoemen.
I would like to express my gratitude to all patients and their families and to all 
colleagues who contributed to this research-project.
Ernie, als co-promotor was het in het begin hard werken: ik had nog geen ervaring en 
na versie vijftien van een manuscript of abstract waren we er allebei wel eens goed 
klaar mee. Maar jij ging toch onverstoord door met corrigeren en suggesties geven. 
Daardoor heb ik deze jaren ontzettend veel geleerd. Ik ben nu erg blij wanneer ik een 
artikel na versie drie kan indienen. Bovenal ben ik blij dat ik met jou als persoon mocht 
samenwerken, onze gesprekken heb ik als erg waardevol ervaren. Bedankt voor alles, ik 
hoop dat we nog jaren samen mogen blijven werken!
Prof. dr. Brunner, beste Han. Na ons maandelijkse overleg had ik nieuwe energie en 
inspiratie, wat me elke keer weer flink vooruit heeft geholpen. Jij hebt nooit twijfel 
geuit over de goede afloop van mijn promotie traject. Jij gaf duidelijk aan wanneer 
goed goed genoeg was en wanneer het tijd was om iets af te ronden en verder te gaan. 
Bedankt voor jouw vertrouwen! 
Prof. dr Knoers, beste Nine. Dankzij jou ben ik dit promotietraject gestart, jij zag een 
onderzoek met Ernie als co-promotor wel zitten. Kort na de start van mijn onderzoek 
ben je vertrokken naar Utrecht, waar je als hoofd van de afdeling genetica van het UMC 
Utrecht op afstand bij mijn onderzoek betrokken bleef. Ik heb jouw goede ideeën over 
de richting van mijn onderzoek en commentaar op mijn artikelen erg gewaardeerd.
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De leden van de manuscriptcommissie: prof. dr. Willemsen, prof. dr. Noordam en dr. 
Bijlsma, bedankt voor het beoordelen van mijn manuscript. 
Lies, Dorien en Jeroen. Dit onderzoek had zonder jullie hulp niet gedaan kunnen 
worden. Lies, jij had veel goede ideeën over kandidaatgenen en strategieën over het 
vinden van nieuwe (kandidaat)genen. Jij zag altijd mogelijkheden en ruimte om 
onderzoek in te passen binnen jullie drukke klinische werkzaamheden. En na het 
vertrek van Lies naar Rotterdam heb jij, Dorien, met jouw kennis van ciliopathieen, dit 
op een zelfde wijze voortgezet.
Jeroen, we hebben samen heel wat tijd besteed aan het opzetten van nieuwe genen 
en kandidaatgenen en het (leren) analyseren van exoom data. En jij hebt heel wat 
kandidaatgenen getest in ons cohort. Bedankt voor alles!
Lieve Charlotte, bedankt dat je mijn paranimf wilt zijn. We zijn bijna vanaf het begin 
collega’s en ik denk met veel plezier aan onze borrels, etentjes en de ski weekenden 
in Damuels. Alhoewel afspreken de laatste tijd met al die zwangerschappen en kleine 
kinderen wat minder lukt, kijk ik uit naar onze etentjes en weekendjes in de toekomst!
Lieve Richèl, al weer ongeveer 15 jaar clubgenoten, ook jij bedankt dat je mijn paranimf 
wilt zijn. Ik ga er van uit dat je geen antwoord hebt hoeven geven op de vragen. Ik hoop 
dat ik jou volgende week ook kan helpen om je zenuwen in bedwang te houden. Op 
naar een volgend mooi feest!
Beste collega’s van de klinische genetica. Ik noem niet alle klinisch genetici, arts-
assistenten, genetisch-consulenten, maatschappelijk werkenden en secretaresses en 
onderzoekers bij naam (dat zijn er te veel en ik zou zomaar iemand vergeten), maar 
werken op onze afdeling voelt vaak niet als werk, voor een belangrijk deel dankzij jullie! 
Datzelfde geldt voor iedereen van het PND-team, met wie het fijn samenwerken is.
Lieve familie en vrienden, bedankt voor jullie steun, het oppassen en natuurlijk voor 
alle gezellige, ontspannende momenten. Nu deze belangrijke mijlpaal is gehaald, 
kunnen we samen nog meer nieuwe herinneringen maken.
Papa en mama, jullie hebben mij altijd gestimuleerd om zoveel mogelijk uit mezelf te 
halen. Tegelijkertijd remden jullie me ook altijd af wanneer dat nodig was. De dag voor 
mijn tentamens hing ik altijd zenuwachtig en gefrustreerd aan de telefoon, want dat 
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oefententamen ging nooit goed. Het advies luidde dan steevast: ‘maak je niet druk, het 
komt allemaal goed. Je kunt nu toch niets meer in je opnemen, ga lekker een wijntje 
drinken in de stad.’ Een goed advies, want goed kwam het daarna uiteindelijk altijd. 
Ook met mijn onderzoek hebben jullie mij gesteund, bedankt voor de goede zorgen 
tijdens de week en weekenden die ik bij jullie heb mogen werken.
Hannah en Lars, jullie waren de belangrijkste stimulans/reden om dit traject af te 
ronden. De tijd die jullie zonder mama hebben doorgebracht is niet voor niets geweest!
Lieve Arno, zonder jouw steun had ik hier niet gestaan. Ik heb jou nooit horen klagen 
over de weekenden die ik aan het werk was en die jij grotendeels alleen met de kinderen 
door hebt gebracht. Je bedacht zelfs zelf mogelijkheden waardoor ik weer aan mijn 
onderzoek kon werken. Ik kan me geen betere echtgenoot wensen. Ik kijk uit naar het 
moment waarop we samen ons derde kindje in ons gezin mogen verwelkomen.
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Sonja de Munnik werd geboren op 13 februari 1984 in Emmen. Na het behalen van 
haar eindexamen Gymnasium aan het Dr. Nassau College in Assen, begon zij in 2001 
aan haar studie geneeskunde aan de Rijksuniversiteit Groningen. Zij behaalde haar 
doctoraal examen in 2005 en haar artsendiploma in 2007. 
Na haar studie werkte zij vijf maanden als ANIOS op de sectie klinische Genetica van 
de afdeling Genetica van het Radboud universitair medisch centrum in Nijmegen. 
Aansluitend werd zij vanaf augustus 2008 tot juni 2013 opgeleid tot klinisch geneticus 
door Prof. Dr. V.V.A. van Slobbe-Knoers en Dr. I. van der Burgt. Naast haar opleiding 
heeft zij vanaf 2010 onder leiding van Prof. Dr. H.G. Brunner, Prof. Dr. V.V.A. van Slobbe-
Knoers en Dr. M.H.F. Bongers wetenschappelijk onderzoek verricht, resulterend in dit 
proefschrift ‘From genotype to phenotype: clinical syndrome delineation in the era 
of genomics’. Momenteel is zij werkzaam als klinisch geneticus bij de sectie Klinische 
Genetica van de afdeling Genetica in het Radboud universitair medisch centrum, 
met als aandachtsgebieden prenatale diagnostiek, erfelijke neurodegeneratieve 
aandoeningen en erfelijke stollingsstoornissen.
Sonja is getrouwd met Arno Otterman en samen hebben zij twee kinderen: Hannah 
en Lars.
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Sonja de Munnik was born on February 13th, 1984 in Emmen, The Netherlands. She 
graduated from secondary school (gymnasium at the Dr. Nassau College) in Assen and 
started Medical School at the Rijks Universiteit Groningen in 2001. She obtained her 
doctoral degree in 2005 and her MD degree in 2007.
After finishing college, she worked as a junior doctor at the Clinical Genetics division 
of the department of Human Genetics of the Radboud University Medical Center in 
Nijmegen for five months. Afterwards, she was trained as a Specialty Registrar in Clinical 
Genetics from August 2008 till June 2013, by Prof. Dr. V.V.A. van Slobbe-Knoers and Dr. 
I. van der Burgt. Simultaneously, from 2010, she worked on her PhD under supervision 
of Prof. Dr. H.G. Brunner, Prof. Dr. V.V.A. van Slobbe-Knoers and Dr. H.M.F. Bongers, 
resulting in this thesis: ‘From genotype to phenotype: clinical syndrome delineation in 
the era of genomics’.
Currently, she works as a Consultant in Clinical Genetics at the department of Human 
Genetics of the Radboud University Medical Center Nijmegen, specializing in prenatal 
diagnosis, hereditary neurodegenerative disorders and hereditary coagulation 
disorders.
Sonja is married to Arno Otterman, and together they have two children: Hannah and 
Lars.
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